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Abstract 
Age-related macular degeneration (AMD) is a debilitating disease and the leading 
cause of blindness in the developed world. It is a disease of the retinal pigment 
epithelium (RPE), the support cells for rods and cones. Currently there are no 
approved methods of treating the failing RPE, however, RPE transplantation is 
proving to be a promising therapy. The royal college of surgeons (RCS) rat has 
been extensively studied as a model for RPE transplantation, although, it does 
not model RPE death, as RPE remain intact in this disease model. In this thesis, 
I examine two alternative mouse models and their suitably for RPE 
transplantation. The first model uses sodium iodate to selectively kill off the RPE, 
which results in rapid retinal degeneration. Chemically removing the RPE frees 
Burch’s membrane for donor RPE attachment. It was discovered that this model 
results in severe loss of outer-retinal photoreceptor function and function was 
unable to be restored with human embryonic stem cell-derived RPE (hESC-RPE) 
transplantation. 
The second model is the rd12 mouse, which has a mutation in rpe65, arresting 
the visual cycle. Thus, improvements in visual function would be specific to the 
visual cycle. This model, showed slow retinal degeneration and an ability for 
retinal function rescue with synthetic chromophore and hESC-RPE 
transplantation, though, no surviving grafted hESC-RPE were found in the retina. 
This study also examines the effects of RPE on melanopsin function. Melanopsin 
labelling and function was significantly reduced in rd12 mice. It was shown that 
supplementing chromophore significantly restored the intrinsic pupillary light 
reflex (iPLR) in rd12 and that this requires retina attached to the iris/ciliary body. 
Restoring rpe65 gene function improves melanopsin function when the gene is 
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placed subretinally and expressed by the RPE and no effect is seen when the 
gene is placed intravitreally. 
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Impact Statement 
This thesis introduces two alternative modes for examining RPE cell 
transplantation. The choice of retinal degenerative model used for studying RPE 
cell grafting has a large impact on what improvements in retinal function can be 
measured. This study draws attention to the benefits and difficulties with the 
NaIO3 and rd12 models for restoring retinal function. This will undoubtedly affect 
the choice of using these models in further studies and how they achieve the 
greatest functional recovery. 
This study has also highlighted melanopsin function as an additional retinal 
readout. The discovery of this photoreceptor is relatively new, and so far, 
underutilised for the assessment of RPE function. This study has shown the 
reliance of the melanopsin system on the RPE visual cycle. It is an important 
retinal function and its restoration should be considered along with outer-retinal 
photoreceptors. It is hoped that this will encourage further studies to examine 
melanopsin function when ascertaining improvements in retinal function following 
RPE cell transplantation. 
Determining the significance of the role of RPE on melanopsin function should 
impact patient care. Patients with AMD or a mutation affecting RPE function may 
have deficits in melanopsin function. This can leave the patient susceptible to a 
plethora of conditions such as seasonal affective disorder and disfunctions in their 
sleep/wake cycle and also it has been linked to cancer, obesity and mental 
illness.   
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Chapter 1 Introduction 
 The Retina 
 Structure of the retina 
The retina is a neuronal layer at the back of the eye, which absorbs and 
processes light (Figure 1.1). Photoreceptors are the cells that absorb light, two 
types of which, rods and cones lie at the back of the neural retina and are most 
important for image forming vision. They hyperpolarise in the presence of light. 
This signal is relayed via horizontal and bipolar cells in the inner nuclear layer, 
which carry out preliminary sorting and pooling of the visual signal. The inner 
nuclear layer contains horizontal cells, bipolar cells, amacrine cells and Müller 
glial cells. Horizontal cells and some amacrine cells are involved in lateral 
connections across the retina. Horizontal cells feedback information to both the 
photoreceptor and the bipolar cell. Amacrine cells are the most diverse cell type 
in the retina and feedback information to bipolar cells. Bipolar cells and amacrine 
cells send the photoreceptor signal on to the ganglion cell layer (GCL) via axons 
in the inner plexiform layer (IPL). Ganglion cells have long axons which lie at the 
vitreal aspect of the retina and send the signal to the brain via the optic nerve. A 
subset of the ganglion cells make-up the third photoreceptor type, called the 
intrinsically photosensitive retinal ganglion cells (ipRGC). Interplexiform cells 
(IPCs) are GABAergic neurons which provide feedback information from 
amacrine cells in the IPL to bipolar cell dendrites in the OPL (Kolb and West, 
1977, Nakamura et al., 1980). 
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 Pooling of signal 
Pooling of the electrical signal allows for fewer axons sending information to the 
brain. The density ratio of rods to rod bipolar cells is roughly 10:1. Around 16-20 
rods converge on one bipolar cell and average divergence is less than 2 bipolar 
cells (Freed et al., 1987). Ganglion cells collect excitatory inputs from several 
bipolar cells (Barlow, 1953), allowing for a high degree of convergence onto a 
single ganglion cell. The number of bipolar cells that converge to a ganglion cell 
depends on the ganglion cell receptive field. In addition to this, inhibitory 
interactions mediated by horizontal and amacrine cells also contribute to the 
structure of the receptive field by lateral interactions, which provide spatial 
information. 
 Centrifugal innervation 
Information from the brain is also sent to the retina, these are called centrifugal 
innervations. Axons from the hypothalamus containing histamine enter the retina 
via the optic nerve, some run around the peripheral retina and terminate in the 
IPL, occasionally alongside retinal blood vessels and others circle the primate 
fovea in the optic fibre layer and appear to return to the optic disc (Gastinger et 
al., 1999). It is believed that these neurons play a circadian role, as their activity 
is highest in the morning. It has been shown that mouse dopaminergic amacrine 
cells (DA-AC) respond to histamine (Frazao et al., 2011). Dopaminergic 
processes have been shown to project to the GCL and to the OPL. Dopaminergic 
pre-synaptic terminals have been imaged next to horizonal cells in the OPL 
(Frederick et al., 1982) and ipRGCs in the GCL (Vugler et al., 2007b).  It is 
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hypothesised that dopaminergic cells in the retina are involved in a feedback loop 
from the SCN and ipRGCs. 
 
Figure 1.1 Layers of the retina 
Rods and cones absorb light at the back of the neural retina. This signal is then 
sent to horizontal, bipolar and amacrine cells which sort and pool signals and 
send the signal to the ganglion cells. This layer of cells further pool and sort the 
signals and project the signal to the brain via the optic nerve. RPE: Retinal 
pigment epithelium; ONL: outer nuclear layer; OPL: outer plexiform cells; INL: 
inner nuclear layer: IPL: Inner plexiform layer; GCL: ganglion cell layer; ipRGC: 
intrinsically photosensitive retinal ganglion cell. 
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 Phototransduction 
 In the dark 
Phototransduction is the process in which light is absorbed by photoreceptors 
and converted into an electrical signal. In darkness, photoreceptors are 
depolarised, which is controlled by the flow of ion currents. There is an outward 
K+ current through non-gated channels. There is a Na+ influx through cyclic GMP 
(cGMP)-gated channels, depolarising the cell (Hagins et al., 1970). This inward 
current is made up mostly (~85%) of Na+, as Na+ is the predominant external 
cation, although Ca2+ and a small amount of Mg2+ also enter the non-selective 
channel (Chen et al., 2003).  This is call the dark current and maintains the cell 
at around -40 mV. cGMP levels are high in darkness to maintain these open 
channels. This depolarisation opens voltage-gated calcium channels, resulting in 
increased intracellular calcium (iCa2+), which causes glutamate release. 
Glutamate, though usually excitatory, inhibits the excitation of post-synaptic rod 
bipolar cells. In on-centre bipolar cells, glutamate binds to metabotropic 
glutamate receptors, causing cation channels to close and hyperpolarises the 
cell. In off-centre bipolar cells, glutamate binds to ionotropic glutamate receptors 
resulting in an inward current and depolarisation of the cell. To maintain an ionic 
balance an energy dependant pump in the photoreceptor inner segments (PIS) 
pumps out Na+ and pumps K+ into the cell. In the photoreceptor outer segments 
(POS), Ca2+ is exported by a Na+/Ca2+, K+ exchanger, which trades one Ca2+ 
and one K+ for four inward Na+ (Figure 1.2). 
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 Illumination 
The visual pigment consists of an opsin, which is a seven trans-membrane 
domain, with a chromophore, 11-cis retinal, that sits in the opsin and is located in 
disk outer-membranes. In darkness, 11-cis retinal acts as an inverse agonist to 
lock rhodopsin in an inactive state. The absorption of a photon isomerases 11-
cis retinal to all-trans retinal, activating the photopigment by a conformational 
change to form metarhodopisn II. Metarhodopsin II is unstable and splits to form 
a free opsin and all-trans retinal. This is the start of the phototransduction 
cascade. 
The opsin binds transducin, a G-protein heterotrimer and catalyses the exchange 
of guanosine triphosphate (GTP) for guanosine diphosphate (GDP) on the α-
subunit (see Figure 1.2). The α-subunit now bound to GTP dissociates from the 
transducin photopigment complex, and binds to the inhibitory γ-subunit of cGMP 
phosphodiesterase (PDE) (Hurley and Stryer, 1982). The photopigment can now 
activate additional transducin molecules. PDE is anchored in the disk membrane 
by its α- and ꞵ-subunits (Baehr et al., 1979). Activated α-subunit-GTP-PDE 
complex hydrolyses cGMP resulting in cGMP-gated channels to close. These 
channels are responsible for cation influx (Hagins et al., 1970), thus their closure 
stops this influx. This causes rods and cones to hyperpolarise. Ca2+ is continually 
exported through the Na+/Ca2+, K+ exchanger. This lowers iCa2+ (Polans et al., 
1996) and terminates the release of glutamate as it is required for glutamate 
vesicles to fuse with the cell membrane. Also, the increased levels of extracellular 
Na+ triggers the uptake of extracellular glutamate by RPE cells (Miyamoto and 
Del Monte, 1994). This loss of glutamate results in depolarisation of on-centre 
bipolar cells and hyperpolarisation of cone off-centre bipolar cells. Cones have a 
much faster photo-response and a quicker termination of phototransduction. This 
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rapid photo-response and recovery allows cones to detect a high temporal 
frequency achieved by faster clearance of Ca2+ as their channels are twice as 
permeable. 
 Amplification 
Rods and cones have adapted this process to cover vision over nine orders of 
luminance magnitude. Rods have adapted to work well under dim light and bleach 
at high light intensities. The larger rod outer-segment, contains much more 
rhodopsin than opsin in cones, which allows a much higher sensitivity. Activation 
of a single rhodopsin molecule can activate 500 phosphodiesterase and 
hydrolyse 4 x 105 cGMP (Yee and Liebman, 1978). Activation of transducin is the 
first amplification step, where a single activated opsin can activate ~20 transducin 
molecules in mouse rods (Krispel et al., 2006, Leskov et al., 2000). In contrast to 
this, activation of PDE is not amplified, although, activated PDE has strong 
catalytic power and hydrolyses cGMP at a high rate. Thus rods can convert a 
single photon into an electrical response (Baylor et al., 1979), due to amplification 
in the phototransduction cascade and a longer photo-response. This sensitivity 
comes at a price of low temporal frequency. Cones, on the other hand, have a 
reduced amplification and thus are not sensitive to low light intensities 
(Tachibanaki et al., 2001). 
 Deactivation of the phototransduction cascade 
Following light activation, the dark current is recovered by deactivation of the 
phototransduction cascade. This recovery requires inactivation of each of the 
activated component of the phototransduction cascade and re-opening of the 
cGMP-gated channels. Low iCa2+ play an important role in recovering from the 
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phototransduction cascade.  The loss of iCa2+ causes Ca-recoverin-rhodopsin 
kinase to dissociate into Ca2+, recoverin and rhodopsin kinase. Activated 
rhodopsin is phosphorylated by rhodopsin kinase (GRK1), which partially 
supresses the activity of the active rhodopsin. Arrestin then binds to the 
phosphorylated rhodopsin stopping any residual activity (Wilden et al., 1986, 
Kuhn and Wilden, 1987). 
Reduced iCa2+ also enables deactivation of transducin. Ca2+ is also bound to a 
GTPase accelerating protein (GAP), regulator of g protein signalling 9 (RGS9). 
With low iCa2+, RGS9 is dissociated and interacts with the α-subunit of transducin 
causing it to hydrolyse GTP to GDP. In rods, the recovery kinetics of transducin 
is 2.5 times slower than active rhodopsin (Krispel et al., 2006), thus, the recovery 
of transducin determines the recovery kinetics of a single photon. RGS9 is more 
plentiful in cones (Cowan et al., 1998, Zhang et al., 2003), and allows for faster 
recovery. The dissociation of transducin α-subunits results in the inactivation of 
α-subunit-GTP-PDE complex, stopping the hydrolysis of cGMP. 
Low iCa2+ also results in the re-opening of cGMP-gated channels. Guanylate 
cyclase activating protein (GCAP) is a Ca-binding protein and as iCa2+ levels 
decrease, GCAP dissociates from Ca2+ and interacts with guanylate cyclase (GC) 
to activate it. GC then transforms GTP to cGMP, replenishing the cGMP levels 
needed for opening the cGMP-gated channels and the restoration of the dark 
current (Figure 1.2). Also, the low iCa2+ increases the sensitivity of the cGMP-
gated channels via the Ca2+-calmodulin complex in the cGMP-gated channels, 
thus, opening the channels in low cGMP levels (Hsu and Molday, 1993). 
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Figure 1.2 Phototransduction Cascade. 
A photon (hv) is absorbed by opsin, in the disk membrane, containing 11-cis 
retinal, which changes to all-trans retinal once activated by light. Activated opsin 
binds transducin, and dissociates from GDP and binds GTP. The α-subunit and 
GTP complex dissociates and binds to the γ-subunit of PDE, forming a complex 
that hydrolyses cGMP to a non-cyclic form, GMP. The loss of cGMP causes 
cGMP-gated channels in the outer membrane to close, stopping the influx of Na+ 
ions, causing rods and cones to hyperpolarise and signal to cells in the INL. 
During the light phase, Ca2+ is continually pumped out and lowers the iCa2+. The 
loss of iCa2+ feeds back negatively and results in the activation of GC which 
transforms GTP to cGMP, replenishing the cGMP levels to re-open the cGMP-
gated channels restoring the dark current. Image modified from (Leskov et al., 
2000). 
 Light adaptation 
The human eye functions from dim to very bright light levels, spanning nine orders 
of magnitude. Yet, at any given moment, contrast ratio can only distinguish 
around 3 orders of magnitude. Thus, an adaptation occurs at the level of the 
retina adjusting to a new definition of what is black, to the surrounding visual 
environment. It can take 20-30 minutes for the eye to fully adapt to darkness and 
around 5 minutes to adapt to bright sunlight. Cones operate at higher light 
intensities than rods and can differentiate between wavelengths, allows for colour 
vision at light levels within the cone sensitivity. 
A major player in light adaptation is the recycling of chromophore. Chromophore 
is required for the detection of light, and following light detection all-trans retinal 
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is transported to the RPE for recycling into the usable form of 11-cis retinal. This 
process of using up available 11-cis retinal is called bleaching. Along with faster 
phototransduction and recovery, cones have also been shown to have an 
alternative source of regenerated chromophore, allowing for a faster recovery of 
bleached opsin (Goldstein and Wolf, 1973). 
Modifications to the elements in the phototransduction cascade also lead to light 
adaptation. In darkness, transducin α- and ꞵ-subunits are found predominantly in 
rod outer-segments, but translocate to the PIS and the INL under bright light 
(Kassai et al., 2005, Sokolov et al., 2002). It is thought that this translocation 
process protects rods under bright light conditions and also contributes to light 
adaptation in rods (Elias et al., 2004). Cone transducin α-subunit was not found 
to translocate (Coleman and Semple-Rowland, 2005, Elias et al., 2004), except, 
at much higher light levels (Chen et al., 2007). This may be due in part to the 
different transducin subtypes found in rods and cones (Fung et al., 1992, Lee et 
al., 1992). 
The reduction of iCa2+ under illumination, triggers negative feedback and 
contributes to light adaptation. Low iCa2+ helps photoreceptors recover from the 
phototransduction cascade and also increases the sensitivity of the cGMP-gated 
channels, resulting in the activated α-subunit-GTP-PDE complex being required 
to hydrolys more cGMP to achieve closed cGMP-gated channels (Hsu and 
Molday, 1993). 
 Colour Vision 
There are three cone types in humans L-, M- and S-cones, named by the 
wavelength of light that they are more sensitive to: long (565 nm), medium (545 
nm) and short (440 nm) wavelengths. The human and old world primate fovea is 
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rich in M- and L- cones. Blue cones compose of less than 6% of the total primate 
cone population (Roorda et al., 2001) and are absent from the fovea, limiting the 
resolution to outside 20-30 degrees of eccentricity (Curcio et al., 1991). A large 
proportion of short-wavelength light is filtered out by the cornea and lens before 
reaching the retina, diminishing the contribution of blue cones for human vision. 
In the mouse retina, cones make up about 3% of the outer-retinal photoreceptor 
population (Carter-Dawson and LaVail, 1979, Jeon et al., 1998). Most new world 
primates and non-primate mammals do not have a gene for L-opsin and are 
dichromatic (Dulai et al., 1999). S- and M- opsin in rodents have a maximum 
spectral sensitivity at 359 nm and 510 nm, respectively (Applebury et al., 2000, 
Jacobs et al., 1991). 
 Electroretinogram 
The electrogram (ERG) is a method of measuring retinal function. It gives a 
reading of the electrical wave that is sent through the retina, from the 
photoreceptors to the nerve fibres, due to the absorption of light. It is used to 
diagnose abnormalities in the retinal signalling. It is non-invasive, making it 
extremely useful for reporting measurements that evaluate changes in 
progressive disease forms. It is amendable for use in a wide range of species, 
including humans, and as such bridges human clinical evaluations and animal 
models of retinal disease. The earliest age at which ERG photoresponses can be 
measured reproducibly in mice is 3 weeks (Pang et al., 2006). An ERG is made 
up of different components, first described by Granit in 1933 (Granit, 1933). The 
two main components studied in this thesis are the a- and the b-wave (Figure 
1.3). 
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 The a-wave 
The a-wave is an initial fast negative wave, representing a light-evoked 
hyperpolarisation of the rod membranes (Brown, 1968, Heynen and van Norren, 
1985, Hood and Birch, 1990, Hood and Birch, 1995). The latency of the a-wave 
is measured from the light onset to the peak of the a-wave. Rodents under 
photopic conditions do not usually produce an a-wave, due to small cone counts. 
 The b-wave 
The b-wave is a large positive wave that follows the a-wave. It is created by 
depolarisation of cells in the inner retina. Its generation is from the input of many 
neurons, including Müller cell processes (Miller and Dowling, 1970, Xu and 
Karwoski, 1994). The amplitude of the b-wave is measured from the trough of the 
a-wave to the peak of the b-wave. The implicit time of the b-wave is a 
measurement taken from the flash of light onset to the peak of the b-wave. 
 
Figure 1.3 Scotopic ERG waveform 
The a-wave is a rapid negative wave, representing the hyperpolarisation of rod 
membranes. This is followed by the positive b-wave, representing the 
depolarisation of cells in the inner retina. 
 Retinal pigment epithelium 
The RPE is a monolayer of pigmented epithelial cells, which lie in the outer-retina 
adjacent to POS and acts as a support cell for outer-retinal photoreceptors. It has 
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a neuroectodermal origin and is therefore considered to be part of the retina. RPE 
cells have an apical and basal polarisation. The basal membrane is a component 
of Bruch’s membrane and interacts with the choroid. The apical membrane has 
large microvilli, which extend to surround the photoreceptor outer-segments 
(POS). This is important to facilitate close communication between RPE cells and 
photoreceptors to optimise the RPE’s functions that enhance photoreceptor 
performance (Figure 1.4). 
 
Figure 1.4 Functions of the RPE. 
The RPE has many functions which are necessary for vision and maintaining 
retinal health. 1) Melanin granules in the RPE give the RPE their dark colour and 
absorb excess light preventing light scatter. 2) Vitamin A is sourced from the diet, 
converted to 11-cis retinal by the RPE and transported to photoreceptors for 
phototransduction. Absorption of light causes 11-cis retinal to be converted to all-
trans retinal and transported back to the RPE where it is recycled to 11-cis retinal 
for phototransduction. 3) The RPE selectively takes up glucose and nutrients and 
transport them to the photoreceptors and pumps out water and ions to the choroid 
to maintain visual clarity. 4) Tight junctions make diffusion between cells difficult 
and contribute to the blood retinal barrier (BRB). 5) Rods and cones shed the tip 
of their outer-segments daily which are phagocytosed and digested by the RPE. 
6) The RPE produces and secretes growth factors, including PEDF into the retina 
and VEGF into the choroid. 
 Blood retinal barrier 
Blood is supplied to the photoreceptors by the choroid, which is separated from 
the retina by the RPE (Tornquist et al., 1990). The RPE acts as part of the blood 
retinal barrier (BRB) preventing blood leaking and the infiltration of immune cells, 
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and controlling the transport across the barrier. RPE cells have tight junctions on 
their lateral side, connected to neighbouring RPE cells, making diffusion between 
cells difficult. This tightly controlled barrier facilitates the immune privilege status 
of the eye. 
 Transport Epithelium 
The RPE selectively takes up nutrients such as glucose, ascorbic acid and fatty 
acids from the blood and transports these nutrients to the photoreceptors. To 
transfer glucose, the RPE contains many glucose transporters on both the apical 
and basolateral membranes. Omega-3 fatty acid is transported because it is 
required for membrane structure of neurons but cannot be synthesised by neural 
tissue. 
The RPE transports ions and water out of the retina. A large volume of water is 
produced in the retina and intraocular pressure leads to a movement of water 
from the vitreous towards the retina (Moseley et al., 1984). Müller cells are 
thought to transport water through the retina (Nagelhus et al., 1999), which is 
pumped out of the retina by the RPE.  Na+-K+-ATPase is located on the apical 
membrane and provides the energy for this transepithelial transport (Ostwald and 
Steinberg, 1980). This flow of water acts as an adhesion force between the neural 
retina and the RPE. Maintaining the retina in a proper state of hydration is also 
important for visual clarity. 
 Excess light absorption 
The retina is exposed to high levels of light throughout the day and can lead to 
photo-oxidative reactions, which can be toxic to neural cells. The RPE contains 
many melanin granules, which give it the dark colour. These pigments absorb 
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excess light. This, not only protects the neural retina, but also the absorption of 
excess light provides clearer vision by preventing light scatter. 
The RPE also contains high levels of antioxidants, which counterbalance the high 
oxidative stress in the retina created by its high oxygen consumption. 
 Secretion 
The RPE produces and secrets a variety of growth factors into the retina or 
choroid. Pigment endothelium-derived factor (PEDF) is secreted into the neural 
retina, which inhibits the growth of blood vessels and prevents apoptosis 
(Cayouette et al., 1999). Vascular endothelial growth factor (VEGF) is secreted 
basally (Adamis et al., 1993). It prevents endothelial cell apoptosis and acts as a 
permeability factor stabilising the fenestrations of the endothelium (Roberts and 
Palade, 1995). 
 Shedding of outer-segments 
Rods and cones have a very high metabolic rate and accumulate toxic photo-
oxidative compounds due to the high light exposure. Thus, rods and cones renew 
their outer-segments continually (Young, 1967, Young and Droz, 1968). 
Photoreceptors synthesise new outer-segment disks at the base of the POS and 
the oldest disks at the tip of the POS are shed daily and phagocytosed by the 
RPE (Young and Bok, 1969). The shedding and phagocytosing of POS is 
controlled by both light and circadian rhythm (Goldman et al., 1980, LaVail, 1980). 
Rod outer-segments are shed at light onset (LaVail, 1976), while the timing of 
cone outer-segment shedding varies by species. In nocturnal rodents, cones 
undergo POS shedding at lights on (Bobu and Hicks, 2009), while gold fish, chick 
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and squirrel cones shed their POS early in the dark phase (O'Day and Young, 
1978, Young, 1978, Long et al., 1986).  
RPE cells phagocytose more material over a lifetime than any other cell type in 
the body. There are three stages to this phagocytic process: recognition, 
internalisation and digestion of shed POS (Figure 1.5). It is understood that these 
processes are like those observed in macrophages. 
 
 
Figure 1.5 Shedding of POS 
Rods and cones shed the tip of their outer-segments diurnally (1). The exposed 
plasma membrane is recognised by the apical microvilli (2). The shed outer-
segment is engulfed by the apical appendages, which form around it (3). The 
phagocytosed outer-segment becomes fused with endosomes and lysosomes 
which break down the contents (4). Waste is excreted to the choroid and re-
usable contents are recycled. 
Recognition of shed outer-segment 
Shed POS are identified by the disruption of the plasma membrane. In an intact 
plasma membrane, phospholipids containing terminal primary amino groups, 
such as phosphatidylserine (PS), are localised in to the cytoplasmic surface 
(Figure 1.6). After disruption of the plasma membrane, PS becomes exposed 
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extracellularly, allowing for recognition of shed outer-segment (Fadok et al., 
2001). PS interacts with secreted binding proteins, milk fat globule-EGF 8 (MFG-
E8) (Hanayama et al., 2002), growth arrest-specific gene 6 (Gas6), (Hall et al., 
2001, Nagata et al., 1996, Nakano et al., 1997) and protein S (Hall et al., 2005). 
MFG-E8 interacts with integrin αvꞵ5, and Gas6 and protein S are ligands for 
MerTK on RPE cells (Finnemann et al., 1997, Nandrot et al., 2004). The binding 
of the MFG-E8 to avꞵ5 mobilises a pool of focal adhesion kinase (FAK), to the 
apical RPE and triggers autophosphorylation. This then causes MerTK 
phosphorylation (Finnemann, 2003). 
 
Figure 1.6 Recognition of shed outer-segments 
The exposure of phospholipids such as PS, following the disruption of the plasma 
membrane are recognised by secreted binding proteins MFG-E8 (MFG), Gas6 
and protein S. MFG interacts with integrin αvꞵ5 on RPE. Gas6 and protein S 
interact with MerTK on RPE. The activation of αvꞵ5 mobilises a pool of FAK which 
phosphorylates MerTK. This initiates the internalisation of the shed outer-
segment. 
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Internalisation of shed outer-segment 
MerTK phosphorylation then initiates internalisation of shed POS by mobilising 
myosin II from the RPE periphery and re-arranges the cytoskeleton (Strick et al., 
2009). The cytoskeleton re-arrangement forms pseudopods which engulf the 
shed outer-segment and must fuse together around it (Figure 1.7). Cadherins are 
a class of membrane-bound protein which bind to other cadherins on adjacent 
membranes, forming adherens junctions (Hulpiau and van Roy, 2009). Catenins 
are another class of protein which lie on the cytoplasmic end of cadherins and 
form a protein complex with the actin cytoskeleton (Ozawa et al., 1989). The 
reorganisation of actin results in the formation of mature adherens junctions and 
fusion of the two membranes. This has not been demonstrated in RPE cells, still, 
it is the most likely approach to engulfing the shed POS. 
 
Figure 1.7 Joining of pseudopods. 
Pseudopods engulf the shed outer-segment and fuse together around it. 
Membrane-bound cadherins bind to cadherins on adjacent membranes. Catenins 
lie on the cytoplasmic side of the membrane and form a complex with cadherins 
and actin to form a mature adherens junction and result in the fusion of the two 
membranes. 
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Once engulfed, the phagosome fuses with endosomes and lysosomes to form a 
phagolysosome, breaking down the contents and recycling re-usable 
components and removing waste to the choroid (Figure 1.8). 
 
 
Figure 1.8 Digestion of phagosome. 
The phagosome fuses with endosomes and lysosomes to form a 
phagolysosome. Useful components are recycled and waste is excreted to the 
choroid for clearance. 
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 The visual cycle 
The RPE plays a crucial role in vision by recycling vitamin A (all-trans-retinol) to 
11-cis retinal, which when combined with opsin forms the visual pigment in 
photoreceptors. All-trans-retinol is sourced from the diet transported to the RPE 
via the choroid. Here, it binds to cellular retinal binding protein (CRBP) and 
becomes esterfied by lecithin retinol acyltransferase (LRAT) to all-trans-retinyl 
ester (Figure 1.9). This is then hydrolysed and isomerised by retinal pigment 
epithelium-specific protein 65 KDa (RPE65) (Redmond et al., 1998) to form 11-
cis-retinol. This then binds to cellular retinaldehyde binding protein (CRALBP) 
where it can be stored to allow a quick conversion from dark to light phase or it 
can be oxidised by 11-cis retinal dehydrogenase to form 11-cis retinal. 11-cis 
retinal is transported to the rods and cones via inter-photoreceptor retinal-binding 
protein (IRBP). In the photoreceptor, 11-cis-retinal sits in the opsin to form the 
visual pigment. Upon illumination, 11-cis-retinal changes to all-trans-retinal and 
is then reduced by retinal dehydrogenase (RDH) to form all-trans-retinol, at which 
point is transported back to the RPE via IRBP for recycling.  
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Figure 1.9 The Visual Cycle 
All-trans retinol enters the RPE from the choroid blood supply and becomes 
esterified by LRAT to form all-trans retinyl ester. It then undergoes hydrolysis and 
isomerisation by RPE65 to form 11-cis retinol. 11-cis retinol can then be oxidised 
by 11-cis dehydrogenase to become 11-cis retinal and can now enter the 
photoreceptor via IRBP where it is taken up by a vacant opsin forming 11-cis 
retinylidene. Upon illumination, a photon (hv) is absorbed by the opsin-
chromophore complex resulting in a conformational change, and converting the 
11-cis retinylidene to all-trans retinylidene and activating transducin, which 
initiates the phototransduction cascade. The chromophore is then released from 
the opsin by hydrolysis and is then reduced by RDH forming all-trans retinol which 
can then be transported back to the RPE via IRBP for recycling. 
 
This visual cycle between photoreceptor cells and the RPE is not the complete 
story as M- and L-cone opsin can be regenerated in isolated retina (Goldstein 
and Wolf, 1973). One possible mechanism is provided by Müller cell’s ability to 
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produce 11-cis-retinol (Das et al., 1992, Fleisch and Neuhauss, 2010). This may 
be necessary to compete with the high turnover of chromophore in cones. 
RPE65, the enzyme responsible for hydrolysing and isomerising all-trans retinal 
ester to 11-cis retinol (Jin et al., 2005, Moiseyev et al., 2005, Redmond et al., 
2005) has been reported in L- and M-cones but not in S-cones, rods nor Müller 
glia (Znoiko et al., 2002, Tang et al., 2011, Ma et al., 1998). Rods are very 
sensitive and can respond from absorbing just one photon (Baylor et al., 1979), 
while cones need a lot of chromophore activation to elicit a response (Ingram et 
al., 2016). It has been proposed that RPE65 acts as a retinoid binding protein to 
stabilise 11-cis retinol and shuttles it along the M- and L-cone outer-segments 
(Tang et al., 2011). 
It has also been discovered that rods, but not cones, can function without REP65 
in mice, albeit at higher luminosity (Seeliger et al., 2001). Rpe65-/- mice have a 
small but robust visual response in photopic conditions, which is now known to 
be rod generated. Comparing ERG or optokinetic responses shows that visual 
responses for rpe65-/- mice and rpe65-/-Cnga3-/- (also knocking out cone function), 
mice are comparable. While, also knocking out rod function (rpe65-/-rho-/-) 
resulted in no detectable response (Cachafeiro et al., 2010, Seeliger et al., 2001). 
The lack of RPE65 is thought to enable rods to respond under conditions that 
would normally bleach rods, due to the decreased sensitivity of rods with limited 
chromophore. It has been discovered through spectral absorbance that the visual 
pigment in rpe65-/- mice is isorhodopsin. This uses 9-cis retinal as it’s 
chromophore supported by 9-cis retinal found in dark-reared rpe65-/- mice. It was 
not possible to determine if these levels are also present in wild type (WT) mice 
reared under normal light dark cycles (Fan et al., 2003). 
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RPE65 
RPE65 is necessary for converting all-trans to 11-cis retinal, established through 
rpe65-/- mouse where 11-cis retinal was absent and all-trans retinyl-esters 
accumulated (Redmond et al., 1998). In rodents, rpe65 mRNA is first detected at 
E18, while protein levels become detectable at P4, this accumulates gradually 
until P12, when it reaches steady state levels (Manes et al., 1998). Rpe65 has a 
daily cyclic expression, with mRNA peaking at ZT14 (2 hours after lights off) in 
the chick retina (Bailey et al., 2004). In contrast to this, as rodents are nocturnal, 
the rat cyclic expression of rpe65 mRNA peaks at lights on (Beatrice et al., 2003). 
Mutations in rpe65 can result in many retinal degenerative diseases, such as 
retinitis pigmentosa and Leber’s congenital amaurosis (LCA) (Morimura et al., 
1998, Marlhens et al., 1997). 
LRAT 
LRAT is another enzyme in the visual cycle, which catalyses the esterification of 
all-trans retinol into all-trans retinyl ester. Mutations in LRAT are responsible for 
a small percentage of LCA cases (Sweeney et al., 2007). The phenotype of 
patients with mutations in LRAT is similar to that of patients with mutations in 
rpe65 (Fan et al., 2008, Senechal et al., 2006). 
RGR 
RPE-retinal G protein-coupled receptor (RGR) is an opsin which is a member of 
the rhodopsin-like receptor subfamily of GPCR. RGR is expressed in the RPE 
and Müller glia (Jiang et al., 1993). After all-trans-retinol is esterfied by LRAT to 
form all-trans-retinyl ester, it is either stored in lipid droplets or goes to a smaller 
isomerase pool to continue the visual cycle via RPE65. All-trans-retinyl esters in 
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the storage pool can be hydrolysed by all-trans-retinyl ester hydrolase to re-form 
all-trans-retinol and re-enter the visual cycle (Figure 1.10). In the dark, RGR 
contains all-trans-retinal (Hao and Fong, 1999) and inhibits all-trans-retinyl ester 
hydrolase and partially inhibits LRAT promoting all-trans-retinyl ester storage. 
Upon light exposure, all-trans-retinal is isomerised to 11-cis-retinal and RGR no 
longer inhibits all-trans-retinyl ester hydrolase or LRAT (Radu et al., 2008). Thus, 
all-trans-retinyl ester hydrolase can hydrolyse all-trans-retinal esters to all-trans-
retinol which then enters the visual cycle and is re-esterfied by LRAT to form all-
trans-retinal ester and converted by RPE65 to 11-cis-retinol. This is then 
subsequently oxidised by 11-cis-retinal dehydrogenase to form 11-cis-retinal 
which is taken up by photoreceptor opsins to detect light. RGR has also been 
associated with retinitis pigmentosa (Bernal et al., 2003, Morimura et al., 1999). 
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Figure 1.10 RGR is an opsin that controls the visual cycle. 
All-trans retinol is taken up by the RPE and becomes esterified by LRAT to form 
all-trans retinyl ester. This then either becomes hydrolysed and isomerised by 
RPE65 and continues with the visual cycle or it becomes stored in lipid droplets. 
In the dark, RGR is bound to all-trans retinal and strongly inhibits all-trans retinyl 
ester hydrolase (REH), which is needed to release all-trans retinyl ester from the 
storage pool. RGR-all-trans retinal also partially inhibits LRAT but promotes the 
storage of all-trans retinyl esters. Upon illumination (hv), RGR-all-trans retinal 
absorbs a photon which isomerises all-trans retinal to 11-cis retinal stopping the 
inhibitory action of RGR. This accelerates the hydrolysis and release of all-trans 
retinly esters from the storage pool by all-trans retinyl ester hydrolase to form all-
trans retinol. This is then re-esterfied by LRAT and released into a smaller pool 
which feeds into the visual cycle. 
IRBP 
IRBP, also known as retinal binding protein 3 (RBP3), is found in the inter-
photoreceptor matrix between outer-retinal photoreceptors and the RPE. It is a 
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large glycoprotein synthesised by photoreceptors. It transports 11-cis-retinal from 
the RPE to the outer-retinal photoreceptors for phototransduction and IRBP 
transports all-trans-retinol back to the RPE following photon absorption (Liou et 
al., 1982). IRBP is also important for fatty acid transport. 
 Intrinsically photoresponsive retinal ganglion cells (ipRGCs) 
IpRGCs are a subset of ganglion cells that are inner retinal photoreceptors 
(Berson et al., 2002), required for non-image forming vision in mice (Guler et al., 
2008). The opsin used by ipRGCs is melanopsin (opn4) (Panda et al., 2005, 
Provencio et al., 2000) and is found in about 2% of ganglion cells (Provencio et 
al., 2000, Hattar et al., 2002). In mice, the melanopsin system is functional from 
birth (Sekaran et al., 2005). Opn4 mRNA reaches peak expression in the retina 
in the early morning (ZT0-4) in chick (Chaurasia et al., 2005) and at early night 
(ZT14) in nocturnal rodents (Sakamoto et al., 2004). These ipRGCs also can be 
identified by the presence of neurotransmitter pituitary adenylate cyclase-
activating polypeptide (PACAP) (Hannibal et al., 2001) and vesicle glutamate 
transporter 2 (VGLUT2) (Purrier et al., 2014). All ipRGCs have intrinsic sustained 
melanopsin responses, but also extrinsic responses from the photoreceptors in 
the outer retina. This creates an initial rapid component of light-evoked inward 
current via inhibitory input from amacrine cells and excitatory input from bipolar 
cells (Zhao et al., 2014, Dacey et al., 2005, Schmidt et al., 2008, Weng et al., 
2013, Zhang et al., 2008). Thus, even in the absence of melanopsin, where 
ipRGCs lose their intrinsic photosensitivity, still innervate the correct brain regions 
and can convey rod and cone input (Lucas et al., 2003, Wong et al., 2007) to 
drive non-image forming visual functions (Lucas et al., 2003, Mrosovsky and 
Hattar, 2003). 
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 Subdivision of ipRGCs 
IpRGCs can be subdivided into five subtypes, M1, M2, M3, M4 and M5 (Figure 
1.11). M1 ipRGCs rely on intrinsic responses more than extrinsic (Schmidt and 
Kofuji, 2010). They have a lower threshold, higher amplitude, faster response 
than the 4 other subtypes, M2-M5. They are the only sub-type to stratify in the 
OFF sublamina of the IPL, which may mediate retrograde visual signalling (Zhang 
et al., 2012, Zhang et al., 2008). Around 1% M1 IpRGCs in mice are displaced in 
the INL (Hattar et al., 2002). M1 ipRGCs are not a uniform population but have at 
least 2 sub-populations defined by the presence or absence of POU transcription 
factor, Brn3b. All non-M1 ipRGCs express Brn3b. The first known function of 
ipRGCs was the entrainment of the circadian clock (Berson et al., 2002, 
Provencio et al., 2000, Lucas et al., 2003, Lupi et al., 1999). This is mostly by 
Brn3b-negative M1 ipRGCs, which make up 10% of all ipRGCs and project into 
the suprachiasmatic nucleus of the hypothalamus, the primary pacemaker in 
mammals (Baver et al., 2008, Chen et al., 2011). It is now known that some but 
not many Brn3b positive ipRGCs also innervate the SCN, although they are not 
necessary for fully functioning circadian photoentrainment (Chen et al., 2011). 
Brn3b-negative ipRGCs also have projections from the retina into the ciliary body 
in mice (Semo et al., 2014), this may mediate the intrinsic pupillary light reflex 
(iPLR). M2-M5 have centre-surround-organised receptive fields allowing spatial 
sensitivity (Zhao et al., 2014). They rely on extrinsic synaptic responses more 
than intrinsic (Schmidt and Kofuji, 2010).  Non-M1 ipRGCs have been shown to 
send axons to the lateral geniculate nucleus (LGN) where spatial and temporal 
information is sorted. This information is then sent to the visual cortex and to the 
superior colliculus which acts as the visual reflex centre (Brown et al., 2010, Ecker 
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et al., 2010) and the olivary pretectal nucleus, which control the PLR (Chen et al., 
2011). 
M2 cells have large dendritic arbores that branch in the ON sublayer. M3-5 
ipRGCs have much weaker melanopsin immunoreactivity (Berson et al., 2010). 
IpRGCs have also been reported to respond to a wide range of motion speeds, 
with M1-M4 classes having different motion speed sensitivity, allowing the 
detection of speed, but not motion direction (Zhao et al., 2014). It has also been 
demonstrated that melanopsin contributes to brightness discrimination (Brown et 
al., 2012) and M4 ipRGCs have been found to enhance contrast sensitivity in 
image forming vision (Schmidt et al., 2014, Allen et al., 2014). 
Topographically, the dorsal and temporal retina is most rich with ipRGCs in mice 
(Vugler et al., 2015). This is likely associated with the horizontal visual streak of 
high RCG-density just dorsal to the optic nerve (Ortin-Martinez et al., 2010, 
Salinas-Navarro et al., 2009). Rodents also have a melanopsin rich plexus in the 
ciliary marginal zone (CMZ) (Vugler et al., 2008b, Semo et al., 2014). In primates, 
ipRGCs increase in density towards the fovea and form a ring around it (Dacey 
et al., 2005).  
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Figure 1.11 ipRGC sub-populations. 
This Schematic diagram illustrates the different subtypes of ipRGCs and their 
projections. M1 ipRGCs stratify in the off sublamina. M2, M4 and M5 ipRGCs 
stratify in the on sublamina. M3 ipRGCs stratify in both on and off subliamina. M1 
have the smallest cell bodies and M4 have the largest cell bodies. M1 ipRGCs 
are subdivided into two populations based on the expression of Brn3b 
transcription factor. Brn3b+ M1 ipRGCs project to the shell of the OPN, which 
controls the PLR. Brn3b- M1 ipRGCs project to the SCN, to control circadian 
photoentrainment and, also, have been found to project into the ciliary body. Both 
Brn3b+ and Brn3b- M1 ipRGCs project to the intergeniculate leaflet (IGL) of the 
LGN. All non-M1 ipRGCs express Brn3b and project to image forming areas of 
the brain such as the LGN and the super colliculus (SC) and to the core of the 
OPN. A few Brn3b+ also project to the SCN. M2-M5 ipRGCs rely more on input 
from the outer retina than intrinsic responses. For simplicity, M1 ipRGCs which 
are displaced in the INL are not depicted in this diagram. 
 Pupil Light Reflex 
Melanopsin also contributes to the pupillary light reflex (PLR) by Brn3b-positive 
ipRGCs innervating the olivary pretectal nucleus (OPN) shell (Hattar et al., 2002, 
Morin et al., 2003, Hattar et al., 2003, Lucas et al., 2003, Chen et al., 2011, Baver 
et al., 2008, Guler et al., 2008, Lucas et al., 2001). They signal to the sphincter 
muscles of the iris via the OPN. The human pupil diameter can change from 7.9 
mm to 2 mm to protect the inner eye against bright light and relaxing to maximise 
the amount of light entering the eye. Cones bleach and compensate for high 
levels of light, this means that they do not communicate irradiance levels. 
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Melanopsin can communicate high irradiance levels much more accurately and 
is necessary for a complete PLR (Lucas et al., 2003). 
An intrinsic pathway also controls the PLR in rodents, bypassing the OPN. This 
was first seen in fish (Seliger, 1962) but also found in amphibians (Barr and 
Alpern, 1963), birds (Tu et al., 2004) and more recently reported in mice (Semo 
et al., 2014, Vugler et al., 2015, Xue et al., 2011). Melanopsin is required to drive 
the iPLR (Xue et al., 2011) and the iPLR is particularly sensitive following dark-
adaptation (Vugler et al., 2015). It has been shown that an intact CMZ is 
necessary for a complete iPLR response, as damage to the CMZ significantly 
reduces the iPLR in axotomized eyes (Semo et al., 2014). The iPLR cannot be 
generated by cones and is unaffected by cone loss, while rod function and 
pigmentation (non-albino) appear to be essential for normal iPLR development in 
mice (Vugler et al., 2015). Also, aged mice have a significantly reduced peak 
constriction compared to adults (Vugler et al., 2015).  
The iPLR develops progressively from P21-49 in mice (Vugler et al., 2015) much 
later than the PLR, which develops from P7-P10, concomitant with outer-retinal 
signalling (McNeill et al., 2011). This may be due to late maturation of Brn3b-
negative M1 ipRGCs, which innervate the ciliary body, as it is known that these 
Brn3b-negative M1 ipRGCs mature their projections into the SCN around P21 
(McNeill et al., 2011). 
 Does Melanopsin require the visual cycle? 
Melanopsin requires chromophore 
Melanopsin also uses 11-cis retinal to capture light energy and converts the 11-
cis retinal to all-trans retinal. This is supported by the action spectrum of ipRGCs 
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fitting to the absorption spectrum of a vitamin A-based photopigment with a peak 
absorbance (λmax) around 480nm (Berson et al., 2002, Lucas et al., 2001). Also, 
mice with an inhibited visual cycle have attenuated melanopsin functions (Doyle 
et al., 2006). In ipRGCs, light causes a depolarisation and an increase of 
intracellular calcium, (Hartwick et al., 2007) similar to rhabdomeric 
photoreceptors found in invertebrates. It is not clear how ipRGCs get 11-cis 
retinal as they are located in the inner retina and are separated by several layers 
of cells from the RPE in the outer retina, the classic site of 11-cis retinal 
isomerisation. Perhaps, 11-cis retinal diffuses through the retina. Another 
possibility is that Müller cells, which have been recognised to play a role in opsin 
recycling for cones (Wang and Kefalov, 2011), regenerate chromophore and/or 
transport chromophore to the inner retina. It has been reported that Müller cells 
are closely associated with ipRGCs but not non-melanopsin ganglion cells (Viney 
et al., 2007). 
Melanopsin can act as a bi-stable pigment 
Melanopsin has also been reported to work as a bi-stable pigment. It has 
photoisomerase capacity generating 11-cis retinaldehyde from all-trans 
retinaldehyde upon exposure to long wavelength light (Melyan et al., 2005, Fu et 
al., 2005). This intrinsic photoisomerisation is also seen in many invertebrate 
rhabdomeric photopigments. Phylogenically, melanopsin shows more kinship to 
invertebrate pigment, some of which are bistable, than to rod and cone pigments 
(Provencio et al., 1998). Another potential source of chromophore is 9-cis-retinal. 
In the absence of 11-cis-retinal, it has been shown that rods can use 
isorhodopsin, with the chromophore 9-cis-retinal, in the absence of the visual 
cycle (Fan et al., 2003). Hence, this is a candidate for chromophore in ipRGCs. 
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But, 9-cis retinal is produced at a much slower rate than 11-cis retinal in a normal 
retina and is unlikely to be produced in sufficient quantities to support a fully 
functioning melanopsin system. Furthermore, 9-cis retinal production may be a 
result of build-up of all-trans retinyl esters in retinas lacking visual cycle enzymes, 
which does not occur in wild-type retina (Imanishi et al., 2004). 
Effects of the visual cycle on melanopsin 
It is known that rpe65-/- mice have attenuated phase shifting responses (Doyle et 
al., 2006) and mice with rpe65-/- or lrat-/- have a less sensitive PLR than WT (Tu 
et al., 2006). The rpe65-/- and lrat-/- mice have a PLR less sensitive than that of 
an rdta or rd1 mice (Tu et al., 2006). Rdta mice express the gene for an 
attenuated diphtheria toxin under the control of a portion of the rhodopsin 
promotor. This eliminates the majority of the ONL by P7, which corresponds 
closely to the onset rhodopsin expression at P5 in the mouse retina (McCall et 
al., 1996). rd1 mice have a mutation in Pde6B needed for phototransduction and 
see loss of photoreceptors by 1 month (Bowes et al., 1990, Pittler and Baehr, 
1991). Rdta mice, with selective deletion of rods exhibited an increased 
magnitude of circadian phase shift compared to WT controls and displayed tonic 
activation of RGCs (Lupi et al., 1999). Furthermore, selectively knocking out rods 
along with visual cycle (rpe65-/-:rdta or lrat-/-:rd1) improves circadian 
photosensitivity and knocking out rods and rpe65 or lrat improves the PLR 
compared to rpe65-/- or lrat-/- alone (Tu et al., 2006), perhaps freeing up some 
chromophore, which otherwise would be taken up by rods. This is supported by 
Doyle et al., which showed that selectively eliminating rods in an rpe65-/-, via rdta 
transgene, can restore circadian photosensitivity and knocking out opn4 and 
rpe65 results in a loss of photoentrainment (Doyle et al., 2006).  
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Rods and cones may influence melanopsin expression in ipRGCs. Royal college 
of surgeons (RCS) dystrophic rat retina has a significant (>90%) reduction of 
melanopsin mRNA and protein levels. This model has a mutation in MerTK, 
resulting in loss of phagocytosis of rod and cone outer-segments and melanopsin 
expression starts to fall after P21, following photoreceptor degeneration 
(Sakamoto et al., 2004). Perhaps the loss of melanopsin expression in the RCS 
dystrophic rat is due to the lack of chromophore being recycled and the 
separation of the RPE from the neural retina by the debris zone of 
unphagocytosed POS tips. IpRGCs are capable of phototransduction in new born 
mice, prior to rod and cone function which occurs after P10 (Hannibal and 
Fahrenkrug, 2004, Sekaran et al., 2005) so ipRGCs may not need rod and cone 
function at this stage of development. 
The melanopsin system is often not considered when assessing visual function 
in retinal degeneration, even though, it has the clear potential to provide 
additional readouts on retinal and RPE function. In this thesis, I will employ 
functional readouts of both outer-retinal function and inner retinal function to 
assess improvements by RPE cell replacement. 
 The iris 
 Function of the iris 
The iris is responsible for controlling the size of the pupil and thus, the amount of 
light entering the retina. In darkness, the pupil dilates, to allow more light to be 
captured, while, in bright light, the pupil constricts to help reduce the brightness 
to an optimal level. Additionally, excessive sun exposure can cause irreversible 
retinal damage (Glickman, 2011). The other effect of the pupil is to control depth 
 60 
 
of field, which is the distance from nearest to the farthest objects that appear 
focused. A constricted pupil increases the degrees of freedom, as light does not 
hit the outside of the lens, reducing the spherical aberration. A dilated pupil allows 
light to enter the eye at the outer lens, which results in increased refraction, and 
thus, a loss of focus. 
 Structure of the iris 
The front of the iris is a pigmented fibrovascular tissue known as the stroma and 
behind this are 2 layers of pigmented epithelial cells. The high levels of pigment 
prevent light passing through the iris. Iris colour is due to variable amounts of 
eumelanin (brown) and pheomelanin (red/yellow) pigments. The outer edge of 
the iris, known as the root, is attached to the sclera and anterior ciliary body. Two 
different muscles are responsible for the constriction and dilation of the pupil, the 
sphincter and dilator muscles, respectively (Figure 1.12). 
 Dilator muscles 
Dilator muscles runs radially in the iris and contracts to dilate the pupil (Figure 
1.12). Myoepithial cells of the dilator muscles are stimulated by the sympathetic 
nervous system. Thus, when the fight or flight response is activated, the pupil 
dilates, temporarily allowing more light to enter the retina. 
 Sphincter muscle 
The sphincter muscle lies on the inside of the iris and contracts in a circular 
motion, causing the pupil to constrict (Figure 1.12). It is innervated by the 
parasympathetic fibres.  
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Figure 1.12 The muscles in the iris 
The stroma lies at the front of the iris and the posterior consists of pigmented 
epithelial cells. Two muscles control the constriction and dilation of the iris. The 
dilator is radial and is the outer muscle. It constricts with sympathetic stimulation, 
causing the pupil to enlarge. The sphincter muscle lies on the inside of the iris 
circulating the pupil. It constricts with parasympathetic stimulation, reducing the 
size of the pupil. 
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 Bruch’s membrane 
Bruch’s membrane lies between the RPE and the choroid. It consists of five 
layers: the basement membrane of the RPE, the inner collagenous zone, elastic 
fibre layer, outer collagenous zone and the basement membrane of the 
choriocapillaris. The elasticity of Bruch’s membrane accommodates changes in 
intraocular pressure and changes in choroidal blood volume. The thickness of 
Bruch’s membrane increases with age from 2 to 4.7 microns (Ramrattan et al., 
1994). 
 Blood supply to the eye 
The ophthalmic artery branches off the carotid artery and supplies blood to the 
eye. This then branches into the central retinal artery, the short and long posterior 
ciliary arteries and the anterior ciliary arteries. The retina is supplied by the central 
retinal artery and the short posterior ciliary artery. The central retinal artery enters 
the retina at the optic nerve and branches to supply the layers of the retina (Figure 
1.13). Humans have an avascular zone at the fovea as veins branch around this 
region. Rodents, which do not have a fovea have a radial branching of the retinal 
vasculature. Retinal veins coalesce into the central vein which exits the eye at 
the optic nerve. 
The short posterior ciliary arteries pierce the sclera around the optic nerve and 
then arborize to form the arteries of the choroid, which supply lobules of the 
choriocapillaries which lie under Bruch’s membrane. These then drain into 
venules which coalesce into one of the vortex veins that pierce the sclera at the 
equator of the eye (Figure 1.13). 
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The vortex veins and central vein merge with the superior and inferior ophthalmic 
vein, this is connected to the cavernous sinus, the pterygoid venous plexus and 
the facial vein. In rodents, the orbital veins form a sinus behind the eye. 
The iris and the ciliary body is supplied by the anterior ciliary arteries, the long 
posterior ciliary arteries and connections to the anterior choroid. The anterior 
ciliary arteries travel along the extraocular muscles and pierce the sclera near the 
limbus and feeds an arterial circle in the iris. The long posterior ciliary arteries 
pierce the sclera at posterior of the eye and travel between the sclera and the 
choroid and then join the arterial circle of the iris. The arterial circle then further 
branches into the iris and ciliary body. Venous draining is directed anteriorly into 
the choroid. 
 
Figure 1.13 Blood supply of the eye 
The ophthalmic artery branches into the central retinal artery, the long posterior 
arteries and the short posterior arteries. The central retinal artery enters the retina 
at the optic nerve and then branches in the retina. Veins in the retina coalesce 
and exit the eye at the optic nerve as the central retinal vein. The short posterior 
ciliary arteries pierce the sclera around the optic nerve and feed the choroid. 
Choroidal veins drain at the equator of the eye as the vortex veins, which merge 
to form the superior and the inferior ophthalmic vein. The iris is fed by the long 
posterior arteries and the anterior ciliary arteries. The long posterior artery pierces 
the sclera at the back of the eye and travels between the sclera and the choroid 
and feed the arterial circle in the iris. The anterior ciliary arteries travel along the 
extraocular muscles and pierce the sclera near the limbus. 
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 RPE transplantation for the treatments of retinal degenerative 
diseases 
With such a strong dependence on the RPE for photoreceptor function it is 
unsurprising that many diseases, resulting in photoreceptor degeneration, are 
primarily diseases of the RPE. Also, many genes involved in the visual cycle can 
result in blindness. For example, mutations in rpe65 or RDH cause LCA, and 
mutations in lrat can cause juvenile retinitis pigmentosa, both resulting in early 
on-set blindness. Additionally, with LCA alone, there are 12 genes, including 
rpe65, associated with forms of LCA (http://www.sph.uth.tmc.edu/Retnet). With 
numerous genes which can result in either recessive or dominant RPE diseases, 
developing a single therapy that can address each individual case is an appealing 
approach. Replacing patient RPE cells with gene corrected RPE cells is a 
possible therapy for correcting all RPE genetic diseases. 
Unfortunately, the large degree of genetic heterogeneity raises significant 
problems with developing new treatments. The frequency of LCA occurrence is 
around 1:80,000 (Stone, 2007), therefore, each of the 12 identified genes 
correspond to a relatively small number of affected patients, thus, techniques 
which are broadly applicable, and, to some extent mutation-independent, may be 
much more feasible in treating large numbers of patients. For some diseases, 
such as dry age-related macular degeneration (AMD), there are many genes 
associated with the development of this disease but no single mutation will 
directly result in the development of AMD. Thus, genetic therapy may not be a 
suitable approach and there are no current treatments available to those with dry 
AMD (90% AMD patients). Replacement of cells using a regenerative medicine 
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approach to produce replacement RPE cells from stem cells may be the only 
option, and this is currently being validated for efficacy (Schwartz et al., 2012). 
 AMD 
AMD is the leading cause of blindness in the developed world and is recognised 
as a disease of the RPE. Degeneration of RPE cells is a fundamental element in 
AMD, which also affects the choroid and Bruch’s membrane. The exact cause 
and pathology of AMD is not fully understood. There are many genetic and 
environmental factors that contribute to the risk and severity of the disease. It is 
believed that, lipofuscin, a by-product of phagocytosis of rod and cone outer-
segments, accumulates with age to form drusen deposits between RPE cells and 
Bruch’s membrane. Lipids also accumulate in Bruch’s membrane, resulting in 
thickening of the membrane, exacerbated by dysregulation of the complement 
system. AMD results in the loss of RPE cells, which lead to rod and cone death 
(Jackson et al., 2002). This advances in 10-15% of patients to wet AMD, where 
leaky blood vessels proliferate into the retina, from choroidal neovascularisation 
(Klein et al., 1997). Monthly injections of anti-vascular endothelial growth factor 
has become the standard treatment for preventing blood vessel growth, but, there 
is no current standard treatment for RPE cell death and the resulting 
photoreceptor loss (Del Priore et al., 2006). It is hoped that stem cells could 
provide a potential therapy by replacing RPE cells (Vugler et al., 2007a). 
Replacement of RPE cells using stem cells is currently being validated as a 
suitable treatment for AMD (Schwartz et al., 2012, Carr et al., 2013, Nommiste et 
al., 2017, Kamao et al., 2014, Reardon and Cyranoski, 2014), with positive results 
seen in patients in initial trials (da Cruz et al., 2018). 
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 Immune environment of the eye 
The eye has a unique environment which aids the prolonged survival of 
incompatible grafts (Medawar, 1948). This is because the eye is immune 
privileged. It has a tightly controlled BRB, which prevents cellular migration from 
the blood. Immune privilege means that the introduction of foreign antigens are 
more readily tolerated and less likely to elicit an inflammatory response. Medawar 
and colleagues showed that skin allografts transplanted to the anterior chamber 
survive without rejection even when the recipient is previously immunized against 
the alloantigens. This immune privilege is only maintained while the BRB is intact 
(Medawar, 1948). The BRB is supported by tight junctions in RPE cells and inner 
retinal vessels. 
This does not mean that the eye is void of immune cells as the eye has resident 
macrophage-like microglia, similar to those in the brain (Ajami et al., 2007, Albini 
et al., 2005, Ginhoux et al., 2010, Paques et al., 2010). The BRB allows the eye 
to form a microenvironment which supresses inflammation and promotes immune 
tolerance. Soluble factor in the aqueous humour (Goslings et al., 1998, Taylor et 
al., 1992, Taylor et al., 1994, Taylor and Yee, 2003, Taylor et al., 1998) and on 
pigmented epithelium (Ishida et al., 2003, Kawazoe et al., 2012, Sugita et al., 
2006, Sugita et al., 2009, Wenkel and Streilein, 2000, Jorgensen et al., 1998) 
regulate this anti-inflammatory environment. Differences in immune privilege 
exist within the eye. It has been shown that injection of an adeno-associated viral 
(AAV) vector into the vitreous, resulting in vector expression in the inner retina, 
produced a humoral immune response against the AAV capsid. This prevented 
the vector expression when re-administered into the vitreous of the partner eye. 
In contrast to this, when the vector was re-administered into the subretinal space 
of the partner eye, vector expression was not affected by the first injection. 
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Alternatively, administering the first injection into the subretinal space did not 
produce a rise in anti-AAV antibodies in the serum and did not inhibit vector 
expression when re-administered either intravitreally or subretinally in to the 
partner eye (Li et al., 2008, Li et al., 2009). 
Survival of RPE cell allografts in the dystrophic RCS rat has been seen up to 12 
months without immunosuppression (Li and Turner, 1991). Donor RPE cells 
came from Long-Evan rats and could sustain the ONL for 6 months before a 
gradual decline in ONL thickness, but, this gradual loss of ONL matched that 
seen in healthy Sprague-Dawley rats (Li and Turner, 1991). Matching of major 
histocompatibility complexes (MHC) has been shown to be important in RPE cell 
allograft survival (Zhang and Bok, 1998). Immunosuppressants are administered 
to help prevent rejection in xenografted RPE cells. Spontaneously immortalised 
human RPE cell line ARPE19 transplanted into immunosuppressed RCS rats 
showed surviving ONL and visual function beyond 6 months (Coffey et al., 2002). 
Preservation of retinal function and ONL is seen in many studies, albeit, often 
only a small percentage of cells survive (Wang et al., 2005). 
 Potential sources of replacement RPE cells 
The eye is an ideal testing ground for stem cell therapies, since it exhibits relative 
immune privilege (Grisanti et al., 1997) and it is readily accessible for monitoring 
and imaging purposes. RPE cells are also the most ideal retinal cell for 
replacement as unlike retinal neurons they do not require synaptic reconnection 
and can be easily grown as a monolayer of cells for transplantation. RPE cell 
transplant studies were first reported in the 1980s, showing that dissociated RPE 
cells could attach to Bruch’s membrane in primate retina (Gouras et al., 1985) 
and that they could prevent photoreceptor degeneration in the RCS rat (Li and 
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Turner, 1988). 
Stem cells provide a means of regenerative medicine by replacing damaged or 
lost tissue. Stem cells are undifferentiated cells, which have the capability of 
reproducing by mitosis, to produce more stem cells, and are able to differentiate 
into a specialised cell. There are many sources of stem cells. Some are found in 
the adult body such as haematopoietic stem cells (HSCs). HSCs are extracted 
from healthy bone marrow and used to reconstitute the immune system after 
leukaemia, lymphoma, various blood or autoimmune disorders and have been 
used in transplants for over 40 years. Unfortunately, these adult stem cells are 
limited in population and their capacity to differentiate. They are multipotent; 
meaning they can only differentiate into a small number of similarly specified 
cells. 
Human embryonic stem cells 
Human embryonic stem cells (hESC) are stem cells derived from the inner cell 
mass of a blastocyst, an early-stage embryo (5 days post fertilisation). These 
cells are pluripotent and as such, can develop into any cell type in the body 
(Thomson et al., 1998) bar the sex cells. They are also renewable, such that stem 
cells derived from one blastocyst can produce cells to treat many patients, while 
avoiding any genetic defects inherited in autologous RPE cells. HESC-RPE cells’ 
shape and organisation are almost identical to that of human macular RPE cells 
(Vugler et al., 2008a). Unfortunately, hESC are associated with ethical 
controversy and although they may suffer rejection from the host, when 
administered with an immunosuppressant hESC-RPE cells have survived 
subretinally in RCS rats for more than 7 months (Lu et al., 2009). 
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Induced pluripotent stem cells 
One way of overcoming rejection is by using induced pluripotent stem cells 
(iPSC), as these can be autologous. These cells can be formed from somatic 
cells from the patient or from a relative, treated with a cocktail of transcription 
factors to re-program the cells to a pluripotent state (Takahashi and Yamanaka, 
2006). These can then be differentiated to form the cell type of interest. 
Unfortunately, as RPE cells derived from iPSC are patient specific, time to 
prepare the cells will be a factor, whereas, hESC-RPE cells can be available as 
needed. iPSC-derived RPE (iPSC-RPE) cells are also likely to incur more costs 
as there are more steps involved and each RPE cell preparation is developed for 
the individual patient. 
ARPE-19 cell line 
Another source of RPE cells is ARPE-19, a spontaneously immortalised human 
adult RPE cell line. They were once thought to be a viable source of cells for 
therapy with less ethical issues associated compared to hESC, but, they may 
pose a greater risk of rejection following transplantation.  This cell line is a 
valuable source of RPE cells for studying and transplantations of RPE cells 
(Wang et al., 2005, Coffey et al., 2002).  
The feasibility of this has been demonstrated by autologous transplantation of 
RPE cells and choroid from periphery to macula (van Meurs and Van Den Biesen, 
2003, da Cruz et al., 2007). This has paved the way for clinical trials. The first of 
which is using human embryonic stem cells (hESC) in suspension injected 
subretinally in AMD and Stargardt’s disease patients (Schwartz et al., 2012, 
Schwartz et al., 2015). The London Project are also carrying out a clinical trial 
where RPE cells are transplanted in a monolayer on a polyester membrane and 
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have treated two patients to date (Carr et al., 2013, Nommiste et al., 2017, da 
Cruz et al., 2018). RPE cells derived from iPSC are also being tested in a clinical 
trial (Kamao et al., 2014, Reardon and Cyranoski, 2014). 
 How to culture RPE cells 
There are many protocols for producing cells with an RPE-like phenotype. These 
protocols have been developed through trial and error. These protocols also 
change depending on the cell source. In general, ARPE-19, hESC and iPS cells 
have a fibroblast shape. When they are first plated they will multiply fast. The 
addition of serum, amino acids and growth factors ensures this. The incubation 
temperature is controlled at 37°C and the CO2 is maintained at 5%, mimicking 
that of mammalian blood. Once the dish is confluent or covered with new cells, 
growth factors are removed to help the cells to develop and the fibroblast 
phenotype is lost. Growing stem cells on a plate often see the spontaneous 
growth of patches of pigmented cells. These are then isolated to create a pure 
pigmented dish with RPE characteristics. Once this new dish is confluent the 
serum levels are reduced. The medium that these cells are developed in is rich 
in nutrients for cells with a high energy demand, such as L-glutamine and amino 
acids. 
 Disease models for testing the function of transplanted RPE stem cells 
To date, the majority of RPE transplant studies have been carried out on the RCS 
rat, a model of retinal dystrophy with progressive and early photoreceptor loss 
(Dowling and Sidman, 1962). The RCS rat has a mutation in mertk. Mer tyrosine 
kinase is a transmembrane protein involved in the phagocytosis of POS. 
Phagocytosis of POS by RPE follows a daily rhythm with a peak of activity 1.5-2 
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h after light onset for rod photoreceptors (LaVail, 1980). Mutations in mertk are 
associated with autosomal recessive retinitis pigmentosa (Ksantini et al., 2012, 
Wang et al., 2001). The mutation in RCS rats result in failure to phagocytose shed 
POS (Edwards and Szamier, 1977, D'Cruz et al., 2000). This results in 
accumulation of shed POS, creating a debris zone between photoreceptors and 
RPE. This separation of RPE from the neural retina results in fast photoreceptor 
degeneration (D'Cruz et al., 2000).  From P21 the ONL is reduced to 2 rows of 
cells and only 1 row at 4 months (Girman et al., 2005). At P60 opsin mRNA is 
undetectable (Agarwal et al., 1992). 
This model of retinal degeneration was discovered almost 80 years ago, and it is 
a well-studied model. Yet, the RCS rat is a less than ideal model for studying the 
effects of RPE transplantation due to the early onset and fast rod and cone 
degeneration, making visual rescue difficult. The death of RGCs in the RCS rat 
is also quite extensive and to date transplantation has failed to prevent RGC 
pathology (Klassen et al., 2001), and RGC stability is an important consideration 
when attempting to restore vision. Photoreceptor preservation in RCS rats and 
improvements in the visual function of these animals can be achieved by an array 
of cells, including hESC-RPE (Idelson et al., 2009, Zhu et al., 2013), iPSC-RPE 
(Carr et al., 2009, Krohne et al., 2012), human RPE (Little et al., 1996), rat RPE 
(Jiang and Hamasaki, 1994), ARPE-19 cells (Coffey et al., 2002), but also, neural 
progenitors (Wang et al., 2008) and Schwann cells (Lawrence et al., 2000). Thus, 
identifying RPE-specific therapeutic effects is complicated as many studies show 
photoreceptor survival are likely due to trophic effects. This is supported by areas 
of photoreceptor rescue larger than the graft of hRPE (Wang et al., 2005), 
suggesting the diffusion of trophic factors is responsible for cell survival. 
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Despite these drawbacks of using the RCS rat model to examine the therapeutic 
effects of RPE transplantation, it is still widely used as a pre-clinical efficacy 
model in the development of cellular therapies for retinal degenerations including 
AMD. AMD is a complicated disease to model and so far, no animal model which 
fully recapitulates the human macular disease has been identified. AMD has a 
very late onset, complex genetics and environmental risk factors. Fortunately, 
there are new models of retinal degeneration with a slower degeneration, which 
may prove more useful in studying the therapeutic effects of RPE transplantation, 
such as the rd12 mouse. 
 Rd12: A model of LCA2 
 Identification of the rd12 mouse 
To study a disease in depth and to develop and investigate the efficacy of 
therapies it is useful to have a reliable model of the disease. In 2005, a naturally 
occurring mouse model of LCA 2 was discovered (Pang et al., 2005), which has 
a mutation in rpe65, also seen in LCA2 patients (refSNP cluster report: 
rs368088025), making it a clinically relevant model. LCA2 is characterised by 
early onset of central vision loss, sensory nystagmus, amaurotic pupils and 
absent signals on ERG. It is one of the earliest and severe forms of inherited 
retinal dystrophies. In these mice, retinal degeneration is caused by a naturally 
occurring nonsense mutation in exon 3 of rpe65. A substitution of a single 
cytosine nucleotide to thymine results in a premature stop codon at position 44 
(Pang et al., 2005). Aminoglycosides were administered to rd12 mice as a 
readthrough therapy. This allows the translation of mRNA to bypass a premature 
stop codon, to produce a full protein. Despite this, the rd12 did not respond to this 
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therapy (Guerin et al., 2008) and it is now understood rpe65 mRNA fails to bind 
to ribosomes to initiate translation in rd12 mice. The mRNA is appropriately 
spliced and is exported to the cytoplasm and is bound to ribosome free 
messenger ribonucleoproteins but is not associated with translating 
polyribosomes (Wright et al., 2014). Thus, the mRNA does not undergo non-
sense mediated decay. The rd12 mice were repeatedly backcrossed to a WT, 
C57BL/6J, to make a congenic inbred strain and C57BL/6J are used as a WT 
control when assessing rd12 mice (Pang et al., 2005). The rd12 mouse has a 
very similar phenotype to rpe65-/- mice. Although, rd12 mice develop distinctive 
white dots throughout the retina that become apparent at around 5 months of 
age, similar to those seem in LCA2 patients (Pang et al., 2005), which are not 
found in rpe65-/- mice. This characteristic of rd12 mice makes it a better model for 
human LCA2, as they are more likely to simulate the actual disease mechanism. 
 Pathology 
The first sign of the rd12 morphology is seen at 3 weeks when lipid-like droplets 
are found in the RPE. At 6 weeks, occasional voids start to appear in the POS 
and by 3 months these voids become obvious, and much larger lipid-like droplets 
appear (Pang et al., 2005). Small punctuate white spots on fundus examination 
appear at 5 months of age, similar to those seen in human LCA. By 7 months, 
the ONL is reduced by 40%, with only 6-7 layers of cells remaining and the POS 
are obviously shorter (Pang et al., 2005, Wright et al., 2014). After 2 years, the 
POS are almost absent and the ONL reduced to just 3-4 layers of cells. At this 
stage, RPE cells are atrophied and hypopigmented (Pang et al., 2005). 
Cones are lost early in the rd12 mouse; by P21, PNA-lectin positive cone count 
is reduced to 55% that of WT, though, cones lose opsin before cone death (Li et 
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al., 2011), so surviving cones may no longer be functional. By P90 PNA-positive 
cone counts are reduced to 16% of WT, and only 15% of these express M/L-
opsin while there is no S-opsin. Regionally, cones are first lost from the central 
and ventral-nasal region of the retina, where S-cones are most highly populated, 
and survive longer in the dorsal-temporal region (Li et al., 2011). RPE65 in WT 
rat development reaches its peak and steady state expression around P10-P12. 
This coincides with peak opsin expression in rat and mouse (Bowes et al., 1988, 
Manes et al., 1998, Hamel et al., 1993) and development of the ERG (Bakall et 
al., 2003). This could help explain the initiation of dramatic cone loss after P14, 
when cones are more demanding for chromophore, while at P14 PNA-positive 
cone counts are similar to WT (Li et al., 2011). 
As early as 3 weeks, the scotopic ERG starts to diminish in rd12 mice. The 
photopic ERG responses are significantly more robust, although amplitudes 
under both dark- and light-adapted conditions decrease with age (Pang et al., 
2005, Pang et al., 2006). Although the photopic ERG responses are more robust, 
it is known that this is rod driven (Seeliger et al., 2001, Cachafeiro et al., 2010, 
Dai et al., 2015). The lack of RPE65 in rd12 mice allows rods to function at 
brighter light intensities without bleaching. More evidence to suggest that the 
remaining visual signal is rod driven, comes from work showing that rd12 mice 
respond to visually evoked potentials at low temporal frequencies whilst 
responses to high frequency stimuli spatially and temporally are lost as early as 
P18 (Nusinowitz et al., 2006). In the rpe65-/- mouse it was shown that the likely 
candidate for the visual pigment used in the residual rods is isorhodopsin, created 
with 9-cis-retinal, perhaps as a result of the excess retinyl esters (Fan et al., 
2003).  
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Positive masking is an increase in activity in response to dim light. This is usually 
seen in nocturnal rodents, but, rd12 mice do not have this positive masking 
response. The visual system in rd12 mice are not sensitive enough to react to a 
dim light. Negative masking is a suppression of activity in bright light, seen in WT 
mice. Rd12 mice actually have increased activity in bright lights. Rd1 mice have 
no outer-retinal-derived visual function and still have a negative masking affect 
(Mrosovsky et al., 1999, Thompson et al., 2008). Thus, it is not just rod and cone 
function that determines negative masking. IpRGCs can maintain negative 
masking in the absence of outer-retinal photoreception, thus, ipRGCs are also 
affected by the loss of the visual cycle, in rd12 mice (Thompson et al., 2008). It 
has been shown that rpe65-/- mice have a shifted circadian behaviour, 
commencing nightly activity about 2 hours before WT (Doyle et al., 2006). 
However, when illumination was increased, rpe65-/- mice were able to phase shift, 
suggesting that entrainment is possible at high light intensities (Doyle et al., 
2006). 
 Treating the rd12 disease 
Many studies show that early intervention in the rd12 animal has the most hope 
for a significant retinal rescue, as there is very early cone loss (Nusinowitz et al., 
2006, Li et al., 2011, Pang et al., 2010). Pang et al initiated gene therapy at P14 
with a rAAV5-CBA-hRPE65 vector, which resulted in RPE65 expression over 
large areas of the RPE. Rhodopsin levels, measured by spectral absorbance, 
rose to 70% WT level and ERG signals to approximately 66% of normal when 
assayed at 7-months of age (Pang et al., 2006). Treatment with gene therapy has 
been shown to keep remaining cones alive and to rescue opsin expression in 
these cones (Li et al., 2011). In animal models of RPE65 deficiency, rods undergo 
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a slow progressive degeneration, which is why restoration of rod vision appears 
to be possible over a broad range of ages.  
The rd12 mouse is an under-utilised animal for cellular transplants. Chaudhry et 
al injected ESC and ESC-derived neuroprogenitors into the rd12 mouse. The 
undifferentiated ESC proliferation was robust and resulted in the disruption of the 
retinal structure and the formation of teratomas beyond 6 weeks of post-
implantation. However, the neuroprogenitors proliferated slowly and 
differentiated and integrated further, although, more neuroprogenitor cells 
integrated into the neural retina than the RPE. This may be due to early loss of 
photoreceptors (Chaudhry et al., 2009). Li et al injected iPSC-RPE cells 
subretinally into 2-day old albino rd12 and showed the presence of pigment in the 
RPE at 5 months although it cannot be determined if these are viable transplanted 
cells, or pigment from the transplants phagocytosed by host RPE. iPSC-RPE 
cells were also injected into rd12 mice crossed with Prkdcscid/Prkdcscid mice for a 
double homozygous with both severe combined immunodeficiency (SCID) and 
rpe65 mutation. While increased b-wave amplitude was seen, the a-wave was 
still absent (Li et al., 2012b).  
Most single nucleotide polymorphisms (SNPs) identified in the human rpe65 gene 
are autosomal recessive mutations (Gu et al., 1997, Hanein et al., 2004, Philp et 
al., 2009, Stone, 2007). Thus naturally, the rd12 mutation was first thought to be 
recessive. However, it was shown to have semi-dominant characteristics (Wright 
et al., 2014). Mice with the rd12 mutation lose all visual acuity measured by 
optokinetic tracking by P90, which is a quicker decline than an rpe65-/- mouse, 
which still has visual acuity until P120. A mouse with one copy of the rd12 allele 
will have slight reductions in the a- and b-wave and some cone loss (Wright et 
al., 2014). Also, rpe65-/- mice do not exhibit the small white dots observed in the 
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retinal fundus of the rd12 mouse and seen in LCA2 patients (Pang et al., 2005). 
Thus, the rd12 mouse is a much closer model to LCA2 in humans, than rpe65-/- 
mice, which will be useful in studying the disease and the ability to treat the 
disease. Also, even though rd12 is a model of LCA, stem cell work on this model 
can be translated to many other forms of retinopathy, such as testing RPE cell 
transplantation for application in age-related macular degeneration. While the 
rd12 mouse is not a model of AMD, it has many advantageous characteristics for 
studying RPE cell replacement therapies, such as a slow rod degeneration and 
a visual cycle specific disease. 
 The benefit of using the rd12 mouse over other rd models 
The rd1 mouse was the first inherited mouse model of retinal degeneration. It has 
a non-sense mutation in the gene encoding the beta subunit of rod cGMP-
phosphodiesterase, Pde6b (Bowes et al., 1990). Pde6B is needed for 
phototransduction, to hydrolyse cGMP on rods and hence, close cGMP-gated 
channels. This mutation results in rod degeneration from P8 until 4 weeks when 
there are no surviving photoreceptors (Bowes et al., 1990, Pittler and Baehr, 
1991). The rd10 mouse also has a mutation in Pde6b, however, this is a missense 
mutation and while it has rapid degeneration of the photoreceptors, its retinal 
degeneration is milder than that of the rd1 (Chang et al., 2007, Rivas and Vecino, 
2009). While the young rd10 retina has better function than the rd12 retina, it has 
a much more aggressive degeneration (Hasegawa et al., 2016). 
The rd2 mouse, first known as rd slow or rds, has a mutation in the gene for 
peripherin 2, Prph2. It is a transmembrane glycoprotein found in rod and cone 
outer-segments. It is thought that peripherin 2 works as an adhesion molecule in 
the stabilization of outer-segment disks and maintaining the curvature of the disk 
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rim. ONL starts degenerating at 2 weeks and by 12 months there is no ONL cells 
(Sanyal et al., 1980). 
The mutation in rd3 is not yet known, although, it is important for stable 
expression of guanylate cyclase in photoreceptors (Dizhoor et al., 2016) and the 
mutation causes LCA12. It has a much faster retinal degeneration than rd12 
(Chang, 2016). ERG is lost by 7 weeks (Chang et al., 1993). 
The rd4 mutation is autosomal dominant, which is homozygous lethal. The ONL 
is lost by 6 weeks in the heterozygotes. At 4 weeks there is retinal vessel 
attenuation, pigment spots and optic atrophy in the fundus (Roderick et al., 1997). 
The mutation occurs in Gnb1, the gene encoding transducin beta1-subunit, 
necessary for phototransduction (Kitamura et al., 2006). 
The homozygous rd5 mouse is a model of Usher syndrome type I. The mutation 
is not yet known. By 5 weeks the POS look disorganised and start to degenerate. 
By 8 months the ONL is lost (Heckenlively et al., 1995). 
The autosomal recessive rd6 mutation sees macrophage appear in the subretinal 
space around 8 weeks and with time show to contain lipofuscin and pigment. An 
abnormal ERG is detected around 1 month and photoreceptors slowly 
degenerate (Hawes et al., 2000). The mutation occurs in the Mfrp gene which 
encodes membrane frizzled-related protein. 
The autosomal recessive rd7 mutation is a frame shift mutation causing a pre-
mature stop codon in Nr2e3, which codes for a photoreceptor-specific nuclear 
receptor. This disorder is unusual as it shows increased S-cones at the expense 
of rods and M/L-cones, which leads to retinal rosetting and a slow degeneration 
(Milam et al., 2002). 
The rd8 mutation is a slow retinal degeneration, which is first detected in the 
ventral retina. Degeneration and pseudo-rosettes can be seen at 8 weeks. The 
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rd8 mutation occurs in crb1, coding for Crumbs homolog 1 and locates in 
photoreceptor inner-segements (PIS) (Mattapallil et al., 2012). 
Rd9 is a semidominant X-linked mutation in the gene encoding retinitis 
pigmentosa GTPase regulator, resulting in pigment loss and a slow degeneration 
of the ONL. Rhodopsin and transducin in rod outer-segments are reduced and 
cone opsins are mislocalised. ERG amplitudes are attenuated and degenerate 
with age up to 24 months (Thompson et al., 2012). 
The rd11 mutation occurs in Lpcat1, the gene encoding lysophosphatidlycholine 
acetyltransferase-1 (LPCAT1), resulting in a truncated protein. This localises in 
the PIS and promotes the conversion of palmitoyl-lysophosphatidylcholine (LPC) 
to dipalmitoylphosphatidylcholine (DPPC). This causes rapid photoreceptor 
dysfunction and degeneration. By P31 the ONL is reduced by 60% and by P47 
this is further reduced to a single row (Friedman et al., 2010). 
The mutation in the rd13 mouse is not yet known, although it has been mapped 
to the distal 4 Mb of chromosome 15. This mutation causes a reduction in cell 
number in ONL containing only 2-3 layers at P12, which, did not seem to have 
reduced further by P40 (Buchner et al., 2004). 
The rd14 is an autosomal recessive mutation on chromosome 18. Large cells 
appear in the subretinal space and blood is observed on some retinas which 
decreased ERG recordings, otherwise the ERG is normal (Zhang et al., 2005). 
The rd15 mutation has been mapped to chromosome 7 and is an autosomal 
recessive mutation. At 4 weeks there is no rod ERG b-wave and a severely 
reduced cone response, yet, retinal degeneration is slow and seen around 9 
months (Hawes et al., 2005). 
The rd16 mouse has an autosomal recessive mutation in CEP290, which is 
associated with LCA10 and important for centrosome and cilia development in 
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photoreceptors. Retinal degeneration is seen at 3 weeks after which the ERG 
response worsens and cannot be detected at 2 months. This mutation results in 
a much faster degeneration than the rd12 mouse (Chang, 2016). 
From this list, the rd12 mouse has the advantage of a slow degeneration allowing 
time to halt the degeneration but also retinal function is severely affected from 
early on so any restoration to function can be observed. The rd12 is also 
advantageous due to mutation being known and that the mutation is RPE specific, 
which is the cell type of interest. Also, this allowed us to investigate the effects of 
the RPE on ipRGCs. 
 Sodium Iodate: The selective RPE killer 
 Benefits of removing the RPE prior to transplantation 
A major issue with RPE cell transplantation is achieving cell integration. Many 
animal models do not mirror RPE cell loss seen in diseases of the RPE like dry 
AMD, in which photoreceptors die subsequent to RPE cell loss. In many studies 
involving sub-retinal transplantation into rodent models where host RPE cells 
remain, the grafted RPE clump together to form a bolus of cells and do not sit 
down in a monolayer (Carido et al., 2014, Li and Turner, 1991, Seaton and 
Turner, 1992, Sheedlo et al., 1991, Carr et al., 2009). Studies have shown that 
RPE cells undergo apoptosis in the absence of a suitable substrate to attach to 
(Tezel and Del Priore, 1997, Tezel et al., 2004). This is known as anoikis. Thus, 
space on Bruch’s membrane needs to be made available for donor RPE cells to 
survive transplantation. In human, it is possible to surgically remove RPE cells 
and this occurs with AMD progression in the form of geographic atrophy. 
Unfortunately, due to the small size of a rodent eye, physical removal of the host 
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RPE cells prior to grafting is unfeasible, with chemical removal of RPE cells being 
a more realistic approach. The loss of RPE cells prior to transplantation will 
damage the BRB (Wenkel and Streilein, 1998) which can complicate donor cell 
survival, but, this is an important factor to address, as this BRB breech is seen in 
AMD patients. Other animal models used for RPE cell transplantation such as the 
RCS rat do not simulate this challenge. 
 Discovery of Sodium Iodate 
Sodium iodate (NaIO3) is a drug, which is selectively toxic to the RPE and causes 
RPE cell necrosis. Between 1926 and 1934, seven cases of blindness were 
reported after the administration of an antiseptic, Septojod. The active chemical 
in Septojod, which when isolated resulted in blindness was identified as sodium 
iodate (Sorsby, 1941). The selective death of RPE cells is followed by 
photoreceptor cell apoptosis. Benefits of using NaIO3 to create a model of retinal 
degeneration include its selective effects on RPE cells after a single 
administration of NaIO3 and the rapid onset of RPE cell death. Oedema has been 
observed 1 hour after administration via the tail vein (Hariri et al., 2013). 
 Method of toxicity 
It is not yet fully understood how NaIO3 is toxic to RPE cells nor why its toxicity is 
specific to RPE cells, despite this, there are many well-supported theories. 
Anstadt et al showed that the tight junctions remain relatively stable and that gaps 
in the RPE layer are a result of direct RPE cell destruction (Anstadt et al., 1982). 
RPE death is due to necrosis, suggesting a chemical or physical injury. 
The choroid, which lies beneath Bruch’s membrane and the RPE, has the highest 
rate of blood flow in the body, needed to supply the retina, the most metabolically 
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active tissue in the body. This high blood flow is also needed for cooling retinal 
tissue, with the choroid acting as a heat sink. It is hypothesised that NaIO3 
specifically affects RPE cells due to this high blood flow and the uptake of NaIO3 
by the RPE. This is supported by studies showing more severe degeneration in 
the central retina (Redfern et al., 2011). The central retina has the highest 
choroidal blood flow and all major blood vessels of the retina and choroid enter 
and exit the eye at the optic nerve head. Nishimura et al. 1990 injected NaIO3 
into primate carotid artery, severe RPE damage was seen in the ipsilateral eye 
but did not affect the contralateral eye (Nishimura et al., 1990). This showed 
varied results, with a dose of 10 mg/Kg, with some eyes only showing damage at 
the posterior pole and others showing complete fundus deterioration. Another 
property of the choroid which leave the RPE susceptible to NaIO3 damage is its 
permeability to sodium. It is at least 50 times more permeable than skeletal 
muscle (Tornquist et al., 1990). 
It is known that Iodate is a powerful oxidising agent, and causes denaturation of 
proteins and co-administering NaIO3 with anti-oxidants reduces the damage to 
the RPE (Heike and Marmor, 1990). Yet, the effects of iodate on the RPE are 
unlikely attributed solely to oxidation as similar oxidising agents such as sodium 
perchlorate and potassium bromate are non-toxic (Baich and Ziegler, 1992). Why 
the RPE is particularly susceptible to oxidative stress is not understood. One 
theory is that NaIO3 reacts with the melanin in the RPE to produce harmful toxins 
via oxidation (Baich and Ziegler, 1992). It is thought that NaIO3 may bring about 
its toxic effect by disrupting the melanosome membrane via oxidation and result 
in the release of potentially toxic melanin and its metabolites. Conflicting this 
theory is that melanin is not specific to the RPE, and NaIO3 has been reported to 
be effective on albino RPE cells (Chowers et al., 2017), which should have a null 
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effect if melanin was necessary. Kiuchi et al claimed that NaIO3 had an identical 
response in pigmented WT mice and albinos (Kiuchi et al., 2002, Chowers et al., 
2017). Another study by Redfern et al., states that albino rats were, in fact, more 
sensitive to sodium iodate (Redfern et al., 2011).  
Another theory is that the RPE is susceptible to photooxidative damage from 
bisretinoid flurophores that form in photoreceptor cells and accumulate with age 
as lipofuscin in RPE cells. ATP-binding cassette transporter (ABCA4) is important 
for transporting all-trans retinaldehyde back to the RPE for recycling, following 
phototransduction. Mutations in Abca4 are known to cause autosomal-recessive 
Stargardt’s macular dystrophy. A build-up of all-trans retinaldehyde occurs in 
POS which are then shed and phagocytosed by RPE cells and form the toxin 
A2E. Abca4-/- mice have an accumulation of these toxic bisretinoids and this 
makes them more susceptible to the toxic effects of NaIO3. This is supported by 
a reduced effect of NaIO3 in rd12 mice, which have low levels of bisretinoids 
(Zhao et al., 2017). 
Other theories suggest that NaIO3 is not specific to RPE cells. Wang et al., 2014 
administered 10, 20 or 30 mg/Kg NaIO3 retro-orbitally in C57 mice and suggested 
a direct effect of NaIO3 on photoreceptors 5 days after NaIO3 administration at 
20 or 30 mg/Kg NaIO3. Although, it cannot be concluded that these effects were 
not a secondary effect of RPE cell death. Also, the effects NaIO3 in vitro were 
examined using ARPE19 cells versus 661W cells, a cell line with characteristics 
of cone photoreceptors. It showed that higher concentrations of NaIO3 were 
needed to kill the APRE-19 cells than 661W cells (Wang et al., 2014). Although, 
the ARPE-19 cells used were only 5 days post-confluency, a time point at which 
these cells do not show characteristics of RPE cells such as shape, protein 
expression or even melanin (Ahmado et al., 2011). Another study suggested 
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direct effects of NaIO3 on dopaminergic neurons. Two weeks after NaIO3 
administration, dendritic fields of DA-ACs, horizontal cells and ipRGCs are 
decreased, but again, there is no evidence to exclude attributing this to secondary 
effects of RPE cell death (Tao et al., 2013). It has been shown by Carido and 
colleagues that bipolar cell dendrites become hypertrophic, along with a loss in 
the number of Pax-6 positive amacrine cells from day 14 after NaIO3. Arguably, 
this is a secondary effect of NaIO3 on RPE cells (Carido et al., 2014). 
NaIO3-induced retinal toxicity has been studied in a wide variety of animals such 
as rabbits (Heike and Marmor, 1990, Yoon and Marmor, 1993), sheep (Nilsson 
et al., 1977), pig (Mones et al., 2016), rats (Chen et al., 2009, Garcia-Layana et 
al., 2009, Gong et al., 2008, Ohtaka et al., 2006) as well as mice (Machalinska et 
al., 2011, Redfern et al., 2011, Carido et al., 2014). 
 Time course of pathology 
The effects of sodium iodate are very rapid, with changes seen within 1 hour of 
NaIO3 administration; RPE cell nuclei become defragmented, fluid accumulates 
between the POS, causing tearing of the POS from the RPE (Hariri et al., 2013). 
Adhesion is reduced between the RPE and Bruch’s membrane (Yoon and 
Marmor, 1993). RPE cytoplasmic organelles start to swell. The basement 
membrane degenerates. Apical microvilli are lost and the POS become 
disorganised. The separation of the RPE and POS, caused by fluid accumulation, 
starts to reduce between 3-12 hours after NaIO3 administration (Hariri et al., 
2013). At this stage, the RPE is necrotic and the retinal layers are not fully 
defined. RPE cells are flattened and devoid of nuclei within 12 hours of NaIO3 
administration (Machalinska et al., 2010). RPE markers Otx2, RPE65 and ZO-1 
are lost by 24 hours (Carido et al., 2014). By day 3, the RPE has disintegrated, 
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nuclei defragmented, with a thin layer of melanin remaining, loss of apical 
microvilli and tight junction and macrophage infiltration (Carido et al., 2014, 
Machalinska et al., 2010). The 3rd day also marks the peak of photoreceptor 
apoptosis (Machalinska et al., 2010). Scotopic ERG responses are abolished 
(Carido et al., 2014). After 1 week, the thickness of the ONL is significantly less 
and the length of the POS and PIS are shortened (Machalinska et al., 2010).  
Hariri et al found that there was a strong variation in timing of morphological 
changes between animals, though, this variation was reduced when the NaIO3 
was administered with an additional subcutaneous saline injection. It also helped 
reduce side effects of drug toxicity such as blood in urine (Hariri et al., 2013). 
 Effects of dose and route of administration 
The severity and time delay in pathology depends greatly on dose and route of 
administration. Also, at a low dose of NaIO3, the RPE in the central retina can be 
selectively targeted, and the peripheral RPE relatively spared. 
Administration via the Orbital Venous plexus 
NaIO3 administered via the orbital venous plexus (the retro orbital sinus) has an 
extremely rapid and severe response. At a dose of 40 mg/kg in mice the whole 
RPE is destroyed within 24 hours and the scotopic and photopic ERG is 
completely diminished by day 3. While, at 20 mg/kg, the peripheral retina is much 
less severely degenerated, with healthy polygonal cells remaining and a small 
remaining photopic b-wave is observed. RPE cells are absent in the centre of the 
eye cup and the remaining peripheral RPE cells become more irregular in shape 
towards the centre. Their border curvature and area increase as they get closer 
to the eyecup centre as the cells rearrange to try cover the area from shed cells. 
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These cells lose their characteristics such as polygonal shape and RPE65, which 
was not recovered 1 month after NaIO3 (Machalinska et al., 2010, Xia et al., 2011, 
Wang et al., 2014). No effect was seen at a dose of 10mg/Kg (Wang et al., 2014). 
Administration via the tail vein 
Administering NaIO3 via the caudal tail vein requires a higher dose to achieve 
similar results as those via the orbital region. Enzmann and colleagues claimed 
that there is no significant effect on the RPE or ONL with a dose of 35mg/kg and 
very few disruptions to the overall morphology even up to 14 days (Enzmann et 
al., 2006). Redfern et al showed that the peripheral retina has less marked 
degeneration than central retinal and closely resembled normal retina after 50 
mg/kg sodium iodate. There was a clear recovery of the peripheral retina 2 weeks 
post-dose and at 4 weeks head tracking tests showed visual acuity had recovered 
to normal levels in Han Wistar rats (Redfern et al., 2011). Carido et al. reported 
that at 70 mg/Kg, RPE was retained at the periphery for longer but the peripheral 
RPE had damaged nuclei and did not label positive for Otx2 (Carido et al., 2014). 
Enzmann et al. demonstrated that at 70mg/kg NaIO3, RPE cells across the whole 
retina were destroyed by day 3 after NaIO3 administration (Enzmann et al., 
2006).15 mg/kg NaIO3 still causes rapid RPE cell loss, even though, the number 
of cell in the ONL does not fall to a significant level until 3 months after the NaIO3 
injection. Whereas, a dose of 25 mg/kg and 35 kg/mg, result in significant loss of 
ONL cells by 14 days and 3 days respectively (Franco et al., 2009). 15 mg/kg 
NaIO3 significant reduces the optokinetic response (OKR) response in mice, 
which decreases until day 7, yet the mice are still capable of performing in the 
water maze (WM) task. After 25 mg/kg the OKR is absent on day 3 but improves 
over the next 3 months, and 35 mg/kg reduces performance in WM on day 14 but 
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OKR is lost by day 3. The RPE benefits from partial recovery 3 months after 
NaIO3, observed by an increase in autofluorescence in whole eye flatmount 
preparations (Franco et al., 2009). RPE cells and Müller glial cells can proliferate 
in response to acute injury, because of this, NaIO3-induced retinopathy can 
improve over time. At a higher dose of 70mg/Kg no recovery of retinal function is 
seen. ERG responses are completely lost by day 14 and OKR is lost by day 21 
(Carido et al., 2014). 
Administration via the intraperitoneal route 
A dose of 100mg/kg NAIO3 administered via the intraperitoneal (IP) route also 
provided rapid necrosis of RPE cells after 6 hours; some RPE cells remained 
after 7 days, although, it affected central and peripheral retina equally. No 
differences were reported between male and female mice (Kiuchi et al., 2002). 
Major blood vessels of the choroidal and retinal circulation enter and exit the eye 
at the optic nerve and have their largest diameter there, thus delivery of and 
perhaps damage from sodium iodate is greatest in this region. Peripheral regions 
may also be repaired more rapidly due to the presence of progenitor cells in this 
region (von Leithner et al., 2010). Caution must be exercised when using 
published data for planning an experiment. It is difficult to extrapolate from 
different studies due to different doses, route of administration, time points, strain 
of animals, age of animal and the examination methods. These results are 
important when considering a suitable model to investigate a regenerative 
therapy. Additionally, it was reported that a dose of 100 mg/Kg administered via 
the IP route resulted in systemic toxicity and high mortality in C57 and BALBc 
mice (Chowers et al., 2017). Although, this is much lower than the LD50 (lethal 
dose for 50% of population), which is 505 mg/Kg (Sigma). 
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Table 1 Effects of route of administration and dose of NaIO3 on RPE and retinal 
function 
Dose Retro-orbitally Intravenously Intraperitoneally 
10-15 
mg/Kg 
No changes in 
fundus or OCT. RPE 
marker expression 
unchanged. Normal 
ERG (Wang et al., 
2014) 
Loss of RPE and 
decrease in OKR 
(Franco et al., 2009) 
 
20-25 
mg/Kg 
Relative sparing of 
peripheral RPE, but 
loss of RPE 
markers. ERGs 
reduced but not 
flatlined 
(Machalinska et al., 
2010, Wang et al., 
2014).  
Loss of RPE and 
transient loss of OKR 
(Franco et al., 2009) 
Inconsistent 
results. Histology 
and ERGs ranged 
from near normal to 
severe (Chowers 
et al., 2017). 
30-35 
mg/Kg 
Relative sparing of 
peripheral RPE, but 
loss of RPE 
markers. Complete 
loss of scotopic and 
photopic b-wave 
(Wang et al., 2014) 
No significant 
changes in 
autofluoresence or 
ONL thickness 
(Enzmann et al., 
2006). Significant loss 
of RPE and loss of 
OKR (Franco et al., 
2009). 
 
40 mg/Kg Total eye cup 
affected. ERG 
flatlined 
(Machalinska et al., 
2010). 
  
50 mg/Kg  Central RPE loss, 
which grew with time 
(Enzmann et al., 
2006). 
ERG significantly 
reduced and loss of 
RPE markers by 24 
h. Total loss of 
RPE markers and 
ERG flatlined by 4 
weeks (Chowers et 
al., 2017). 
70 mg/Kg  Total eye cup 
affected. OKR and 
ERG responses 
eliminated (Carido et 
al., 2014, Enzmann et 
al., 2006) 
 
100 
mg/Kg 
  RPE death (Kiuchi 
et al., 2002). High 
mortality rate 
(Chowers et al., 
2017). 
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Evidence of proliferation and retinal recovery 
Expression of markers for mitosis peak 2-3 days after NaIO3 administration 
(Redfern et al., 2011). 3 days after NaIO3 administration there is evidence of 
Müller cell proliferation, macrophage migration and RPE cell regeneration (Kiuchi 
et al., 2002). It was shown that stem or progenitor cells in the blood start homing 
into the retina 3 days after NaIO3 injection. Despite this, functional recovery is 
not achieved by these stem cells (Machalinska et al., 2011) and synaptophysin, 
a marker for synaptic vesicles in the PIS, is depleted, even after 6 weeks (Redfern 
et al., 2011). Thus, the natural process of cell replacement and proliferation is too 
late and ineffective at preventing photoreceptor loss. 
 Cell studies using the NaIO3 model 
The NaIO3 model has been used to study transplantation of bone-marrow derived 
stem cells (Harris et al., 2006), mesenchymal stem cells (Gong et al., 2008), 
hESC-derived retinal progenitors (Amirpour et al., 2012) and hESC-RPE cells 
(Carido et al., 2014). Atmaca-Sonmez et al carried out a study to decide the 
optimum time for cell transplantation following 50 mg/Kg NaIO3 injected 
intravenously. Using GFP+ bone marrow-derived and haematopoietic stem cells, 
optimum transplantation times were observed by transplanting these cells in to 
the tail vein in a range of days following NaIO3-treatment. Their results showed 
that 5-7 days after NaIO3 is best for bone marrow-derived and haematopoietic 
stem cell incorporation and survival in the subretinal space (Atmaca-Sonmez et 
al., 2006). These GFP+ cells stained positive for RPE65. It was shown that stem 
or progenitor cells in the blood homing into the retina 3 days after NaIO3 injection 
(Atmaca-Sonmez et al., 2006). The same group mobilised bone marrow-derived 
stem cells and directed them to the retina three days after an intravenous injection 
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of 25 mg/Kg NaIO3 in mice. They saw significant improvements in the OKR 21 
and 28 days after NaIO3 administration (Enzmann et al., 2017). 
hESC-RPE cell transplantation 
Between 100-200,000 hESC-RPE cells were transplanted subretinally into C57 
mice 1 week after 70 mg/Kg NaIO3 administered via the tail vein. The hESC-RPE 
cells formed extensive monolayers in the sub-retinal space, attached to Bruch’s 
membrane, highlighting the value of removing host RPE cells prior to 
transplantation. The transplanted RPE cells had correct apical-basolateral 
organisation, with basal nuclei and apical melanosomes and microvilli. While 
there was evidence of phagocytosis by the grafted HESC-RPE cells and 
preservation of the ONL, no functional recovery was observed by ERG. Cells 
were not transplanted until 7 days post NaIO3, when there was already a 
significant reduction in photoreceptors and a complete loss of all normal ERG 
responses (Carido et al., 2014). NaIO3 is a fast-acting chemical; it has been 
reported that RPE cell death occurs within 12 hours and by 3 days the RPE cells 
are destroyed (Hariri et al., 2013, Machalinska et al., 2010). It is possible that 
although the grafted hESC-RPE cells could phagocytose rhodopsin positive 
debris, these cells were not sufficiently differentiated to perform the visual cycle. 
In support of this, there was no confirmation that the hESC-RPE cells used in the 
study by Carido and colleagues could express visual cycle markers either in vitro 
or in vivo (Carido et al., 2014). It is also important to consider the possibility that 
the number of surviving human RPE cells was insufficient to significantly improve 
the ERG (which is a fields potential) in the study by Carido and colleagues. A 
review of the literature suggests that the clearance rate of NaIO3 is unknown. 
NaIO3 is likely to be cleared quickly as time frames for cell death are similar 
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regardless of the dose used and at smaller doses of NaIO3 the peripheral RPE is 
spared. 
Another study on albino rabbits transplanted 50,000 hESC-RPE cells subretinally 
in to eyes treated with 50 µL 1mM NaIO3 subretinally. They found that hESC-
RPE cells did not integrate into areas of degenerated outer-retina but were 
located in areas with preserved photoreceptor nuclei and POS. 2 months post 
transplantation the pigmented donor RPE did not label positive for RPE65, 
although, by 8 months RPE65 was expressed in these cells (Petrus-Reurer et al., 
2017).  
The NaIO3 model of retinopathy is very useful for the study of RPE stem cells 
transplant as no naturally occurring models of RPE death in adult animals are 
available. The NaIO3 model is a rapid model to generate, with effects seen after 
a single injection. It has a powerful rapid effect and loss of RPE cells is dose 
dependent. It is also cheaper than inducible knock out models, which are 
expensive and difficult to produce (Longbottom et al., 2009).  It is not yet known 
if lasting retinal recovery from NaIO3 toxicity is possible but this would be an 
important pre-clinical readout for RPE stem cell therapy. This model could also 
be used in conjunction with the rd12 model to clear RPE cells, to give space for 
the transplanted RPE cells to settle down. Still, caution should be exercised when 
comparing acute retinal injury to a chronic disease such as AMD. A key difference 
between this model and naturally occurring retinopathy is that NaIO3 is a fast-
acting, once off insult, while most retinopathies are slow and progressive. 
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Aims and objectives of the Thesis 
Given the shortcomings of the RCS rat described above, the aim of this thesis is 
to investigate two alternative models for studying RPE cell transplantation and to 
determine the importance of the RPE on the function of the melanopsin system. 
The first model uses NaIO3 to chemically remove RPE cells prior to grafting RPE 
cells into the subretinal space and may have a benefit of clearing Bruch’s 
membrane to allow transplanted cells to anchor. The second model is the rd12 
mouse, which has a mutation in rpe65, resulting in the loss of the visual cycle. 
The possible benefit of this model is that any improved functional effects are likely 
to be visual cycle specific. The value of these models for studying RPE cell 
transplantation is determined by examining residual retinal function and histology, 
and determining if retinal function can improve with synthetic chromophore prior 
to assessing retinal function improvements with grafted hESC-RPE cells. 
The reliance of the melanopsin system on the RPE will be examined by assessing 
the effect of chemically removing RPE cells and the loss of the visual cycle on 
melanopsin function and if either synthetic chromophore or rpe65 gene 
restoration can improve melanopsin function in the rd12 mouse. 
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Chapter 2 Methods 
 Animal housing 
All procedures were conducted according to the Home Office (UK) regulations, 
under the Animals (Scientific Procedures) Act of 1986, and with local (UCL-
Institute of Ophthalmology, London, UK) ethics committee approval. C57BL/6 
(C57) mice and rd12 mice were used in this study. All animals were housed under 
a 12:12 hour light dark cycle (lights on a 7 a.m.), with food and water available ad 
libitum. All studies were age and sex matched. 
 Functional Assessment of animal visual responses 
 Electroretinography 
To record an ERG, Animals were dark adapted for overnight and anesthetised 
under dim red light with Ketamine (6 mg/100g; Narketan® 10, vétoquinol) and 
Medetomidine Hydrochloride (0.1 mg/100 g; Domitor, Orion Pharma) in injection 
water (Norbrook, Newry, UK) via IP route 20 minutes before retinal recording. 
Pupils were dilated, to allow maximum light stimulus, with 1% tropicamide 
(Bausche and Lomb, Kingston-on-Thames, UK) and 2.5% phenylephrine 
(Bausche and Lomb, Kingston-on-Thames, UK). Tropicamide is an anti-
muscarinic drug, which prevents the iris sphincter muscle from contracting. 
Phenylephrine is an α1-adrenergic receptor agonist, which activates the pupil 
dilator muscle. Viscotears® (Alcon) was applied to the cornea to maintain 
hydration. Active gold loop electrodes, were placed on the corneas and held in 
position with Viscotears®. The reference electrode was inserted subcutaneously 
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on the head between the ears. The ground electrode was inserted 
subcutaneously on the back of the animal. ERGs were recorded from both eyes 
under scotopic and photopic conditions. Scotopic flash intensity range was -5 to 
1 lg cd/s/m2 in a ganzfeld colour dome by LED stimulator. In order to investigate 
the rod response at high intensities, some animals were also recorded from a 
high intensity scotopic protocol with flash intensity from -4.5 to 3.5 lg cd/s/m2. 
After light adaption for 15 minutes, photopic responses were recorded at a 
background light intensity of 20 cd/m2 and increasing flash intensities of -1 to 1.5 
lg cd/s/m2. The responses were measured using espion Diagnosys software. 
Where the wave was absent in the recording the amplitude was recorded as zero 
and the latency/implicit time was omitted from results. Where both eyes are 
treated equally, they are analysed as separate subjects. Animals were recovered 
from medetomidine hydrochloride with antipamezole (0.1 mg/100 g; Antisedan, 
Vétoquinol) in injection water (Norbrook, Newry, UK) via the IP route. All ERG 
recordings were carried out between 9 a.m. and 4 p.m. with animals alternated 
from control or experimental group where to possible to counter act effects of 
circadian changes in the recordings. While, the use of candelas as a recording of 
light intensity may pose controversy as it is weighted by the sensitivity of the 
human eye to different wavelengths, this is the measurement generally reported 
in studies using rodents (Carido et al., 2014, Li et al., 2011, Li et al., 2012b, 
Machalinska et al., 2010, Nusinowitz et al., 2006, Pang et al., 2010, Pang et al., 
2005, Pang et al., 2006, Wang et al., 2014, Wright et al., 2014).  
 Behavioural Light Aversion (BLA) 
Normally mice will prefer to be in dark or dim light and would choose this over 
bright light when presented with the choice. Melanopsin alone can drive this 
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effect, but it is not required for this effect to occur, although with melanopsin the 
behavioural light aversion increases with time (Semo et al., 2010). Methods to 
assess BLA have previously been reported in Semo et al., 2010. In brief, an open 
field arena was used, illustrated in Figure 2.1, with a closed back half that is kept 
in darkness and an open front half which is either illuminated (600 µW/cm2/1,300 
Lux) or also in darkness. This arena allowed a mouse to pass to either side easily. 
A naïve mouse was placed in the open front half and monitored for 31 minutes 
where it travelled using infrared light. The first minute was always discounted, to 
give the mouse time to acclimatise to the new surroundings. Comparisons were 
made between groups and within a group comparing animals in an arena with 
the front half under a bright light compared to a completely dark arena. Total time 
spent in the dark was analysed by a one-tailed Mann Whitney U t-test. Time spent 
in the dark was also analysed in 5-minute bins by two-way repeated measures 
ANOVA with post-hoc Holm-Sidak’s multiple comparisons test and linear 
regression. All BLA tests were run between 9 a.m. and 12 p.m. and animals were 
alternated from control and experimental groups to counteract effects of circadian 
changes in behaviour. 
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Figure 2.1 Open Field Arena for testing Behavioural Light Aversion 
A mouse placed in the open front half could move freely between the open front 
half and the dark back half, by an opening in the centre. Comparisons were made 
between behaviours when the front half was illuminated with behaviours when 
both halves were under complete darkness. Figure adapted from Semo et al., 
2010. 
 Pupillary Light Reflex 
The PLR is used to measure both outer-retinal photoreceptor and ipRGC function 
in live animals. The PLR was measured in un-anaesthetised mice dark-adapted 
for at least 2 hours. Equipment used to record the PLR was previously descried 
in Semo et al., 2010. Eyes were illuminated with infra-red light and stimulated 
with a broad-spectrum white light from a xenon-arc lamp (Lambda DG-4, Linton 
Instrumentation) which was heat filtered for wavelengths >600 nm and guided 
through a fibre optic cable which terminated 5 cm from the eye. Animals were 
recorded and stimulated for 60 s by white light. A range of light intensities were 
used to assess the PLR. The 30 s prior- and 60 s post-light stimulus were also 
recorded. Spatially binned (2x2) frames at 4 Hz were collected. Pupil area was 
estimated off-line by an observer using customized MATLAB software at frame 
times -30, -25, -20, -15, -10, -5, 0, 1, 2, 3, 4, 5, 7, 11, 15, 20, 30, 40, 50, 60, 61, 
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69, 77, 85, 93, 101, 109, 117, 125, 133, 141 and 149s, where T0 indicated the 
point at which the light is stimulated. Measurements of pupil area are expressed 
as normalised to pupil area at T0. Two-way ANOVA and post-hoc Holm-Sidak’s 
multiple comparisons test were carried out on PLR constriction traces. Repeated 
measures were not applied to the ANOVA as these recordings were on live 
animals and some time-points during the recording were not captured as the pupil 
was out of focus. Maximum pupil constriction was defined by the lowest point of 
constriction within the first 30 seconds of lights on. Two-way ANOVA was used 
to analyse the maximum constriction over the different light powers. Latency to 
90% peak constriction was also analysed by two-way ANOVA. Baseline pupil 
area at time zero was analysed by two-tailed Mann Whitney t-test. 
All PLR recordings were carried out between 10 a.m. and 3 p.m. and animals 
alternated from control and experimental group to counteract effects of circadian 
changes. A group is determined to have a constriction if the average pupil size 
during light on is significantly less than 1 (pupil area at time 0). 
 Intrinsic pupillary light reflex 
The iPLR is used to measure isolated melanopsin function. While ipRGC function 
can be recorded in the PLR, these recordings are an output of both ipRGC and 
outer-retinal photoreceptors (Chen et al., 2011, Guler et al., 2008, Hattar et al., 
2003, Lucas et al., 2001, Lucas et al., 2003). Using the PLR to assess ipRGC 
function in a model of inhibited visual cycle may make it difficult to distinguish 
ipRGC from outer-retinal photoreceptor function. Thus, recording the iPLR allows 
the isolation of melanopsin function (Semo et al., 2014, Xue et al., 2011). To 
record this the eye must not receive input from the brain, thus eyes are excised 
from culled animals. This means that this procedure is a final functional recording 
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and may not be appropriate when perfusion is the preferred method of fixation. 
Methodology for recording iPLR in whole eyes was previously described in Vugler 
et al., 2015 and recordings in isolated anterior chamber were described 
previously by Semo et al., 2014. In brief, mice were dark adapted overnight. Mice 
were culled swiftly under dim red light by cervical dislocation and the eyes 
enucleated and placed in Neurobasal® culture medium (12348-017; Invitrogen) 
which had been pre-heated to 37°C. Eyes were illuminated with infra-red light 
and stimulated with a broad-spectrum white light as described in PLR 
methodology. The fibre optic cable terminated 1.5 cm from the cornea, delivering 
40 mW/cm2 to the eye. Baseline video recording of pupil was made for 30 
seconds using infrared camera followed by light stimulation for 60 seconds and 
then 60 seconds in darkness to monitor pupil recovery. Recordings and analysis 
are as described in the PLR methodology. iPLR recordings were all carried out 
between 9 a.m. and 12 p.m. and animals alternated between control and 
experimental groups to counteract the effects of circadian changes. 
 Histology 
 Fixation of tissue 
Animals were first perfused to fix the tissue and remove background auto-
fluorescence from blood. Animals were euthanised by a 10 ml/Kg injection of 
Sodium Pentobarbital. Once reflexes were lost, a cut was made along the 
sternum, then the diaphragm was cut along the bottom and the ribs were cut up 
towards the head on the outside of the lungs to expose the heart. The left ventricle 
was cut to allow the cannula to enter the ascending aorta. Once the cannula tip 
was visible in the aorta, the cannula was clamped into place. The right atrium was 
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then punctured, allowing the return circulation to escape. 0.1M phosphate buffer 
saline (PBS, approximately 50 mL) was pumped through the cannula and into the 
aorta, this was then followed by 4% paraformaldehyde (PFA), until the body 
becomes stiff (approximately 100 mL). The eyes were then removed, the cornea 
punctured and placed in 4% PFA at 4°C to allow further fixation. All perfusions 
were carried out at the same time of day and alternated between control and 
experimental animals to counteract effects of circadian changes to protein 
expression. 
 Sectioning and immunostaining retinas 
Eyes were fixed in 4% PFA overnight, then cryoprotected in 30% sucrose in 0.1 
M PBS overnight at 4°C. Corneas and lenses were removed from the eyes, which 
were frozen in tissue-Tek® O.C.T (VWR) and stored at -80°C. The eyes were cut 
in 16 µm sections along the sagittal axis from the middle third of the eye using 
the cryostat (Leica CM1850). Cut sections were thaw-mounted onto Superfrost 
Plus slides (BDH, Poole, UK) and allowed to dry at room temperature overnight 
and stored at -80°C. 
To label the protein with fluorescent marker, the sections were incubated in 5% 
normal donkey serum (NDS) in 0.3% triton X-100 (BDH Cat#366324N) in PBS 
for 1 h. The sections were then incubated overnight at room temperature with the 
primary antibody diluted in 1 % NDS in 0.3% Triton X-100 in PBS. Contol slides 
were treated identically, except the primary antibody was omitted. Slides were 
washed multiple times in PBS before secondary antibodies were applied. 
Secondary antibodies were diluted in 2% NDS in 0.3% Triton X-100 in PBS and 
were incubated with the sections in the dark for 1 h. the sections were then 
incubated with 0.02% DAPI in PBS for 1 minute, after which the slides were 
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washed multiple times with PBS and then multiple times with tris-buffered saline 
(TBS), mounted with Vectashield (Vector Laboratories) and coverslipped. 
 Flatmounting and immunostaining 
Depending on the protein of interest, retinas were flatmounted to get a composite 
view of the retina. After perfusion, eyes were fixed for 2 h in 4% PFA at 4°C. Each 
eye was then pinned to a wax plate and the cornea and lens removed. Cuts were 
made in the dorsal, nasal, ventral and temporal retina. The retina was teased 
away from the RPE and cut away from the optic nerve and placed in 4% PFA. 
The retina was then placed on a slide with the inner retina facing up. A non-fibrous 
paper was then placed on top of the retina, which sticks to it, due to the presence 
of the vitreous. This was then placed in 4% PFA for 20 minutes followed by a 
wash in PBS where the retina floats off the paper removing the vitreous. The 
retina or RPE was blocked for 2 h in 5% NDS in 3% Triton X-100 in PBS on a 
shaker. Primary antibodies were prepared in 1% NDS in 3% Triton X-100 in PBS 
and the samples were incubated with this preparation overnight on a shaker. After 
multiple washes in PBS, secondary antibody was made up in 2% NDS in 0.3% 
Triton X-100 in PBS and incubated with the samples for 2 h in darkness on a 
shaker. The tissue was then incubated with 0.02% DAPI (4',6-diamidino-2-
phenylindole, Sigma Aldrich) in PBS for 1 minute in the dark. After this the tissue 
was washed multiple times in PBS then multiple times in TBS, then mounted in 
vectashield and coverslipped. 
 Imaging and Analysis of flatmounted retinal tissue 
Confocal images were taken on either a Zeiss LSM 710 or 700 microscope. For 
flatmount analysis of melanopsin, Brn3a, Fos and TH, regions covering 399.72 
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µm x 399.72 µm were sampled from four retinal quadrants: superior-temporal 
(ST); superior-nasal (SN); inferior-nasal (IN) and inferior-temporal (IT). Z-stacks 
were taken to ensure capture of displaced cells. The maximum intensity 
projection was then used for analysis. Confocal files were coded and a single 
observer made counts of melanopsin and Brn3a cells. Soma counts, size and 
staining intensity were analysed using MATLAB which could define the 
boundaries of each soma. Staining intensity was measured in grey level (0-255). 
Melanopsin-positive neurites were assessed in a programme written in MATLAB 
described previously in Semo et al., 2016, where images were filtered to enhance 
elongated structures and only neurites with a length >20 pixels were considered 
for quantification. A range of thresholds of normalized greylevel were applied to 
images to identify both weakly and strongly stained neurites (low threshold of 
0.02) or to isolate strongly stained neurites (high threshold of 0.1). 
 Ocular Treatments 
 Administration of NaIO3 by IP and retro-orbital route 
NaIO3 was dissolved in sterile saline and either injected via IP or retro-orbitally. 
Animals which received NaIO3 retro-orbitally were anaesthetised with Ketamine 
(12 mg/100g; Narketan® 10, vétoquinol) and Medetomidine Hydrochloride (0.07 
mg/100 g; Domitor, Orion Pharma) in injection water (Norbrook, Newry, UK) via 
the IP route. NaIO3 was made up at a concentration of 20 mg/mL and a dose of 
40 mg/Kg was administered into the orbital plexus of the right eye. Viscotears® 
(Alcon) was applied to the cornea to maintain hydration. Animals were recovered 
from medetomidine hydrochloride with antipamezole (0.3 mg/100 g; Antisedan, 
Vétoquinol) in injection water (Norbrook, Newry, UK) via the IP route. 
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 Administration of replacement chromophore 
9-cis retinal is widely used in vision experiments as it is easily synthesised and 
more stable than 11-cis retinal. Under dim red light, 25mg 9-cis-Retinal (sigma) 
was dissolved in 250 µL ethanol and then diluted in 10% Bovine Serum albumin 
(Sigma), 0.9% NaCL to a concentration of 1 mg/100 µL. 9-cis retinal was omitted 
for a saline control. 1 mg 9-cis retinal solution (9-cis) was injected via IP into 
animals under dim red light and animals were placed in the dark for 16 hours. 
This method is an amalgamation of two previous published methods (Fu et al., 
2005, Tu et al., 2006).  
 RPE cell transplantation 
To investigate the ability of RPE cell suspension to integrate into mouse retina 
Shef 6 hESC-RPE cells were transplanted in to the subretinal space in mouse 
retina. Shef 6 hESC-RPE cells (Passage 2) were incubated with accutase at 37˚C 
for 80 minutes, until the cells become round. They were then put through a cell 
strainer. A sample was taken to look at cell viability by mixing 1:1 cell 
solution:trypan blue. Trypan blue is a dye which healthy cells, with intact cell 
membranes will not absorb, but it can transverse the membrane of a dead cell. 
Thus, the number of dead cells in a sample can be counted to determine viability 
of the cells. Cells were spun down and re-suspended in Dulbecco’s modified 
eagle’s medium (DMEM) cell resuspension solution (DRS: 0.005% DNase1, 
0.5mM NAC in DMEM F12) to a concentration of 50,000 cell/µl. Animals were 
anesthetised with Ketamine (12 mg/100g; Narketan® 10, vétoquinol) and 
Medetomidine Hydrochloride (0.07 mg/100 g; Domitor, Orion Pharma) in injection 
water (Norbrook, Newry, UK) via the IP route. Pupils were dilated, to allow the 
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observation of the back of the eye, with 1% tropicamide (Bausche and Lomb, 
Kingston-on-Thames, UK) and 2.5% phenylephrine (Bausche and Lomb, 
Kingston-on-Thames, UK). Observing the back of the eye during this procedure 
aids the delivery of the cells to the correct retinal layer and the success of the 
surgery is determined visually, by observing retinal detachment and no retinal 
bleeding. Viscotears® (Alcon) was applied to the cornea to maintain hydration. 
1.5 µl cell suspension was injected into the sub-retinal space and a counter-punch 
was delivered to the cornea to relieve pressure and avoid reflux of cells out of the 
eye. Animals were recovered from medetomidine hydrochloride with 
antipamezole (0.3 mg/100 g; Antisedan, Vétoquinol) in injection water (Norbrook, 
Newry, UK) via the IP route. Mice had been given 170mg/L cyclosporine 
(Norvartis) in the drinking water three days prior to the transplantation. Animals 
remained on the immunosuppressant for the remainder of the experiment. 
 rpe65 gene therapy 
Animals were anesthetised with Ketamine (12 mg/100g; Narketan® 10, 
vétoquinol) and Medetomidine Hydrochloride (0.07 mg/100 g; Domitor, Orion 
Pharma) in injection water (Norbrook, Newry, UK) via IP route. Pupils were dilated 
with 1% tropicamide (Bausche and Lomb, Kingston-on-Thames, UK) and 2.5% 
phenylephrine (Bausche and Lomb, Kingston-on-Thames, UK). Viscotears® 
(Alcon) was applied to the cornea to maintain hydration. 1.5 µL virus preparation 
(1 x 1012 particles/ml) was injected into the sub-retinal space between the RPE 
and photoreceptors of the Left eye and 2 µL was injected into the vitreous of the 
right eye, using a 32-gauge needle attached to a Hamilton syringe. A counter-
punch was delivered to the cornea to relieve pressure and avoid reflux of virus. 
Animals were recovered from medetomidine hydrochloride with antipamezole 
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(0.3 mg/100 g; Antisedan, Vétoquinol) in injection water (Norbrook, Newry, UK) 
via IP route. 
 Statistical Analysis 
All statistics were analysed using graphPad Prism (Graphpad Software, San 
Diego, CA). For comparing two groups with one variable a non-parametric Mann 
Whitney test was used and or more than two groups a non-parametric Kruskal-
wallis test and post-hoc Dunn’s multiple comparisons test was used. For two-
variables Two-way Analysis of variance (ANOVA) was calculated followed by 
Holm-Sidak’s multiple comparisons test as this is a powerful test. Where data 
was missing and an ANOVA was not possible to be carried out, the Holm-Sidak 
comparisons test was used to analyse the data. All graphs plot the mean ± SEM. 
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Chapter 3 NaIO3: Model of AMD 
 Introduction 
In this chapter, NaIO3 will be used to selectively kill RPE cells to mirror the death 
of RPE cells seen in dry AMD. The aim is to look at the potential benefits and 
examine the limitations of using this model for studying RPE cell transplantation. 
One of the exciting possibilities of this model is the anchoring of donor RPE on 
Bruch’s membrane seen in mice (Carido et al., 2014) and rabbits (Petrus-Reurer 
et al., 2017). In studies where host RPE remain, grafted RPE cells can be found 
as clumps in the subretinal space (Carido et al., 2014, Li and Turner, 1991, 
Seaton and Turner, 1992, Sheedlo et al., 1991, Carr et al., 2009). Based on 
published work, it is hypothesised that NaIO3 will create conditions similar to 
those seen in dry AMD and will be a useful model for studying RPE cell 
transplantation. 
But, before using the model for transplanting RPE cells, an optimum dose and 
route of administration of NaIO3 must first be determined. There is much variation 
in the literature surrounding the route of administration, dose of NaIO3 given and 
the time delay following NaIO3 administration, with severity and time delay in 
pathology depending greatly upon dose/route of administration. Therefore, the 
overall aim in this chapter is to determine optimal parameters for creating an RPE 
cell deficient retinal environment, which retains the ability of effectively signal the 
restoration of photoreceptor function following RPE cell transplantation. 
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 Validating the toxic effect of NaIO3 on the retina 
 Introduction 
Comparing the literature there are 3 common methods used for delivering NaIO3: 
intravenous, IP and retro-orbital. While administering NaIO3 via the caudal tail 
vein requires a higher dose to achieve similar results to those obtained via the 
orbital plexus (Enzmann et al., 2006, Machalinska et al., 2010, Redfern et al., 
2011), animals require general anaesthesia for retro-orbital injection. General 
anaesthetic is not required for either IP or intravenous injection. Anaesthetising 
animals involves the risk of poor recovery and it is desirable to avoid this extra 
procedure if possible. NaIO3 administered via the tail vein has a more powerful 
effect on the RPE than IP injection. 70 mg/Kg injected into the tail vein resulted 
in RPE cell loss in the whole retina (Carido et al., 2014, Enzmann et al., 2006), 
whereas, 100 mg/Kg administered via IP did not result in total loss of RPE cells 
(Kiuchi et al., 2002). After our preliminary attempts to administer saline via the tail 
vein, it was realised that this method was quite difficult and hence too dangerous 
for me to preform, therefore, NaIO3 was administered via IP in the first instance 
in a small pilot study to confirm the functioning of the chemical. 
 Methods 
NaIO3 Administration 
A 25g mouse was administered 60 mg/Kg NaIO3 in sterile 0.9% NaCl IP at a 
volume of 200 µL. Two control mice, weighing 24-25g, were also injected IP with 
200 µL sterile 0.9% NaCl. RPE cell death was reported 3 days post NaIO3 
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administered via IP injection (Enzmann et al., 2006), thus this is the time point 
chosen to be examined in this experiment. 
ERGs 
Scotopic and Photopic ERGs were recorded 3 days after NaIO3 treatment as 
described in chapter 2 (page 93). As this was a small pilot experiment, perfusion 
was not performed, instead, following ERG recordings, animals were culled by 
cervical dislocation and their eyes excised, the cornea pierced and placed in 4% 
paraformaldehyde overnight. 
Flatmounts 
After fixation, the retina was removed from the left eye cup and the RPE was 
stained with DAPI (1:5000 in PBS). 
Rhodopsin staining 
Right eyes were cryoprotected, sectioned and stained as described in Chapter 2 
page 99. The primary antibody used was anti-rhodopsin raised in rabbit diluted 
1:1000 (abcam) and the secondary was donkey anti-rabbit FITC, diluted at 1:200 
(Jackson Immuno Research, West Grove, PA, USA). Images were captures on 
the Zeiss 700 confocal microscope. 
 Results 
Effect of 60 mg/Kg NaIO3 on the ERG 
ERG responses were reduced in NaIO3-treated mice and the wave was often 
negative (Figure 3.1).  In saline-treated mice, the b-wave is seen at -5 Lg cd.s/m2, 
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and the a-wave appears at -2 Lg cd.s/m2. These waves are not identifiable in the 
NaIO3-treated mouse. 
 
Figure 3.1 Scotopic ERG 3 days following 60 mg/Kg NaIO3. 
This figure displays scotopic ERG traces from a saline-treated mouse and NaIO3-
treated mouse from -5 to 1 Lg cd.s/m2. NaIO3-treated mice do not have an 
obvious a- and b-wave but show a negative ERG at higher light intensities. Both 
right (RE, black) and left (LE, grey) eye traces are displayed. The vertical scale 
indicates 500 µV and the horizontal scale indicates 200 ms. 
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The photopic b-wave is also strikingly reduced and appears negative at the higher 
light intensity (Figure 3.2). 
 
Figure 3.2 Photopic ERG 3 days following 60 mg/Kg NaIO3. 
This figure displays photopic ERG traces from a saline-treated mouse and NaIO3-
treated mouse from -1 to 1.5 lg cd.s/m2. NaIO3-treated mice still have a b-wave 
at high light intensities, though, it is markedly reduced and appears on a negative 
wave. Both right (RE, black) and left (LE, grey) eye traces are displayed. The 
vertical scale indicates 100 µV and the horizontal scale indicates 50 ms. 
Death of RPE cells following 60 mg/Kg NaIO3 
RPE nuclei have mostly disappeared 3 days following NaIO3-treatment and those 
remaining appear swollen (Figure 3.3). 
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Figure 3.3 Nuclear labelling in flatmount RPE 3 days following 60mg/Kg NaIO3. 
Nuclei (blue) in the RPE have mostly disappeared. Remaining nuclei appear 
swollen. Scale bar represents 50 µm. 
Effects of 60 mg/Kg NaIO3 on rods 
Rhodopsin labelling in NaIO3-treated animals was disorganised and not restricted 
to POS compared to control animals (Figure 3.4). 3 days following NaIO3 
treatment POS are disorganised as well as ONL, which has reduced layers of 
cells. 
 
Figure 3.4 Rhodopsin labelling 3 days following 60mg/Kg NaIO3. 
While rhodopsin labelling (green) is present, 3 days after NaIO3-treatment, the 
POS are disorganised and rhodopsin labelling is also found in the PIS. The ONL 
is also disorganised and has a reduction in the number of layers. Scale bar: 20 
µm. 
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 Discussion 
During preliminary work, it was decided that administering NaIO3 via the tail vein 
was an unsafe method of administration and thus, the IP route was then 
examined for the injection NaIO3. This pilot experiment aimed to validate NaIO3 
as an effective toxin to ablate RPE cells and the IP route as a suitable method of 
administration. At 3 days post NaIO3 treatment the ERG recordings are strikingly 
reduced, RPE cells are lost and rod degeneration can clearly be seen. Following 
these results, it is concluded that IP injection appears to be an effective route of 
delivering NaIO3 and the next step is to expand on these results and investigate 
the impact on retinal function by a range of NaIO3 doses delivered IP. 
 Dose response of NaIO3 injected IP 
 Introduction 
Having established that NaIO3 is effective delivered IP and that a dose of 60 
mg/Kg had a marked effect on both RPE cell death and retinal function, a range 
of doses up to 60 mg/Kg were then investigated for their ability to suppress retinal 
function as measured by ERG. As not many studies deliver NaIO3 via the IP route, 
a dose response study was helpful in determining a good dose with would offer 
maximum RPE death. The death of RPE cells was assessed qualitatively in 
eyecup wholemounts.  
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 Methods 
Doses of 0, 15, 30 or 60 mg/Kg NaIO3 diluted in 0.9% NaCL were given to animals 
weighing 24 – 35g (100 µL IP). Scotopic and Photopic ERGs were recorded 3 
days after NaIO3 treatment as described in 2.2.1. 
Statistical Analysis 
a-wave and b-wave peaks were attained from the diagnosys software and 
analysed by repeated measures two-way ANOVA and Holm-sidak multiple 
comparisons test. Each eye was an individual entry, n = 8 for each dose. 
Flatmounts 
Following ERGs animals were culled by cervical dislocation and their eyes were 
fixed in 4% PFA overnight. Animals were not perfused to reduce the time delay 
following ERGs and this study focused on visual function and not much histology 
was carried out. Left eyes had the retina removed and the RPE was stained with 
DAPI for 1 minute (1:5000 in PBS). 
 Results 
Effects of NaIO3 dose response on ERG 
The effects of NaIO3 after 3 days has had a significant reduction on the scotopic 
b-wave amplitude, but the scotopic a-wave was present. The scotopic a-wave 
amplitude in NaIO3-treated animals increased in amplitude with increased light 
intensity (Figure 3.5), similar to control animals. There is not a significant effect 
of the dose of NaIO3 on the scotopic a-wave (Table 2), except at the highest light 
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intensity, which shows untreated animals have a greater a-wave amplitude 
compared to NaIO3-treated animals. 
While the scotopic b-wave amplitude also shows a trend of increasing amplitude 
with light intensity (Figure 3.5), this increasing amplitude is significantly reduced 
in NaIO3-treated animals. There is a clearer dose effect of NaIO3 on the scotopic 
b-wave amplitude, with the smaller dose of 15 mg/Kg NaIO3 having a greater 
amplitude than the higher doses of 30 and 60 mg/Kg (Figure 3.5). 
 
Table 2 Two-way ANOVA of Scotopic ERG 3 days after NaIO3 at different doses 
Two-way RM 
ANOVA 
Scotopic A-wave Scotopic B-wave 
F (DFn, DFd) P-value F (DFn, DFd) P-value 
NaIO3 Dose F (3, 28) = 0.04172 P = 0.9884 F (3, 28) = 12.87 P < 0.0001 
Light Intensity F (6, 168) = 90.20 P < 0.0001 F (6, 168) = 35.96 P < 0.0001 
Interaction F (18, 168) = 1.945 P = 0.0155 F (18, 168) = 5.591 P < 0.0001 
Subjects 
matching 
F (28, 168) = 3.717 P < 0.0001 F (28, 168) = 6.407 P < 0.0001 
 
 
Figure 3.5 Scotopic ERG 3 days after NaIO3 IP dose response. 
The scotopic a-wave is quite robust in NaIO3-treated animals at 3 days. At the 
highest light intensity there is some significant differences between animals 
treated with 15 mg/Kg (grey) or 30 mg/Kg (pink) NaIO3 compared to saline-
treated animals. Scotopic b-wave amplitudes are decreased in all NaIO3-treated 
animals and show a dose response where the lower NaIO3 dose of 15 mg/Kg 
(grey) is less reduced than higher doses of 30 (pink) and 60 mg/Kg (wine). 
Asterisks indicate significant levels from post hoc tests, colour coded to match 
dosage groups: *P < 0.05, **P < 0.01, ***P< 0.001, ****P < 0.0001. 
 
The Photopic b-wave amplitude (Figure 3.6) in NaIO3-treated mice appears to be 
less affected than the scotopic b-wave amplitude (Figure 3.5). The photopic b-
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wave amplitude shows a trend of increasing amplitude with increasing light 
intensity and NaIO3-treated animals have a lower amplitude than control animals 
(Table 3). 
Table 3 Two-way ANOVA of photopic b-wave amplitude 
Two-way RM ANOVA F (DFn, DFd) P-value 
Dose F (3, 28) = 5.646 P = 0.0037 
Light Intensiy F (3, 84) = 208.9 P < 0.0001 
Interaction F (9, 84) = 2.508 P = 0.0136 
Subjects (matching) F (28, 84) = 2.298 P = 0.0019 
 
 
Figure 3.6 Dose response of NaIO3 on photopic ERG after 3-days. 
Photopic ERG b-wave amplitudes are reduced in NaIO3-treated animals 
compared to control animals, although, there is not a clear effect of the different 
doses of NaIO3 on the photopic b-wave amplitude. Asterisks indicate significance 
from post-hoc tests: **P < 0.01, ****P < 0.0001. 
 
While diminishing effects are seen in the ERG of animals treated with NaIO3 on 
the ERG, there is not an obvious correlation between dose and effect on ERG. 
This is supported by the variation in traces within groups (Figure 3.7 and Figure 
3.8), where the effect of NaIO3 is not entirely consistent even at the highest dose 
of NaIO3 administered. 
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Figure 3.7 Scotopic ERG traces at 1 log cd/s/cm2 3 days after NaIO3. 
This figure displays the average scotopic trace of both eyes for each animal at 1 
log cd/s/cm2. The vertical scale bar indicates 500 µV and the horizontal scale 
indicates 200 ms. The variability between animals which received the same dose 
of NaIO3 is clear. RE: right eye; LE: left eye. 
 
 
Figure 3.8 Photopic ERG traces at 1.5 log cd/s/cm2 3 days after NaIO3. 
This figure displays average photopic traces of both eyes for each animal at 1.5 
log cd/s/cm2 3 days after NaIO3 administration. The photopic ERG appears to be 
less affected than the scotopic ERG (Figure 3.7). There is some variation 
between animals receiving the same dose of NaIO3. RE: right eye; LE: left eye. 
Effects of NaIO3 dose response on RPE cell death 
The survival of RPE cells in animals from the various dosage groups was 
analysed qualitatively in RPE flatmount stained with DAPI to show RPE nuclei. 
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There was a clear degree of variability in RPE cell survival between animals in 
the same/different dosage groups of NaIO3 (Figure 3.9). 
 
Figure 3.9 Flatmount of RPE Nuclei following NaIO3 
This figure displays RPE flatmounts stained with DAPI 3 days after NaIO3 
treatment. The images are taken from beside the optic nerve. The results are 
varied and some flatmounts show greater loss of RPE nuclei than other treated 
with the same dose of NaIO3. Columns show flatmounts from different animals in 
the same dosage groups. 
 Discussion 
It is clear that NaIO3 has a diminishing effect on retinal function and this is most 
pronounced in the scotopic b-wave. Flatmounts illustrate the loss of RPE cells in 
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the central retina. However, there is much variability between animals receiving 
the same dose of NaIO3. 
 Reversing the functional deficits induced by IP delivery of NaIO3. 
 Introduction 
Having identified NaIO3 induced deficits in the ERG 3 days post-NaIO3 
administration, it is important to investigate if this loss of retinal function can be 
reversed. A key aspect of investigating NaIO3 as a model of AMD with the aim to 
treat with RPE cell transplantation, is the ability to preserve the retina and its 
capacity to function. Due to RPE cell loss, the decreased ERG amplitudes may 
be a direct result of a loss of the visual cycle This possibility will be tested in the 
current pilot experiment, which examines retinal function following NaIO3 
treatment, supplemented with a synthetic chromophore, 9-cis retinal. 
 Methods 
NaIO3 administration 
Three animals weighing 19-21 g were administered 100 µL 60 mg/Kg NaIO3 in 
0.9% NaCl by IP injection. Low numbers were used in this experiment because it 
used a new untested technique. 
9-cis retinal administration 
9-cis retinal was prepared and administered as described in paragraph 2.4.2. Two 
days after NaIO3-treatment, 2 animals, received 9-cis retinal. The remaining 
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animal received a saline vehicle injection. The animals were then kept in 
darkness overnight prior to ERG recording the following day. 
ERG 
Scotopic and photopic ERGs were carried out as described in paragraph 2.2.1.  
 Results 
Effects of 9-cis retinal on ERG following 60 mg/Kg NaIO3 
These scotopic traces cannot confirm increased ERG with 9-cis, however, this is 
because NaIO3 did not have a noticeable effect on the ERG (Figure 3.10). 
Examining the scotopic traces, it is clear that there is too much variability with this 
NaIO3 method. The NaIO3-treated animal which received saline had a largely 
unaffected ERG, with an a- and b- wave that falls within the normal range. This 
suggests that the NaIO3 did significantly affect the ERG in the control animal. 
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Figure 3.10 Traces of scotopic ERG following 60mg/Kg NaIO3 IP and 9-cis retinal. 
This figure shows scotopic ERG traces from animals treated with 60mg/Kg NaIO3 
and then either given saline or 9-cis retinal. The traces are from increasing light 
intensities of -5 to 1 log cd/s/cm2. The vertical scale bar indicates 500 µV and the 
horizontal scale shows 200 ms. Both left eye (grey) and right eye (black) are 
shown. 
 
Photopic ERG results (Figure 3.11) tell a similar story to those seen in the 
scotopic ERG. These results also show strong photopic b-wave in animas treated 
with NaIO3 and thus no effect of 9-cis retinal can be seen. 
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Figure 3.11 Photopic ERG traces following 60mg/Kg NaIO3 IP and 9-cis retinal. 
This figure displays individual photopic ERG traces from animals treated with 60 
mg/Kg NaIO3, who then received either saline or 9-cis retinal. The vertical scale 
bar indicates 100 µV and the horizontal scale shows 100 ms. Both left eye (grey) 
and right eye (black) are shown. 
 Discussion 
While this experiment did not show a significant benefit of 9-cis retinal, this is 
likely due to the variability of NaIO3, and the limited number of animals studied. 
While injecting IP is a simple method of administering NaIO3, it is clear from the 
data presented above in the experiments 3.3 and 3.4 that this method has a lot 
of variability. Thus, injecting retro-orbitally, may be more suitable for the purposes 
of this thesis. 
 Retro-orbital injection of NaIO3 
 Introduction 
Given the issue of variability of the effect of NaIO3 using the IP route of 
administration, it was decided that a retro-orbital approach may help to reduce 
this variability as the chemical is being delivered to the target site. The literature 
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shows that a dose of 40 mg/kg delivered retro-orbitally in mice results in the whole 
RPE being destroyed within 24 hours and a completely diminished the scotopic 
and photopic ERG by day 3. A lower dose of 20 mg/kg, resulted in the peripheral 
retina much less severely degenerated, with healthy polygonal cells remaining 
and a small remaining photopic b-wave observed (Machalinska et al., 2010, Xia 
et al., 2011). Thus, a dose of 40 mg/Kg NaIO3 was chosen for removing RPE 
cells. While a range of time points were used for histology assessment, the 
timepoint of 1 month was chosen for examining functional tests as this was a 
realistic time point for assessing post-grafting efficacy of RPE cells, the main 
objective of this chapter. 
  
 Methods 
Administering NaIO3 retro-orbitally 
Female mice aged 11-12 weeks, weighing 19-21 g, were injected retro-orbitally 
behind the right eye with 40 mg/Kg NaIO3, made up to a concentration of 20 
mg/mL, as described in paragraph 2.4.1. Control mice were untreated. 
ERG 
ERG’s were carried out at 1-month post NaIO3 administration as previously 
described in paragraph 2.2.1. 7 animals which received 40 mg/Kg NaIO3 were 
examined and 11 control animals. A-wave and b-wave peaks were analysed by 
repeated measures two-way ANOVA and Holm-sidak multiple comparisons test. 
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BLA 
The presence of BLA 1 month after 40 mg/Kg NaIO3 was investigated as 
previously described in paragraph 2.2.2. 8 NaIO3-treated mice and 15 control 
mice were placed in the arena when the front half was illuminated. 
PLR 
Effects of RPE cell loss on the PLR were tested 1 month after NaIO3 
administration. Only right eyes were tested and the PLR was examined as 
described in paragraph 2.2.3. Light intensities used were from 0.8 – 8000 
µW/cm2/s, increased in log units. The n numbers used are presented in Table 4. 
PLRs recorded at 800 and 8000 µW/cm2/s were not analysed statistically due to 
the low number of controls recorded. 
Table 4 numbers of animals examined by pupilometry. 
Light Power 8000 800 80 8 0.8 
Control 1 1 6 3 2 
NaIO3 1 1 8 3 3 
Histology 
At 3, 7, 30 and 90 days after NaIO3, animals were fixed with 4% PFA by perfusion 
as described in paragraph 2.3.1 and eyes were cryopreserved, sectioned and 
stained as described in paragraph 2.3.2. The antibodies used were: anti-RPE65 
raised in rabbit (1:500, ab175936; Abcam) or anti-Rhodopsin raised in rabbit 
(1:1000, Abcam) with the secondary antibody raised in donkey against rabbit 
tagged with Alexa Fluor 568 (1:2000, ab10042; Abcam), and anti-melanopsin 
raised in rabbit (1:5000, UF006; Advanced Targeting Systems, San Diego, CA, 
USA)  double labelled with anti-S-opsin raised in goat (1:200, SC-14363, Santa 
Cruz) with secondary antibodies: anti-rabbit IgG raised in donkey tagged with 
Alexa Fluor 568 (1:2000, ab10042; Abcam) and anti-goat raised in donkey tagged 
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with FITC (1:200, Jackson ImmunoResearch, West Grove, PA, USA). Confocal 
stacks were taken on either a Zeiss LSM 700 microscope and a maximum 
intensity projection was obtained using Zen software. 
 Results 
Comparison of ERG recordings from right and left eyes 1 month after NaIO3 
Following the NaIO3 injection retro-orbitally to the right eye, it was important to 
determine if NaIO3 had different effects on the left and right eye. ERGs were 
recorded 1 month after NaIO3 administration and the left eye amplitudes were 
compared to those of the right eyes (Figure 3.12). No differences were seen 
between left and right eye A- and B- wave amplitudes in the scotopic or photopic 
ERG (Table 5). The two-way ANOVAs determined the effect of increasing light 
intensity on the ERG. Both scotopic a-wave and b-wave amplitudes were quite 
reduced but increase with increasing light intensity, while photopic b-wave 
amplitudes did not (Figure 3.12). Given the similar effects of NaIO3 on left and 
right eyes both eyes are used for assessing the effect of NaIO3 on the ERG. 
Table 5 Two-way ANOVA NaIO3 1 month LE vs RE 
Two-way ANOVA LE Vs RE Light Intensity Interaction 
Scotopic A-wave 
Amplitude 
F (1, 6) = 0.5546 F (6, 36) = 2.886 F (6, 36) = 0.5176 
P = 0.4846 P = 0.0212 P = 0.7910 
Scotopic B-wave 
Amplitude 
F (1, 6) = 0.9725 F (6, 36) = 3.549 F (6, 36) = 0.5857 
P = 0.3621 P = 0.0073 P = 0.7393 
Photopic B-wave 
Amplitude 
F (1, 6) = 0.002419 F (3, 18) = 1.375 F (3, 18) = 0.5068 
P = 0.9624 P = 0.2822 P = 0.6825 
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Figure 3.12 ERG amplitudes of left and right eyes following 40 mg/Kg NaIO3. 
This figure displays graphs of scotopic a-wave (A) and b-wave amplitude (B), and 
photopic b-wave amplitude (C) from left (LE, grey, n = 7) and right (RE, black, n 
= 7) eyes. There were no significant differences between ERG responses from 
left and right eyes. 
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Effects of 40mg/Kg NaIO3 on the scotopic and photopic ERG 
The effects of retro-orbital administration of NaIO3 on the ERG were striking 
(Figure 3.13, Figure 3.14 and Figure 3.15). The a-wave and b-wave amplitudes 
were significantly reduced compared to saline treated animals ( 
Table 6). The average traces illustrate that the a-waves and b-waves were almost 
flatlined (Figure 3.14 and Figure 3.15). 
 
Table 6 Two-way ANOVA of ERG 1-month after 40mg/Kg NaIO3 
Two-way 
ANOVA 
Scotopic A-wave 
Amplitude 
Scotopic B-wave 
Amplitude 
Photopic B-wave 
Amplitude 
NaIO3 F (1, 34) = 79.62 F (1, 34) = 129.8 F (1, 34) = 163.0 
P < 0.0001 P < 0.0001 P < 0.0001 
Light 
Intensity 
F (6, 204) = 99.50 F (6, 204) = 105.5 F (3, 102) = 56.37 
P < 0.0001 P < 0.0001 P < 0.0001 
Interaction F (6, 204) = 42.37 F (6, 204) = 49.77 F (3, 102) = 68.95 
P < 0.0001 P < 0.0001 P < 0.0001 
Subjects 
(matching) 
F (34, 204) = 2.339 F (34, 204) = 5.073 F (34, 102) = 2.124 
P = 0.0001 P < 0.0001 P = 0.0020 
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Figure 3.13 Scotopic and Photopic ERG amplitude, latency and implicit time 1 
month after 40 mg/Kg NaIO3. 
This figure displays the results of scotopic and photopic a- and b-wave amplitudes 
from animals treated with 40 mg/Kg NaIO3 (red, N = 14) and control animals 
(black, N = 22). NaIO3 has a significant dampening effect on scotopic and 
photopic amplitudes. Asterisks indicate significance of post-hoc tests: **P < 0.01, 
****P < 0.0001. 
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Figure 3.14 Scotopic ERG traces 1 month after 40 mg/Kg NaIO3. 
This figure shows average scotopic ERG traces ± SEM of NaIO3-treated animals 
(red) and controls (black), increasing in log units from -5 to 1 Lg cd.s/m2. The 
vertical scale indicated 200 µV and the horizontal scale indicates 100 ms. 
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Figure 3.15 Photopic ERG traces 1 month after 40 mg/Kg NaIO3. 
This figure shows average ± SEM photopic ERG traces of NaIO3-treated animals 
(red) and controls (black) in increasing light intensities: -1, 0, 1 and 1.5 lg cd.s/m2. 
The vertical scale indicated 50 µV and the horizontal scale indicates 20 ms. 
Effects of NaIO3 on BLA 
Rodents have a natural aversion to bright lights, but, following treatment with 
NaIO3, this aversion is significantly reduced (Figure 3.16). Animals treated with 
NaIO3 spent significantly (P = 0.0052, t-test) less time in the dark (29% ± 5) than 
control animal (48% ± 4). Analysing the percentage of time, the animals spend in 
the dark over a 30-minute period neither control nor NaIO3-treated animals 
significantly increase the percentage of time in the dark with time (Table 7) (P = 
0.6, F (1, 134) = 0.2). However, control animals consistently spend around 20% 
more time in the back half compared to NaIO3-treated animals (P < 0.0001, F (1, 
135) = 27.9). 
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Table 7 Linear Regression of time spent in the dark over 30 minutes 
Linear Regression Control (n = 15) NaIO3 (n = 8) 
Equation of the line Y = 0.4639*X + 40.32 Y = 0.2595*X + 24.04 
Slope 0.4639 ± 0.2759 0.2595 ± 0.3123 
R square 0.03113 0.01479 
Is the slope significantly 
non-zero? 
F (1, 88) = 2.828 F (1, 46) = 0.6906 
P = 0.0962 P = 0.4102 
 
Table 8 Two-way ANOVA of time spent in the dark over 30 minutes 
Two-way RM ANOVA F (DFn, DFd) P value 
NaIO3 F (1, 21) = 8.264 P = 0.0091 
Time F (5, 105) = 1.724 P = 0.1354 
Interaction F (5, 105) = 0.2758 P = 0.9255 
Subjects (matching) F (21, 105) = 5.837 P < 0.0001 
 
 
Figure 3.16 BLA is reduced in NaIO3-treated animals 
The first graph shows the percentage of total time animals spent in the dark. 
NaIO3-treated animals (N = 8) spent significantly less time in the dark compared 
to control animals (N = 15). The second graph shows the percentage of time 
spent in the dark in 5-minute bins. Asterisks indicate significance level: *P < 0.05, 
**P < 0.01. 
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Effects of RPE cell death on the PLR 
Interestingly the PLR is still quite robust in animals 30 days after NaIO3 treatment 
(Figure 3.17), although NaIO3 has a significant effect on the PLR at all light 
intensities (Table 9). NaIO3 appears to have the greatest impact on the lower light 
powers. A significant constriction is seen in control animals at 0.8 µW/cm2/s light 
power (P < 0.0001), while no constriction is seen in the NaIO3-treated animals 
(Figure 3.17.A). Maximum constriction was 1 ± 0.22 in NaIO3-treated animals and 
0.26 ± 0.02 in controls. At 8 µW/cm2/s, a significant constriction is seen in the 
NaIO3-treated mice (P = 0.0003) (Figure 3.17.B), reaching a maximum 
constriction of 0.62 ± 0.17 and in controls (P = 0.0002), reaching 0.52 ± 0.15 in 
controls. At 80 µW/cm2/s, significant constriction is seen in both NaIO3-treated 
animals (P < 0.0001) and controls (P < 0.0001). Control animals’ constriction 
became significant 1 second after lights on and stayed significantly constricted 
during light stimulation and the constriction in NaIO3-treated animals became 
significant from 4s onwards. Maximum constriction was 0.29 ± 0.04 in NaIO3-
treated animals and 0.10 ± 0.008 in controls (Figure 3.17.C). At the two higher 
light powers, only 1 animal from each group was tested, as these animals were 
showing clear constriction and because these light levels may be uncomfortable. 
Maximum constriction in NaIO3-teated mice was 0.038 and 0.057 at 800 and 
8000 µW/cm2/s and 0.057 and 0.025 in controls (Figure 3.17.D and E). Two-way 
ANOVA analysis of the maximum pupil constriction is displayed in Table 10. Post-
hoc multiple comparisons test only produced a significant difference at the lowest 
light power of 0.8 µW/cm2/s (P < 0.01) (Figure 3.17.F). Baseline pupil area in 
control and NaIO3-treated animals were 11.01 ± 1.78 and 9.19 ± 1.026, 
respectively, which is not significantly different (P = 0.5, t-test). 
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Table 9 Two-way ANOVA on PLR 1 month after NaIO3 
Two-way RM 
ANOVA 
0.8 µW/cm2/s 8 µW/cm2/s 80 µW/cm2/s 
NaIO3 F (1, ) = 23.13 F (1, ) = 0.3484 F (1, ) = 9.943 
P = 0.0086 P = 0.5867 P = 0.0083 
Time F (5, ) = 6.155 F (18, )= 4.492 F (23, ) = 75.06 
P = 0.0013 P < 0.0001 P < 0.0001 
Interaction F (5, ) = 14.94 F (18, ) = 1.003 F (23, ) = 9.077 
P < 0.0001 P = 0.4668 P<0.0001 
Subjects 
(matching) 
F (4, ) = 1.587 F (4, ) = 20.11 F (12, ) = 29.25 
P = 0.2166 P < 0.0001 P<0.0001 
 
 
Table 10 Two-way ANOVA of maximum pupil constriction 1 month after NaIO3 
Two-way ANOVA F (DFn, DFd) P value 
NaIO3 F (1, 19) = 5.524 P = 0.0297 
Light Power F (4, 19) = 9.556 P = 0.0002 
Interaction F (4, 19) = 3.037 P = 0.043 
 
 132 
 
Figure 3.17 PLR 
constriction 1 month 
after NaIO3 
treatment 
This figure displays 
PLR constriction at 
increasing light 
power and 
representative video 
stills before (dark) 
and after (light) light 
stimulation. At 0.8 
µW/cm2/s, there is no 
constriction in the 
NaIO3-treated 
animals, while a 
robust constriction is 
seen in control 
animals (A). At 
higher intensities, 
NaIO3-treated 
animals have a PLR 
(B-E). Constriction 
traces and video 
stills at each light 
power show a 
stronger constriction 
in control animals 
compared to NaIO3-
treated animals. The 
maximum pupil 
constriction mirrors 
this (F). Asterisks 
indicate significance 
level: **P < 0.01. 
Analysing the effects 
of NaIO3 on the 
dilated pupil area 
shows that NaIO3 
does not affect the 
baseline pupil area 
(G). 
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Effects of RPE cell loss on opsins in the retina 
RPE65 expression is a good marker for healthy RPE cells and loss of this maker 
can indicate RPE cell death. In control retina, RPE65 labelling is specific to the 
RPE layer, just 3 days after NaIO3 treatment RPE65 labelling is severely 
diminished, even though there is still pigment in the subretina, although, it is 
unorganised and not restricted to the RPE layer but found in the POS layer. The 
RPE layer also does not stain for nuclei. Thus, is can be concluded that the RPE 
cells are dead but the melanin has yet to be cleared (Figure 3.18).  
Studying photoreceptor opsins by immunohistochemistry provides information on 
the level of opsin expression and the location of opsin expression which can be 
interpreted to determine the health and functionality of the photoreceptor. 
Rhodopsin, which is located in the POS, shows disorganisation of the POS 3 
days after NaIO3 treatment (Figure 3.19). At 7 days after NaIO3 treatment the 
pigmented RPE layer becomes patchier as pigment is lost (Figure 3.18) and POS 
appear shorter (Figure 3.19). 30 days after NaIO3 treatment no RPE65 labelling 
is identified and much of the RPE pigment is lost. At 90 days pigment is seen 
spanning the retina (Figure 3.18). It is found in the INL and IPL and appears to 
be travelling through the retina by Müller glia, which spans the layers of the retina. 
Similar images to this are reported 3-months after NaIO3 administration 
(Machalinska et al., 2013). The ONL is reduced to around 7 layers and S-opsin 
labelling is severely reduced and mislocated to the PIS and ONL. Melanopsin 
labelling is faint in the GCL, while, melanopsin labelling is still strong in the off 
sublamina (Figure 3.20). 90 days after administering NaIO3 there is no evidence 
of RPE cells, except for some pigment mislocated to the inner retina. The ONL is 
reduced to 1-2 layers and now lie directly on top of the choroid (Figure 3.18). No 
rhodopsin labelling is detected (Figure 3.19). 
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Figure 3.18 RPE65 labelling in NaIO3-treated animals 
RPE65-labelling (red) is seen in RPE cells in the control retina. Images with 
transmitted light show the RPE as a distinct pigmented row of cells. 3 days after 
NaIO3 administration, RPE65-labelling is greatly diminished and the pigmented 
row of RPE cells are less organised with pigment in the POS layer and no nuclei 
stained in the RPE. At 7 days post NaIO3 treatment the pigment is patchy. 30 
days after NaIO3 administration no RPE65-labelling is identified and the ONL is 
reduced to around 7 layers and much of the RPE pigment is lost. 3 months after 
administering NaIO3 there is no evidence of RPE cells, except for pigment that is 
mislocated to the inner retina. The ONL is reduced to 1-2 layers and now lie 
directly on top of the choroid. Scale bar indicates 50 µm. 
 
 
Figure 3.19 Rhodopsin labelling in NaIO3-treated animals. 
Rhodopsin labelling (red) is located in POS. 3 days following NaIO3-treatement 
the POS appear disorganised. At 90 days there is no rhodopsin labelling and the 
ONL is reduced to one layer. Scale bar indicates 50 µm. 
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Figure 3.20 Melanopsin and S-opsin labelling 1 month after NaIO3. 
At 1 month after NaIO3-treatment S-opsin labelling (green) is severely diminished 
and mislocated to the PIS. Melanopsin labelling (red) is faint in the GCL, while, 
melanopsin labelling is still strong in the off sublamina. Scale bar indicates 50 
µm. 
 Discussion 
Evaluating the new method of delivering NaIO3, the results show much less 
variability between animals, compared to the results obtained from administering 
NaIO3 IP. While NaIO3 is administered retro-orbitally on the right eye, the left eye 
shows to be equally affected in the ERG. Studies which have used this method 
in mice, often do not specify whether NaIO3 was administered to both eyes or just 
one and thus do not specify any differences between eyes in their results 
(Machalinska et al., 2010, Wang et al., 2014, Xia et al., 2011). But, this has been 
looked at in papers which have looked at other animals. Rats injected with 40 or 
60 mg/Kg NaIO3 via the retro-orbital route also showed a significant loss in the 
scotopic a- and b-wave amplitude in the contralateral eye, although this effect 
was significantly milder than that in the ipsilateral eye (Kadkhodaeian et al., 
2016). Another study in rabbits given 40 mg/Kg NaIO3 also showed an effect in 
the contralateral eye. Comparison between contralateral and ipsilateral was not 
possible in this study as eyes had been treated differently prior to NaIO3 
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administration (Textorius et al., 1985). A study on primates which were injected 
into the carotid artery with 10 mg/Kg NaIO3 saw damage in the ipsilateral eye but 
no affect in the contralateral eye (Nishimura et al., 1990). 
The scotopic ERG is significantly diminished. At high light intensities where the 
scotopic a-wave is pronounced in the control ERG, there is significant differences 
detected between NaIO3-treated eyes and controls. The scotopic b-wave is also 
significantly reduced in NaIO3-treated animals again this is more pronounced at 
higher intensities where the scotopic b-wave is very distinguished in control eyes. 
This is also true for the photopic b-wave. There is a significant reduction in the 
photopic b-wave of NaIO3-trreated animals compared to controls, especially at 
high light intensities where the control photopic b-wave is detected. These results 
mirror that seen the literature (Machalinska et al., 2011), where both scotopic and 
photopic b-waves are lost in animals treated with 40 mg/Kg NaIO3 retro-orbitally. 
At 1 month after NaIO3 administration no RPE65 labelling is identified and S-
opsin is strikingly reduced and mislocated to the PIS and ONL justifying results 
seen in the photopic ERG. This may be due to the loss of chromophore due to 
RPE cell death. It has been shown in rpe65-/- mice that replacing chromophore 
can restore cone opsin to POS (Rohrer et al., 2005). It is thought that 
chromophore is required for cone opsin folding and trafficking. The same is not 
true for rhodopsin, which is located in the POS of NaIO3-treated animals. 
Although, rhodopsin labelling is still present in the POS, and the ONL, while 
reduced, has still around 7 layers of cells, the scotopic ERG is almost completely 
lost. This is most likely because of the lack of chromophore. 
Mice have a natural aversion to light and seek out dark environments (Misslin et 
al., 1989, Semo et al., 2010). Both melanopsin and outer-retinal photoreceptors 
can drive BLA (Semo et al., 2010). NaIO3 significantly reduces the BLA in mice. 
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Ideally this experiment would be repeated with mice run in a completely dark 
arena, to compare. Unfortunately, this was not possible due to restriction in the 
number of animals available. Thus, it cannot be determined if the BLA is 
completely lost. However, it is known from immunohistochemistry that 
melanopsin expression is reduced and thus its function is also likely reduced. 
Vision is not the only factor that drives the BLA, anxiety also plays a part in this 
choice (Hascoet et al., 2001, Misslin et al., 1989). C57 mice show less anxious 
behaviour compared to other mice strains and different behaviours in these 
light/dark choice tests (Kopp et al., 1999). This may explain differences between 
these results and experiments run with other mouse strains. The arena is 
designed so that the animal is placed into the open half of the arena and it is 
given a choice if it wants to enter the dark closed half or stay in the illuminated or 
dark open half. This creates a bias for the open half of the arena. This is why it is 
important to compare the experimental animals to WT controls, as the preference 
for the front or back half cannot be determined by a 50/50 choice. 
The PLR is another functional readout which is driven by both melanopsin and 
the outer-retinal photoreceptors (Lucas et al., 2003). In NaIO3-treated animals the 
PLR is still quite robust although the constriction is reduced compared to WT. The 
greatest deficit in the PLR is seen at low light powers and the maximum 
constriction graph resembles that seen in an rd cl mice (Lucas et al., 2003), where 
melanopsin drives the PLR at high light irradiances and cannot drive a 
constriction at lower irradiances of 11 log photons/cm2/s, comparable to 0.8 
µW/cm2/s used in this study. Opn4-/- mice have a PLR at this irradiance and lower 
irradiances, which is driven by outer-retinal photoreceptors (Lucas et al., 2003). 
This suggests that any residual function of the outer-retinal photoreceptors in the 
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NaIO3-treated animals is not enough to drive the PLR. This also supports the 
results from the ERG. 
Thus, it is established that, 1 month following NaIO3 treatment, RPE cells are 
dead and the pigment is being cleared. Cone photoreceptors are severely 
diminished and remaining cones have opsin mislocated to the PIS. Rods are still 
present; however, they are disorganised, there are reductions in the ONL and the 
function of the outer-retinal photoreceptors is severely diminished. While 
melanopsin labelling is diminished, it appears that it may still be able to drive the 
PLR. 
 Can retinal function be rescued in NaIO3-treated animals? 
 Introduction 
We know from the last experiment that while outer-retinal photoreceptors have 
severely diminished responses, rod photoreceptors are still present even 30 days 
after NaIO3 treatment. Perhaps these rods are not functioning due to the loss of 
the visual cycle following RPE cell death. It is an important factor to consider as 
the purpose of investigating this model is for its use in RPE cell transplantation. 
Carido and colleagues used NaIO3 as a model of RPE degeneration for RPE cell 
transplantation. They were able to show good RPE cell integration, with grafted 
RPE cells forming a monolayer in the subretinal space. However, despite the 
success of RPE cell transplantation, no functional recovery was seen (Carido et 
al., 2014). There could be a number of factors that resulted in the inability of the 
grafted RPE cells to restore function. While the grafted RPE cells were able to 
phagocytose POS, it is unknown if these RPE cells were able to perform the 
visual cycle (Carido et al., 2014). It is also unknown if function in these remaining 
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photoreceptors can be rescued. In this experiment, this is examined. 9-cis retinal 
is a synthetic chromophore which can be administered to NaIO3-treated animals. 
This bypasses the need for a functioning visual cycle and it can be determined if 
the remaining photoreceptors are functional and if visual responses can be 
rescued. 
 Methods 
NaIO3 administration 
C57 mice were anaesthetised and injected with 40 mg/Kg NaIO3 retro-orbitally on 
the right eye as described in the methods section of this chapter, page 101. The 
ability of 9-cis retinal to recover visual function was tested 3, 7, and 30 days after 
NaIO3 treatment by ERG. 
Chromophore Replacement 
9-cis retinal was prepared and administered I.P to mice under dim red light as 
described in 2.4.2, which were then placed in the dark for 16 hours before the 
ERG was recorded. 
ERG 
Animals were anaesthetised and prepared for ERG recordings as described in 
paragraph 2.2.1. However, as there was a finite amount of chromophore available 
only scotopic ERGs were recorded and only the brightest intensity flash was 
used. Flash stimuli of 1 lg cd.s/m2 were presented three times with 1-minute 
intervals in a ganzfeld colour dome by LED stimulator and responses were 
measured using Espion Diagnosis software. Differences between left and right 
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eyes were first determined and once it was shown that the right and left eye were 
equally affected by NaIO3 both eyes were used in the analysis and were entered 
as separate values. Untreated animals were also recorded for comparison. The 
n numbers were 6 controls, 3 days post NaIO3 had 8 in the saline and 8 in the 9-
cis retinal group and 7 days post NaIO3 had 8 in the saline and 6 in the 9-cis 
retinal group. The same animal was not used for examining the effects of 9-cis 
reitinal on NaIO3-treated animals in the control and experimental group because 
of the rapid degeneration that occurs in the retina at 3 and 7 days after NaIO3 
administration.  At 30 days after NaIO3 administration the retinal degeneration 
has slowed down and it was decided that he same animals could be used prior 
to-  and after 9-cis retinal administration. The 30 days post NaIO3 group used the 
same 6 animals for NaIO3 and NaIO3 following 9-cis retinal ERGs, giving an n of 
12 for both groups. Animals were given saline via an IP injection at 26 days after 
NaIO3 and the ERG was recorded and animals were recovered. On Day 33 after 
NaIO3 the same animals were given 9-cis retinal and their ERG was recorded. 
This removed the question of variability in effects of NaIO3. 
Statistical Analysis 
To determine if there were any differences between left and right eyes in NaIO3 
and saline-treated or NaIO3 and 9-cis retinal-treated animals a two-way repeated 
measures ANOVA and post hoc Holm Sidak’s multiple comparisons test was 
used with the different ERG components as the second factor. For analysing the 
ability of 9-cis retinal to recover the ERG, the different ERG components were 
analysed by non-parametric Kruskal-Wallis test and Dunn’s multiple comparisons 
test. 
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 Results 
Restoring the ERG 3 days after NaIO3 treatment 
Prior to analysis, both NaIO3 saline and NaIO3 9-cis retinal results were tested for 
differences between left and right eyes but two-way repeated measures ANOVA 
and no statistical significance was found, suggesting that both left and right eyes 
were affected equally by NaIO3. 
Similar to the experiment 3.3, which looked 3 days after NaIO3 administration, 
NaIO3 at 3 days has a greater reduction on the scotopic b-wave than the a-wave. 
NaIO3 also increased the time to peak amplitude of both and a- and b-wave. 9-
cis retinal was able to improve these losses to the b-wave amplitude in some but 
not all animals and it did not improve the latency or implicit time. 
A-wave amplitude (Figure 3.21.A) showed no significant differences (P = 0.0958) 
between untreated (-162.2 ± 10.6 µV), NaIO3 saline (-249.2 ± 26.05 µV) and 
NaIO3 9-cis retinal (-235.3 ± 53.49 µV). A-wave latency saw a significant 
difference (P = 0.0005). The average a-wave latency was 13.58 ± 2.396 ms in 
untreated animals, 80.25 ± 3.255 ms in NaIO3 saline-treated animals and 55.31 
± 12.39 ms in NaIO3 9-cis retinal-treated animals. Animals treated with NaIO3 had 
a significantly longer a-wave latency compared to untreated animals (Figure 
3.21.B). B-wave amplitude (Figure 3.21.C) also was significantly different (P = 
0.0408). The average b-wave amplitude was 431.3 ± 40.61 µV in untreated 
animals, this was significantly reduced to 231.7 ± 43.38 µV in NaIO3 saline-
treated animals but was rescued to 408.3 ± 91.41 µV in NaIO3 9-cis retinal-treated 
animals. B-wave implicit time (Figure 3.21.D) was also significant (P = 0.045). 
The average b-wave implicit time was 92 ± 9.304 ms in untreated animals, 187.8 
± 30.69 ms in NaIO3 saline-treated animals and 168.3 ± 22.37 ms in NaIO3 9-cis 
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retinal-treated animals. Similar to the a-wave, the b-wave saw an increase in the 
implicit time in NaIO3-treated animals. 
While no significant differences were seen in NaIO3 saline-treated animals and 
NaIO3 9-cis retinal-treated animals 3 days after NaIO3 treatment in the different 
ERG components, there was also no significant difference between NaIO3 9-cis 
retinal-treated animals and untreated animals. This is likely due to large variation 
in the NaIO3 9-cis retinal-treated animals. Looking at the individual ERG traces it 
becomes clear that 3 days after NaIO3 treatment some animals respond to 9-cis 
retinal treatment, while other animals do not (Figure 3.21.E). 
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Figure 3.21 ERG 3 days post NaIO3 with 9-cis retinal. 
This figure shows graphs of the scotopic a- and b-wave amplitude, latency and 
implicit time in animals 3 days after NaIO3-treatment followed by treatment with 
saline (red, N = 8) or 9-cis retinal (grey, N = 8). Recordings from untreated 
animals are included for comparison (black, N = 6). The a-wave amplitude is not 
significantly different between the three groups; however, the latency is increased 
in NaIO3-treated animals compared to untreated animals. B-wave amplitude is 
significantly reduced in NaIO3 saline-treated animals compared to untreated 
animals. Asterisks indicate significance levels revealed in post-hoc tests: *P < 
0.05, **P < 0.01. The traces are from individual animals 3 days after NaIO3-
treatment which had been treated with saline or 9-cis retinal. The a-wave is still 
a strong component of the ERG 3 days after NaIO3 treatment. Only half of the 
animals responded strongly to 9-cis retinal treatment. The vertical scale bar 
indicates 200 µV and the horizontal scale bar represents 200 ms. 
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Can the ERG be restored 7 days after NaIO3 treatment? 
At 7 days after NaIO3-treatment, the a-wave is still a strong component of the 
ERG, albeit with increased latency, but the b-wave is completely lost at this time. 
At 7 days after NaIO3-treatement, 9-cis retinal was unable to restore the b-wave 
in any animal. 
Comparing left and right eyes in both NaIO3 saline- and NaIO3 9-cis retinal-
treated animals by two-way repeated measures ANOVA, showed no statistical 
difference. Thus, both eyes were used in analysis. WT untreated data in this 
analysis is the same as that used when looking at 3 days post NaIO3 treatment. 
There were no significant differences to the a-wave amplitude (Figure 3.22.A 
between groups (P = 0.09136). The average amplitude 7 days after NaIO3 
administration was -216.8 ± 52.24 µV and -147.4 ± 15.76 µV in animals treated 
with saline and 9-cis retinal, respectively. There was a significant effect on A-
wave latency (P = 0.0002). The a-wave latency was significantly longer in NaIO3-
treated animals (P < 0.01), even with 9-cis retinal (P < 0.05). No significant 
difference was found between NaIO3 saline-treated animals and NaIO3 9-cis 
retinal animals (Figure 3.22.B). The average a-wave latency in NaIO3 saline-
treated animals was 63.6 ± 8.5 ms and 46.5 ± 0.6 in NaIO3 9-cis retinal animals. 
B-wave amplitude also had a significant difference (P = 0.0003). The b-wave in 
the untreated animals was significantly less than animals treated with NaIO3 
which received either saline (P < 0.5) or 9-cis retinal (P < 0.01). No significant 
difference was found between the NaIO3-treated groups (Figure 3.22.C). The 
average b-wave amplitude 7 days after NaIO3 treatment was 128.6 ± 40.3 µV in 
animals treated with saline and 54.4 ± 15.9 µV in animals treated with 9-cis 
retinal. These statistics are further supported by the ERG traces (Figure 3.22.D), 
no improvements on the ERG recordings are seen in the 9-cis retinal group. 
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Figure 3.22 ERG 7 days after NaIO3 with 9-cis retinal. 
This figure displays a- (A)and b-wave amplitudes (C), a-wave latency (B) 7 days 
after NaIO3 treatment followed by treatment with saline (N = 8) or 9-cis retinal (N 
= 6). Untreated animals are displayed for comparison (N = 6). A-wave amplitude 
is not significantly different between groups. NaIO3-treated animals with either 
saline or 9-cis retinal have significantly longer a-wave latency and reduced b-
wave amplitude than untreated animals. Asterisks indicate significance level in 
post-hoc tests: *P < 0.05, **P < 0.01. The traces are from individual animals 7 
days after NaIO3-treatement and treated with either saline or 9-cis retinal (D). 
These NaIO3-treated animals have a negative ERG and no improvements in the 
ERG are seen in animals which received 9-cis retinal. The vertical scale indicated 
200 µV and the horizontal scale bar indicates 200 ms. 
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Rescuing visual function 30 days after NaIO3 treatment 
Prior to assessing effects of 9-cis retinal, two-way ANOVA determined that there 
was no significant difference between left and right eyes after NaIO3 treatment or 
after 9-cis treatment. Thus, both eyes were used in the analysis. 
At 30 days the ERG is flatlined in NaIO3-treated animals. The a-wave which had 
been present at 3 and 7 days after NaIO3-treatment is lost. Interestingly, 9-cis 
retinal was able to improve both the a- and b-wave amplitudes of NaIO3-treated 
animals at this time. This was not possible at 7 days after NaIO3-treatment.  The 
a-wave latency and b-wave implicit time are both significantly greater NaIO3- 9-
cis retinal-treated animals than untreated animals. 
There was a significant difference between untreated, NaIO3-treated and NaIO3 
9-cis retinal-treated a-wave amplitude (P < 0.0001). There is a significant 
increase in the a-wave amplitude in NaIO3-treated animals after receiving 9-cis 
retinal compared to ERG recording prior to 9-cis retinal-treatment (P < 0.0001). 
Average a-wave amplitude reached was -60.2 ± 12.2 µV in NaIO3-treated 
animals, which improved to -230.2 ± 23.1 µV with 9-cis retinal administration, 
comparable to WT (Figure 3.23.A). A-wave latency was not recorded for NaIO3-
treated animals due to the low amplitude. NaIO3-9-cis retinal-treated animals 
have a significantly longer a-wave latency compared to untreated animals (T-test, 
P = 0.0006). Average a-wave latency in NaIO3-treated animal was 95.5 ± 6.4 ms 
following administration of 9-cis retinal and untreated animals’ latency was 13.6 
± 2.4 ms (Figure 3.23.B).  
B-wave amplitude was also significantly different among groups (P < 0.0001). 
NaIO3 animals had a significantly reduced b-wave amplitude compared to 
untreated animals (P < 0.0001). 9-cis retinal significantly increased the b-wave 
amplitude of NaIO3-treated animals (P < 0.01), albeit, lower than WT. The 
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average b-wave amplitude 30 days after NaIO3 treatment was 74.2 ± 10.1 µV and 
245.6 ± 36.7 following 9-cis retinal treatment (Figure 3.23.C). B-wave implicit time 
was not recorded from NaIO3-treated animals prior to 9-cis retinal administration 
as the amplitude was low. The b-wave latency of NaIO3-9-cis retinal-treated 
animals was significantly greater than untreated animals (P = 0.0134). Average 
b-wave implicit time 30 days after NaIO3 was 249.6 ± 22. ms after receiving 9-cis 
retinal (Figure 3.23.D). 
Interestingly, 30 days after NaIO3 treatment, 9-cis retinal is able to increase the 
a- and b-wave amplitudes, having failed to do to at 7 days after NaIO3. However, 
the latency and implicit time are significantly longer than that in untreated animals. 
The a-wave amplitude can be rescued to levels comparable to untreated animals, 
while the b-wave cannot. This loss of the b-wave and increased implicit time 
reflect retinal damage resulting from the NaIO3. Examining the ERG traces before 
and after 9-cis retinal it is clear to see an increase in the a- and b- wave 
amplitudes (Figure 3.23.E). 
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Figure 3.23 ERG 30 days after NaIO3 with 9-cis retinal. 
This figure plots a- (A) and b-wave (C) amplitudes, a-wave latency (B) and b-
wave implicit time (D) 30 days after NaIO3 and again following 9-cis retinal-
treatment (N = 14). There was a significant difference between groups for each 
of the ERG components. Asterisks indicate significant results in post-hoc tests: 
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. E show average traces of 
animals 1 month after NaIO3 treatment in the left column and a repeated 
recording following 9-cis retinal-treatment on the right. The vertical scale 
indicates 500 µV and the horizontal scale indicates 200 ms. 
 149 
 
 Discussion 
It was shown in the previous experiment that rods are present up to 30 days, thus 
in this experiment, the functionality of rods is tested. It was shown that despite 
rods remaining in the retina, the ERG was significantly diminished and the PLR 
somewhat mirrored that seen in rodless/coneless animals. One theory was that 
the remaining rods are not able to function due to a lack of chromophore, thus 
this was tested by administering chromophore supplement in the form of 9-cis 
retinal. 3 days after NaIO3 treatment the a-wave response is still seen although 
the latency is significantly increased. The b-wave is significantly reduced. At this 
stage 9-cis retinal greatly improves the ERG in around half of the animals. This 
result was not significant when examining a- and b-waves, it is possible that 
increasing the number of animals used at this time point may have shown a 
clearer result. 7 days after NaIO3 treatment the a-wave is still present but the b-
wave is lost and unable to be rescued with 9-cis retinal. 30 days after NaIO3 
treatment the ERG has almost flatlined, however, at this stage 9-cis retinal is able 
to rescue a lot of retinal function and significantly increases the a- and b-wave 
amplitude. The a- wave is restored to levels comparable to WT. Although, the 
latency and implicit time are significantly longer than that seen in untreated 
animals. This experiment shows that retinal recovery is possible 30 days after 
NaIO3 treatment. It is unknown why retinal recovery was not possible at 7 days 
but improves by 30 days, this may be due to retinal recovery which has been 
reported in other studies (Franco et al., 2009, Machalinska et al., 2013, Redfern 
et al., 2011). 
 150 
 
 RPE cell transplant into NaIO3-treated eyes. 
 Introduction 
Carido and colleagues administered 70 mg/Kg NaIO3 to mice via the tail vein. 
One week later 100,000 – 200,000 hESC-RPE cells were transplanted 
subretinally. 3 weeks later hESC-RPE cells had formed extensive monolayers in 
the sub-retinal space, with correct apical-basolateral organisation and attached 
to Bruch’s membrane. There was also evidence of phagocytosis by the grafted 
HESC-RPE cells, despite this, no functional recovery was seen by ERG (Carido 
et al., 2014). In this experiment, a similar approach is taken; 40 mg/Kg NaIO3 is 
administered retro-orbitally, our preferred method of NaIO3 delivery. Also, 
following the result in the previous experiment, cells will be administered 3 weeks 
after NaIO3 treatment, with the aim of assessing the capacity for functional 
recovery by ERG 3 weeks following cell transplantation. 
 Methods 
Administration of NaIO3 retro-orbitally 
7 Animals were anaesthetised and 40 mg/Kg NaIO3 was administered retro-
orbitally to the right eye as described in paragraph 2.4.1. 
hESC-RPE cell preparation and transplantation 
3 weeks after NaIO3 was administered, 75,000 hESC-RPE cells were injected 
subretinally into the left eye of the mice. This was the maximum number of cells 
that could be delivered on the day. This is determined by the number of dishes of 
hESC-RPE suitable for transplantation, on the day, and the number of cells on 
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the dish. These cells then need to be in a workable cell suspension of 50,000 
cells per µL and a minimum volume of 20 µL to allow the cell suspension to be 
drawn up into the needle without air bubbles. This protocol is described in 
paragraph 2.4.3. 
ERG post-transplant 
Animal’s ERG was recorded 3 weeks after they received the cell transplant. 
Animals were dark-adapted, anaesthetised and their scotopic and photopic ERG 
was recorded, as previously described in paragraph 2.2.1.  
9-cis retinal administration 
To test the capacity for rescue in the NaIO3-treated retina, 9-cis retinal was 
administered to the animals the day after their ERG was recorded and the 
animals were placed back into the dark overnight to be re-assessed by ERG. 9-
cis retinal was prepared and administered as previously described in paragraph 
2.4.2. 
ERG after treatment with 9-cis retinal 
The next day, animals were prepared for ERG recordings as described in 
paragraph 2.2.1. 
Histology 
Animals were fixed by perfusion with 4% PFA as described in 2.3.1 and eyes 
were sectioned and labelled by immunohistochemistry as described in 2.3.2. 
Eyes were labelled with anti-human mitochondria (1:500, MAB1273, Millipore) 
and secondary anti-mouse raised in donkey tagged with TRITC (1:200, Jackson 
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ImmunoResearch, West Grove, PA, USA). Eyes were also labelled with RPE65 
raised in rabbit (1:500, ab17936, Abcam) with secondary antibody raised in 
donkey against rabbit tagged with Alexa Fluor 568 and anti-human nuclei tagged 
with Alexa Fluor 488 (1:200, MAB1281A4, Milipore). Images were captured with 
zeiss 700. 
 Results 
Scotopic ERG recordings in NaIO3-treated eyes after RPE cell transplantation 
The scotopic a-wave and b-wave amplitudes are notably reduced for all animals 
as expected following NaIO3-treatment. The scotopic ERG did not see any 
significant improvements with RPE cell transplant. The a-wave amplitude had a 
worse a-wave amplitude in eyes which received cells (Figure 3.24.A). The 
scotopic b-wave amplitude (Figure 3.24.B) shows no difference between eyes 
which received cells and eyes which did not (Table 11).  
 
Table 11 Two-way ANOVA of ERG amplitude following NaIO3 and hESC-RPE 
Two-way ANOVA a-wave amplitude b-wave amplitude 
Light Intensity F (6, 36) = 4.1, P = 0.0032 F (6, 36) = 5.8, P = 0.0003 
hESC-RPE transplant F (1, 6) = 11.9, P = 0.0136 F (1, 6) = 1.3, P = 0.2916 
Interaction F (6, 36) = 3.6, P = 0.0070 F (6, 36) = 1.1, P = 0.3921 
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Figure 3.24 Scotopic ERG in NaIO3-treated eyes, which received RPE 
transplantation. 
This figure displays scotopic a- (A)and b-wave (B) amplitude of NaIO3-treated 
animals which received cells (black, N = 7) or control eyes (red, N = 7). Eyes that 
did not receive cells had a greater a-wave amplitude. There was no significant 
difference between eyes which received cells and eyes which did not in the b-
wave. Asterisks indicate significance levels in post-hoc tests: *P < 0.05, ***P< 
0.001. C displays average traces ± SEM for increasing light intensities for eyes 
which received cells (black) and eyes which did not (red). The vertical scale 
indicates 50 µV and the horizontal scale indicates 50 ms. 
Photopic ERG recordings in NaIO3-treated eyes after RPE cell transplant 
In the photopic ERG there is a significant loss in the photopic a-wave in eyes 
treated with hESC-RPE, similar to that seen under scotopic conditions. Usually 
under photopic conditions only the b-wave is examined. This is because the a-
wave is very small. The a-wave is driven by photoreceptors and under photopic 
conditions in a WT mouse this is the cones, which are not very numerous, and 
hence produce a small output. While animals which were treated with NaIO3 have 
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a strikingly small photopic a- and b-wave, it is clear from the photopic ERG traces 
that the a-wave is completely lost in animals treated with hESC-RPE (Figure 
3.25.C). There is a significant difference between the a-wave amplitude of eyes 
which received a subretinal injection of hESC-RPE and eyes which did not 
(Figure 3.25.A,  Table 12). There is no significant difference in the photopic b-
wave amplitude of eyes which received hESC-RPE cells and the eyes which did 
not (Figure 3.25.B). 
Table 12 Two-way ANOVA of photopic ERG following NaIO3 and hESC-RPE 
Two-way ANOVA a-wave amplitude b-wave amplitude 
Cells F (1, 6) = 6.58, P = 0.0426 F (1, 6) = 0.421, P = 0.5404 
Light Intensity F (3, 18) = 2.8, P = 0.0698 F (3, 18) = 1.66, P = 0.2120 
Interaction F (3, 18) = 4.82, P = 0.0123 F (3, 18) = 0.868, P = 0.4759 
 
 
Figure 3.25 Photopic ERG in eyes which received RPE cell transplant following 
NaIO3 treatment. 
This figure displays the photopic a-wave amplitude (A) and b-wave amplitude (B) 
in eyes treated with NaIO3 followed by RPE cell transplantation (black, N = 7) or 
control eyes which did not receive cells (red, N = 7). Asterisks indicate 
significance level of post-hoc tests: *P < 0.05, **P < 0.01. The traces (C) 
represent the average trace ± SEM at -1, 0, 1 and 1.5 cd.s/m2 in eyes which were 
treated with cells (black) and eyes which did not receive cells (red).The vertical 
scale represents 10 µV and the horizontal scale indicates 20 ms. 
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Is visual function recoverable by 9-cis retinal? 
Scotopic ERG recordings following chromophore supplementation 
To determine if retinal function could be restored in these NaIO3-animals, they 
received 9-cis retinal and ERGs were recorded again. These results showed a 
significant increase in scotopic a- and b-wave amplitudes (Table 13). This shows 
that the eyes treated with NaIO3 could be rescued, but that the subretinal injection 
of hESC-RPE was unable to rescue retinal function (Figure 3.26). 
 
Table 13 Two-way ANOVA ERG following NaIO3, hESC-RPE and 9-cis retinal 
Two-way RM 
ANOVA 
Scotopic a-wave amplitude Scotopic b-wave amplitude 
9-cis retinal F (1, 13) = 16.73, P = 0.0013 F (1, 13) = 19.91, P = 0.0006 
Light Intensity F (6, 78) = 20.53, P < 0.0001 F (6, 78) = 11.50, P < 0.0001 
Interaction F (6, 78) = 9.683, P < 0.0001 F (6, 78) = 1.825, P = 0.1049 
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Figure 3.26 Scotopic ERG in eyes treated with NaIO3, hESC-RPE cells and 9-cis 
retinal. 
A-wave amplitude is significantly increased with supplementary chromophore (A). 
Asterisks indicate significance level from post-hoc tests: *P < 0.05, ****P < 
0.0001. Asterisks in black show a significant difference between eyes which 
received hESC-RPE cells before and after chromophore supplementation. 
Asterisks in red show a significant difference between eyes which did not receive 
cells before and after chromophore supplementation. C shows average traces of 
eyes which did not receive cell (N=7) on the left before (red) and after (orange) 
9-cis supplementation and eyes which receive cells on the right (N = 7) before 
(black) and after (grey). Vertical scale represents 50 µm and horizontal scale 
represents 50 ms. 
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Effect of chromophore supplementation on photopic ERG 
9-cis retinal was also able to improve the photopic ERG. This improvement was 
greatest in eyes which did not receive hESC-RPE transplantation. This suggests 
that the injection of hESC-RPE impacted negatively on retinal rescue. Perhaps 
the injection further damaged the already weakened retina. Under these 
conditions an a-wave was seen in the photopic wave form, as described in (Figure 
3.25). 9-cis retinal created a significantly greater photopic a-wave amplitude in 
eyes treated with NaIO3 (Figure 3.27.a). This improvement in the a-wave was not 
seen in eyes which received a subretinal injection of hESC-RPE. These eyes did 
not have a photopic a-wave prior to 9-cis retinal supplementation. The b-wave is 
significantly increased with 9-cis retinal in eyes which were treated with hESC-
RPE and eyes which did not receive cells (Figure 3.27.B). Statistical results are 
located in Figure 3.27 (Table 14). Average traces (Figure 3.27) illustrate the 
increased a-wave in NaIO3-treated eyes after receiving 9-cis retinal and the 
greater b-wave with 9-cis retinal-treatment. 
 
Table 14 Statistics for photopic ERG of NaIO3-treated mice with RPE-cell grafting 
and 9-cis retinal. 
Two-way RM 
ANOVA 
Photopic a-wave amplitude Photopic b-wave amplitude 
F (DFn, DFd) P value F (DFn, DFd) P value 
Light Intensity F (3, 39) = 12 P < 0.0001 F (3, 39) = 14.3 P < 0.0001 
9-cis retinal F (1, 13) = 7.1 P = 0.0193 F (1, 13) = 11.5 P = 0.0048 
Interaction F (3, 39) = 7.2 P = 0.0006 F (3, 39) = 4.88 P = 0.0057 
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Figure 3.27 Photopic ERG in eyes treated with NaIO3, hESC-RPE cells and 9-cis 
retinal. 
There is a significant increase in the photopic a-wave in eyes which did not 
receive RPE cell grafting when given 9-cis retinal (A). Both eyes which received 
RPE-cell grafting and eyes which did not receive cells had a significantly greater 
photopic b-wave amplitude (B). Asterisks indicate statistic level from post-hoc 
tests: *P < 0.05, **P < 0.01, ****P < 0.0001. Average traces of eyes which did not 
receive cell (N=7) are displayed on the left before (red) and after (orange) 9-cis 
supplementation. Average traces from eyes which received cells are displayed 
on the right (N = 7) before (black) and after (grey). Vertical scale represents 20 
µm and horizontal scale represents 20 ms. 
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Cell transplant histology 
No hESC-RPE cells were found in the subretinal space of transplanted eyes. 
Eyes were labelled for anti-human mitochondria, which was raised in mouse and 
thus, created a large background stain with the anti-mouse secondary antibody 
tagged with Alexa Fluor 568 (Figure 3.28.C). While using an antibody raised in 
mouse to stain mouse tissue is not ideal, this anti-body was helpful in screening 
for cells. Selected slides were also labelled for RPE65 (Figure 3.29.D) anti-human 
nuclear antigen (HNA) (Figure 3.29.E), but no cells positive for these markers 
were detected. hESC-RPE cells were also labelled as a positive control. 
 
Figure 3.28 labelling of human mitochondria. 
A shows nuclei staining (blue) and transmitted light in hESC-RPE cells. B shows 
human mitochondria (red) and nuclei (blue) labelling in hESC-RPE cells. C is an 
image of retina which received hESC-RPE cells and labelled for human 
mitochondria (red) and nuclei (blue). D is the same image as C with transmitted 
light. This is an image around the site of injections. There is a cluster of pigmented 
cells subretinally, but these do not stain positively for human mitochondria. No 
cells positive for human mitochondria were found in transplanted eyes. Scale bar 
indicates 50 µm. 
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Figure 3.29 labelling of RPE65 and human nuclear antibody. 
A, B and C are images of hESC-RPE cells labelled for RPE65 (red), HNA (green) 
and nuclei (blue) with transmitted light. D, E and F are images of an eye which 
received a graft of RPE cells. No cells positive for RPE65 or HNA were found in 
transplanted eyes. The scale bar represents 50 µm. 
 Discussion 
Carido and colleagues administered 70 mg/Kg NaIO3 to mice via the tail vein. 
One week later 100,000 – 200,000 hESC-RPE cells were transplanted 
subretinally. 3 weeks later hESC-RPE cells had formed extensive monolayers in 
the sub-retinal space, with correct apical-basolateral organisation and attached 
to Bruch’s membrane. While, there was evidence of phagocytosis but the grafted 
cells, no functional recovery was seen by ERG (Carido et al., 2014). Given these 
results and the results of experiment 3.6, which saw a recovery effect using 9-cis 
retinal at 1 month after NaIO3 treatment, it was decided that grafting hESC-RPE 
cells 3 weeks after NaIO3 administration may be an optimum for detecting 
improvements in retinal function. Despite this, no improvements were seen in the 
scotopic or photopic ERGs. Unfortunately, no hESC-RPE cells were found in the 
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retina 3 weeks after transplantation. While the subretinal space is an immune 
privileged space, most studies grafting cells into the subretinal space still have 
poor survival, possibly due to resident microglia. In the case of NaIO3-treated 
eyes, had the extra burden of disruption to the BRB, which, reduces graft survival 
(Xian and Huang, 2015). These were also xenografts, contributing to immune 
rejection. From these results, it is difficult to gauge how useful this model is for 
studying RPE transplantation, but rescue of rod retinal function is possible in 
these eyes, as demonstrated by supplementing the animals with chromophore. 
The possibility of retinal recovery in NaIO3-treated eyes with grafted hESC-RPE 
cells, cannot be ruled out, but the model poses many challenges for establishing 
this as a model for studying RPE transplantation. 
 General Conclusions 
In this chapter, NaIO3 was used to selectively kill RPE cells to reflect the death of 
RPE seen in dry AMD, with the aim of assessing potential benefits and 
discovering the limitations of using this model for studying RPE cell 
transplantation. In studies where host RPE cells remain, they can be found as 
clumps in the subretinal space (Carido et al., 2014, Li and Turner, 1991, Seaton 
and Turner, 1992, Sheedlo et al., 1991, Carr et al., 2009). Thus, the removal of 
host RPE cells prior to transplantation, may allow grafted RPE cells to attach to 
Bruch’s membrane and survive in the subretinal space. 
One of the major difficulties in studying this model, is the variability in the literature 
in the route of administration, dose of NaIO3 and the time delay following NaIO3 
administration. Ideally NaIO3 would kill the RPE in the whole retina, to allow 
detection of functional improvements following transplantation of hESC-RPE 
cells. 
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Comparing the literature there are 3 common methods used for delivering NaIO3: 
intravenous, IP and retro-orbital. While administering NaIO3 via the caudal tail 
vein requires a higher dose to achieve similar results to those obtained via the 
orbital plexus (Enzmann et al., 2006, Machalinska et al., 2010, Redfern et al., 
2011), animals require general anaesthesia for retro-orbital injection. Thus, 
administration of NaIO3 by intravenous injection into the caudal tail vein was the 
first route explored. However, this is a difficult technique and NaIO3 is a 
dangerous chemical, and so this route of administration was regarded unsafe. 
Following this, administration of NaIO3 via the IP route was examined. While this 
method validated the efficacy of NaIO3, it became clear that this route of 
administration did not reliably kill RPE cells and some animals had ERG results 
within normal parameters. There was too much variability to assess potential 
improvements in retinal function. Thus, retro-orbital administration of NaIO3 was 
investigated. Given the issue of variability in the effects of NaIO3 using the IP 
route of administration, it was decided that a retro-orbital approach may help to 
reduce this variability as the chemical is delivered to the target site. 
Studies using this route of administration reported total RPE cell loss within 24 
hours and a completely diminished scotopic and photopic ERG by day 3 after a 
dose of 40 mg/Kg NaIO3 (Machalinska et al., 2010). A lower dose of 20 mg/kg, 
resulted in the peripheral retina being much less severely degenerated, with 
healthy polygonal cells remaining and a small residual photopic b-wave observed 
(Machalinska et al., 2010, Xia et al., 2011). Thus, a dose of 40 mg/Kg NaIO3 was 
chosen for removing RPE cells. 
When evaluating the new method of delivering NaIO3, it was found that the results 
had much less variability between animals, compared to data obtained from 
administering NaIO3 IP. Even administering the NaIO3 retro-orbitally to the right 
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eye gave similar results in the left eye, with no statistical differences found 
between ERG recordings from left and right eyes. Previous studies which have 
used this method in mice, often do not specify whether NaIO3 was administered 
to both eyes or just one and thus do not specify any differences between eyes in 
their results (Machalinska et al., 2010, Wang et al., 2014, Xia et al., 2011). Thus, 
this was an important factor to examine in this thesis. 
In this thesis, the dose of 40 mg/Kg NaIO3 delivered retro-orbitally to the right eye 
gave a consistent result of a significantly diminished scotopic and photopic ERG. 
At 1 month after NaIO3 administration, no RPE65 labelling was identified and S-
opsin was strikingly reduced and mislocated to the PIS and ONL, being consistent 
with results seen in the photopic ERG. Rhodopsin labelling is still present in the 
POS at 1 month but the ONL is reduced to around 7 layers of cells and the 
scotopic ERG is almost completely lost. It was believed that this is most likely 
because of the lack of chromophore, as rods are present but their function is 
almost completely lost and it has been seen in rpe65-/-  mice that cones are lost 
first and their opsin mislocates because cone opsin requires chromophore for 
correct folding and trafficking (Rohrer et al., 2005). 
Analysis of the effects of NaIO3 on the melanopsin system after 1 month saw a 
significant reduction in BLA, however, this behavioural response to light is driven 
by both melanopsin and cones (Semo et al., 2010). The PLR is another functional 
readout which is driven by both melanopsin and the outer-retinal photoreceptors 
(Lucas et al., 2003). In NaIO3-treated animals the PLR is still quite robust, 
although, the constriction is reduced compared to WT. The greatest deficit in the 
PLR is seen at low irradiances and the maximum constriction graph resembled 
that seen in the rd/rd cl mouse, without rod and cone function (Lucas et al., 2003), 
where melanopsin drives the PLR at high light irradiances but cannot drive a 
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constriction at lower irradiances of 11 log photons/cm2/s, comparable to the 0.8 
µW/cm2/s used in this study. Thus, it is likely that at these low irradiances, where 
melanopsin cannot drive the PLR, the loss of the PLR in NaIO3-treated animals 
signifies the loss of outer-retinal photoreceptor function. Opn4-/- mice have a PLR 
at this and lower irradiances, which is driven by outer-retinal photoreceptors 
(Lucas et al., 2003), suggesting that any residual function of the outer-retinal 
photoreceptors in the NaIO3-treated animals is not enough to drive the PLR. This 
supports the results from the ERG. Even though the PLR at high irradiances is 
still quite robust, the constriction does fall short of that of WT, suggesting that 
there may also be a small loss in melanopsin function. Consistent with the 
functional data, immunohistochemical labelling also showed a loss of melanopsin 
expression in the on sublamina, but robust express in the off sublamina of IPL. 
The important question of whether retinal function can be restored in NaIO3-
treated mice was initially answered by supplying chromophore. If the remaining 
rods and the retinal circuitry were still functional, then there was a possibility of 
functional rescue. At 3 days after NaIO3 treatment, an improvement in the 
scotopic ERG was seen in half of the animals, by 7 days, 9-cis retinal did not 
show any improvements in the scotopic ERG. Interestingly, by 30 days after 
NaIO3 administration the ERG had almost flatlined, but 9-cis retinal was able to 
rescue a lot of retinal function and significantly increases the a- and b-wave 
amplitudes, although, the latency and implicit time were significantly longer than 
that seen in untreated animals. Thus, this experiment showed that retinal 
recovery is possible 30 days after NaIO3 treatment. 
Many studies have reported improvements in retinal function and retinal histology 
with time, following NaIO3 administration (Franco et al., 2009, Kiuchi et al., 2002, 
Redfern et al., 2011, Machalinska et al., 2013). There is evidence of mitosis, 
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Müller cells proliferation and macrophage migration following NaIO3 
administration (Kiuchi et al., 2002, Redfern et al., 2011), which may play a role in 
the late improvement in NaIO3-treated animals. This may be the reason that 
retinal function rescue was possible at a later time point, while it was not possible 
at 7 days after NaIO3 administration. 
Carido and colleagues administered 70 mg/Kg NaIO3 to mice via the tail vein. 
One week later 100,000 – 200,000 hESC-RPE cells were transplanted 
subretinally. 3 weeks later hESC-RPE cells had formed extensive monolayers in 
the sub-retinal space, with correct apical-basolateral organisation and attached 
to Bruch’s membrane. There was also evidence of phagocytosis by the grafted 
hESC-RPE cells, yet, no functional recovery was seen by ERGs recorded at day 
0, 3, 7, 14, 21 and 28 after hESC-RPE cell transplantation (Carido et al., 2014). 
This indicats that either the transplanted hESC-RPE cells were not fully 
functional, or that the grafted human cells did not survive in sufficient numbers to 
support a light-driven response. No quantification of surviving hESC-RPE cells 
was performed in their study and the cells were not shown to express visual cycle 
markers after transplantation. Thus, given the lack of improvement reported by 
Carido and colleagues and the lack of improvements in the scotopic ERG seen 
earlier in this chapter using 9-cis retinal at early timepoints, it was decided that a 
later timepoint for grafting RPE cells may be advantageous for detecting 
improvements in retinal function. As such, in the final experiment of this chapter, 
hESC-RPE cells were transplanted subretinally 3 weeks after NaIO3 
administration and the ERG was recorded 3 weeks after cell grafting. 
Unfortunately, no improvements were seen in the scotopic or photopic ERGs after 
hESC-RPE cell transplantation. This may have been due to the death of 
transplanted human cells as unfortunately, no viable hESC-RPE cells were found 
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in the retina 3 weeks after transplantation. These cells were administered into a 
hostile retinal environment with serve loss of the BRB, which leave the stem cells 
exposed to the immune system. The possibility of retinal function rescue was 
validated with chromophore supplementation, which confirmed that retinal 
function rescue was possible at in these NaIO3-treated eyes. 
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Chapter 4 Retinal function in the rd12 mouse 
 Introduction 
In this thesis, the rd12 mouse is proposed as an alternative model for studying 
RPE stem cell replacement. The rd12 mouse has previously been used in a study 
to analyse RPE cell transplantation (Li et al., 2012b), but it is an underutilised 
model. The rd12 mouse, has a naturally occurring mutation in rpe65, disabling 
the recycling of chromophore needed to preform phototransduction. The rd12 
mouse is also a model of LCA, a rare inherited disease that has an early onset 
but produces a slow degeneration of the retina. In the rd12 mouse, cone death is 
rapid, although, retinal degeneration is slow (Pang et al., 2005). By replacing rd12 
RPE cells with hESC-RPE cells, which do not have the mutation it may be 
possible to restore visual function. As this model has a relatively slow 
degeneration and a specific need for chromophore, trophic factors would not be 
expected to have a huge impact, making any functional results from cell 
transplantation most likely to be donor RPE specific. Prior to attempting cell 
transplantation in this model, the course of retinal degeneration and residual 
retinal function will be assessed. In addition to the outer-retina (rods/cones), this 
chapter will focus on the anatomical and functional integrity of the inner retinal 
(melanopsin) system, which has not previously been examined in rd12 mice and 
may provide a novel readout of grafted RPE cell function. 
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 Retinal degeneration in the rd12 mouse. 
 Introduction 
While the rd12 mutation results in a slow retinal degeneration, the morphological 
changes have an early onset. At 3 weeks, lipid-like droplets are found in the RPE 
(Pang et al., 2005) and the PNA-lectin positive cone count is reduced to 55 % (Li 
et al., 2011), with cone opsin lost prior to cone cell death. By 3 months, cone 
counts are further reduced by 16 % and S-opsin expression is lost (Li et al., 2011). 
By 7 months the POS are distinctively shorter and the ONL is reduced to 6-7 cells 
thick (Pang et al., 2005, Wright et al., 2014). By 2 years the POS are almost 
absent and the ONL is reduced to 3-4 layers  (Pang et al., 2005). 
 Methods 
Animals 
Two breeding pairs of rd12 mice (B6(A)-rpe65rd12/J) were obtained from the 
Jackson Laboratory, US. The progenies of these mice were used for all 
subsequent experiment. C57 mice were used as control mice (WT). 
Fixation of Tissue 
3-month-old adult Rd12 and WT animals were fixated by perfusion with 4% 
paraformaldehyde as described in paragraph 2.3.1. 
Sectioning and immunostaining 
As described in paragraph 2.3.2, eyes were cryopreserving, sectioned and 
immunolabelled. Anti-RPE65, raised in rabbit (diluted 1:200), provided by Dr T. 
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Michael Redmond, National Eye Institute, Bethesda, Maryland, US (Ma et al., 
2001, Pang et al., 2005), anti-RGR raised in rabbit (1:800 dilution, kind gift from 
Henry Fong, UCLA), anti-rhodopsin raised in rabbit (1:1000, Abcam) and anti-
M/L opsin raised in rabbit (1:15000, Milipore) were used as a primary antibody 
with a secondary antibody raised in donkey against rabbit IgG tagged with Alexa 
Fluor 568 (ab10042; Abcam) diluted at 1:2000. Anti-M/L opsin was double 
labelled with anti-S-opsin raised in goat (SC-14363, Santa Cruz), diluted to 1:200 
with secondary antibody anti-goat raised in donkey tagged with FITC diluted to 
1:200 (Jackson ImmunoResearch, West Grove, PA, USA). 
Imaging sections 
Labelled sections were imaged in a z-stack using the Zeiss 700 microscope. 
These z-stacks were then flattened to extract a maximum intensity projection 
using zen software. 
 Results 
Validation of the model 
To validate the absence of RPE65 in our rd12 mice, retinal sections from rd12 
and WT mice were labelled for RPE65. In the WT retina, RPE65 labelling is 
specific to the RPE layer. No RPE65 labelling is seen in the rd12 retina (Figure 
4.1). RGR was also labelled, to investigate if expression of other isomerase 
enzymes in the visual cycle were disrupted due to the rd12 mutation. RGR is an 
opsin expressed in the RPE and Müller glia (Jiang et al., 1993). In the dark, RGR 
contains all-trans-retinal (Hao and Fong, 1999) and controls the visual cycle 
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production of 11-cis retinol until illumination (Radu et al., 2008). RGR labelling is 
seen in the RPE of both WT and rd12 mice (Figure 4.2). 
 
 
Figure 4.1 Absence of RPE65 labelling in the rd12 retina. 
This figure displays RPE65 labelling (red) and transmitted light in WT and rd12 
retina. RPE65 (red) is seen in the RPE in WT retina. No RPE65 labelling is seen 
in the rd12 retina. Scale bar indicates 50 µm. 
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Figure 4.2 RGR labelling in rd12 retina. 
RGR labelling (red) is seen in the RPE in both WT and rd12 retina. Scale bar 
indicates 50 µm. 
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Loss of rods and cones in the rd12 retina 
At 3 months, rhodopsin levels are still comparable to WT levels (Figure 4.3). 
Cones are more notably affected by the rd12 mutation. No M/L-opsin was 
detected (Figure 4.4). S-opsin can still be seen, although, the number of cones 
expressing S-opsin was notably reduced and S-opsin is seen mislocated to the 
PIS, ONL and outer plexiform layer (OPL). S-opsin expression is stronger in the 
ventral retina, and, it is known that S-cones are more abundant in the ventral 
retina (Ortin-Martinez et al., 2014). 
 
Figure 4.3 Rhodopsin labelling in rd12 retina. 
Rhodopsin labelling (red) is seen in the POS in both 3 month WT and rd12 retina. 
Scale bar represents 20 µm. 
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Figure 4.4 Cone opsin labelling in 3-month rd12 retina. 
Top images display nuclei staining (blue) with M/ L- (red) and S-opsin (green) 
labelling in 3-month WT and rd12 retinas. M/L-opsin labelling is not detected in 
3-month rd12 retina. The number of cones expressing S-opsin is reduced and S-
opsin is mislocated to the PIS and the outer plexiform layer. Scale bar indicates 
50 µm. Sagittal section of rd12 retina shows loss of M/L-opsin and S-opsin 
mislocation. 
 Discussion 
The rd12 mouse was validated by immunohistochemistry. No RPE65 was 
identified in the rd12 RPE. This antibody was kindly provided by Dr T. Michael 
Redmond, National Eye Institute, Bethesda, Maryland, US (Ma et al., 2001) and 
was also used by Pang and colleagues to validate the rd12 mouse (Pang et al., 
2005).  
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RGR was also labelled to investigate other visual cycle protein levels and was 
seen in the RPE layer in rd12 mice. Since this experiment, Zheng and colleagues 
have found 7 visual cycle-associated proteins which have altered proteomics, 
including: CRALBP, retinol-binding protein 1 (RBP-1), IRBP, RDH-2, RDH-5, 
LRAT, and ezrin-radixin-moesin-binding phosphoprotein 50 (EBP-50) (Zheng et 
al., 2015). 
The loss of the visual cycle has a destructive effect on outer-retinal 
photoreceptors. At 3 months, M/L-opsin is lost. Li and colleagues showed that the 
number of cones is significantly reduced by P21 in the rd12 retina (Li et al., 2011). 
In WT rat development rpe65 reaches its peak and steady state expression 
around P10-P12, which coincides with peak opsin expression in rat and mouse 
(Bowes et al., 1988, Manes et al., 1998, Hamel et al., 1993). Li and colleagues 
showed that P14 PNA-positive cone counts are similar to WT, but, after this, cone 
loss is rapid. A slower degeneration of S-cones in the rd12 retina was observed. 
However, the opsin was mislocated to the PIS, ONL and OPL. This mislocation 
of cone opsins is also seen in the rpe65-/- mouse and can be appropriately 
localised with the treatment of chromophore (Rohrer et al., 2005). Chromophore 
has been shown to be required for cone opsin trafficking to outer-segments 
(Bandyopadhyay et al., 2013). This slower loss of S-opsin, seen in these results, 
is contradicting results reported by Li and colleagues, who found no S-opsin at 2 
months (Li et al., 2011), however, their study looked in flatmounts, which may not 
detect S-opsin that has been mislocated to the ONL and OPL. Also, a different 
antibody was used, which may not detect a mis-folded protein. Pang and 
colleagues described how rpe65 gene therapy at P35 protected M/L-cone loss 
but S-cones could only be saved with earlier treatment at P14 (Pang et al., 2010). 
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However, treatment with chromophore was more successful in correcting the 
localisation of M/L-opsin than S-opsin (Rohrer et al., 2005). 
Rods on the other hand, are lost at a slower rate. Rhodopsin staining intensity in 
the POS appeared similar in rd12 compared to WT. This is supported by results 
showing no significant alterations in rhodopsin mRNA levels in the rpe65-/- up to 
8 weeks (Znoiko et al., 2005). Unlike cones, chromophore is not required for 
rhodopsin trafficking. While rhodopsin protein levels are strong, rhodopsin 
spectral absorbance is not detectable (Pang et al., 2005), presumable due to the 
absence of chromophore. 
 Is Melanopsin expression affected by the loss of RPE65 in rd12 
mice? 
 Introduction 
Melanopsin is the opsin used by the ipRGCs in the inner retina. It’s action 
spectrum indicates that it uses a vitamin A-based photopigment (Berson et al., 
2002), converting 11-cis retinal to all-trans retinal upon the capture of light. It is 
not clear where this chromophore is generated as ipRGCs are separated by 
several retinal layers from the RPE. Melanopsin has many characteristics that 
resemble rhabdomeric photoreceptors, such as depolarisation upon illumination 
(Hartwick et al., 2007) and more importantly, its ability to work as a bi-stable 
pigment with photoisomerase capacity to generate 11-cis retinaldehyde from all-
trans retinaldehyde upon exposure to long wavelength light (Melyan et al., 2005, 
Fu et al., 2005). However, this bi-stable property may not be enough for normal 
melanopsin function, as rpe65-/- mice have attenuated melanopsin functions 
(Doyle et al., 2006). 
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To date no studies have assessed the melanopsin system in rd12 mice. As such, 
in this experiment, melanopsin in the rd12 retina is labelled by 
immunohistochemistry and analysed to determine if the rd12 mutation influences 
melanopsin expression. As a control, the influence of this mutation on general 
ganglion cell health is also assessed using the RGC specific marker Brn3a. 
 Methods 
Retinal preparation and immunohistochemistry 
1-, 3- and 8-month animals were sacrificed and the tissue fixed by perfusion as 
described in paragraph 2.3.1. Retinas from the left eye were stained as described 
in paragraph 2.3.3. Retinas were double labelled with primary antibodies raised 
in rabbit against melanopsin (1:5000, UF006; Advanced Targeting Systems, San 
Diego, CA, USA) and a goat antibody raised against Brn3a (1:200, sc-31987; 
Santa Cruz Biotechnology, Dallas, TX, USA). Secondary antibodies used were 
antibodies raised in donkey against rabbit FITC-labelled and against goat TRITC-
labelled (1:200, Jackson ImmunoResearch, West Grove, PA, USA). 
Imaging and analysis 
Using the Zeiss 700 confocal microscope, images were taken of the SN, ST, IN 
and IT regions of the retina and SN rim and IN rim. Analysis of images is 
described in paragraph 2.3.4. Thresholds used for dendrite analysis were 0.1, 
0.05 and 0.02, where 0.1 is the highest threshold to detect strongly stained 
neurites. 
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Entire retinal images of melanopsin labelling were taken using the Zeiss 710 
confocal microscope, where multiple z-stacks were captured and stitched using 
the Zen software. 
Statistical Analysis 
For this experiment a range of ages were examined: 1 month (WT n = 4, rd12 
n=4), 3 months (WT n = 4, rd12 n = 4) and 8 months (WT n = 3, rd12 n = 3). 
Regional analysis includes all ages and is analysed by two-way repeated 
measures ANOVA with post-hoc Holm-Sidak’s multiple comparisons tests. Nasal 
Vs Temporal melanopsin+-cell counts were analysed by Mann Whitney one-tailed 
t-test for both WT and rd12. Age analysis used average data from the four regions 
of each animal and was analysed by two-way ANOVA and post-hoc Holm-Sidak’s 
multiple comparisons tests. Dendrite analysis used two-way repeated measures 
ANOVA and post-hoc Holm-Sidak’s multiple comparisons tests. 
 Results 
As shown in Figure 4.5 below, the rd12 retina had a striking reduction in 
melanopsin labelling. 
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Figure 4.5 Melanopsin labelling in rd12 retinal flatmount. 
Melanopsin staining at 3 months of age in retinal flatmounts. Strong melanopsin 
labelling is seen in the WT retina (left), compared to a very weak signal in the 
rd12 (right). Scale bar indicates 1 mm. 
Regional analysis of melanopsin 
In the rd12 retina there is a striking reduction in melanopsin labelling compared 
to WT. The number of melanopsin+-cells was reduced by 46% in rd12 mice 
(Figure 4.6), with WT retina having an average of 106 ± 4 melanopsin+-cells per 
mm2, while the rd12 retina has an average of 71 ± 4 melanopsin+-cells per mm2. 
Retinas were divided into four quadrants: superior-temporal (ST), superior-nasal 
(SN), inferior-nasal (IN) and inferior-temporal (IT). Two-way ANOVA showed a 
significant difference between rd12 and WT (P < 0.0001, F (1, 20) = 39.46), also, 
a significant difference among regions (P = 0.0004, F (3, 60) = 7.071). This 
regional difference was similar in both WT and rd12 (P = 0.9, F (3, 60) = 0.2). 
This differential regional distribution suggests that the different quadrants may 
contain different populations of melanopsin+-cells. Although, the reduction in 
melanopsin+-cell density in rd12 retinas occurs across the retina. Post-hoc 
analysis shows significant reduction in melanopsin+-cells in all quadrants in the 
rd12 retina (Figure 4.6). Examining the populations of melanopsin+-cells in the 
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different retinal regions revealed an increase in melanopsin+-cells in the temporal 
retina in both WT (t-test, P = 0.0017) and rd12 (t-test, P = 0.0089). WT retina 
have 26% more melanopsin+-cells in the temporal retina (118 ± 5 per mm2) 
compared to nasal (93 ± 5 per mm2). Similarly, the rd12 retina has a 28% increase 
in melanopsin+-cells in the temporal retina (79 ± 4 per mm2) compared to nasal 
(62 ± 5 per mm2). 
Melanopsin-labelling in ipRGC somas is also reduced by 30% in rd12 retinas 
compared to WT (Figure 4.6). Average greylevel of rd12 melanopsin+-cells is 
reduced to 56 ± 2.6 compared to 80.2 ± 3.1 seen in WT. Two-way repeated 
measures ANOVA shows that this difference between WT and rd12 is significant 
(P = 0.0016, F (1, 20) = 13.37). Melanopsin-labelling in ipRGC is also significantly 
different among different regions in the retina (P < 0.0001, F (3, 60) = 11.32), with 
the strongest labelling seen in the IN region in both WT and rd12 retinas. The 
regional differences of melanopsin expression in melanopsin+-cells, while 
significantly reduced in rd12, is similar to WT regional paterns (P = 0.4, F (3, 60) 
= 1.1). Post-hoc tests show a significant difference between staining intensity in 
WT and rd12 mice in each region of the retina. 
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Figure 4.6 ipRGC regional soma analysis in WT and rd12 retina. 
This figure displays graphs of the density of melanopsin+-cells and the intensity 
of this labelling in melanopsin+-somas in the different retinal regions in WT (black, 
n = 11) and rd12 (white, n = 11). The density of melanopsin+-cells is significantly 
reduced in the rd12 retina in each quadrant. There is a significantly higher density 
of melanopsin+-cells in the temporal retina compared to nasal in both WT and 
rd12. Melanopsin intensity in somas is significantly reduced in rd12 ipRGCs in 
each retinal quadrant. The brightest melanopsin+-somas are in the inferior nasal 
quadrant in both WT and rd12 retinas. Asterisks indicate statistical power *P < 
0.05, **P < 0.01, ***P < 0.001. Representative images of each quadrant in 3--
month WT and rd12 retinas are shown on the right, where the reduction in 
melanopsin+-cell density and melanopsin-labelling in rd12 retina is clear. Scale 
bar indicates 100 µm. 
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The ipRGC dendrites are also less visible in the rd12 retina (Figure 4.6). 
Melanopsin expression in dendrites was quantified using a thresholding method 
as demonstrated in Figure 4.7. Here, a low threshold of 0.02, recognises 
dendrites with low levels of melanopsin expression as well as brightly stained 
dendrites. Higher thresholds do not recognise axons with low levels of 
melanopsin, and he highest threshold, 0.1, recognises only dendrites labelling 
strongly for melanopsin. A threshold of 0.1 recognises all pixels above greylevel 
255 x 0.1. This method also filters out cell bodies and so only axons are analysed. 
Two-way ANOVA determined a significant difference in dendrites between WT 
and rd12 mice (P < 0.0001, F (1, 20) = 40.72). The different thresholds created a 
significant difference in dendritic coverage (P < 0.0001, F (2, 40) = 177.3), 
showing the difference of the different populations of weak- and strong-
expressing melanopsin+-dendrites. These different populations were significantly 
different between WT and rd12 (P < 0.0001, F (2, 40) = 24.69), with greater loss 
in rd12 at the higher threshold. Post-hoc tests determined a significant difference 
in dendritic coverage between WT and rd12 at all thresholds tested. There was a 
60% reduction in the area covered by dendrites above threshold 0.02 in rd12 
retinas compared to WT retinas (P < 0.0001). Above a threshold of 0.05, there 
was a 73% reduction in area covered by dendrites in rd12 compared to that in 
WT (P < 0.0001). At the high threshold of 0.1, only very bright dendrites were 
recognised, most likely the M1 dendrites (Schmidt et al., 2011). At this threshold, 
dendritic coverage is reduced by 70% in rd12 retinas compared to WT (P < 0.01). 
Dendritic coverage of the different retinal regions was analysed by two-way 
ANOVA; which, did not show regional differences as significant. 
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Figure 4.7 ipRGC dendrite 
analysis in WT and rd12 
mice. 
This figure displays a 
representative image of 
WT and rd12 melanopsin 
labelling taken from the IT 
region in 3-month mice. 
Beneath are 
representations of these 
images filtered at the 
different thresholds. Scale 
bar represents 100 µm. 
The graph presents the 
percentage of area 
covered by dendrites at 
different thresholds in WT 
(n = 11) and rd12 (n = 11). 
Regional analysis was 
averaged per retina. 
Asterisks indicate 
significance levels: **P < 
0.01, ****P < 0.0001. 
  
 183 
 
As shown in Figure 4.8, melanopsin labelling was analysed in mice of 1, 3 and 8 
months of age. Density of melanopsin+-cells, intensity of melanopsin labelling and 
dendritic coverage were analysed by two-way ANOVA, including age as a factor, 
and showed that age was not a significant factor for any of these measures. 
Analysis of each measure was consistent in showing that there was a significant 
difference between WT and rd12 mice but age did not affect these results. 
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Figure 4.8 Melanopsin labelling at different ages in WT and rd12 mice. 
Melanopsin labelling does not change significantly between 1 and 8 months in 
either WT or rd12 retinas. Representative images of WT and rd12 retina at 
different ages are taken from the IT region. Scale bar indicates 100 µm. Graphs 
display density of melanopsin+-cells, labelling intensity per soma and the 
percentage of area covered by melanopsin+-dendrites. None of these 
measurements were significantly altered with age in WT or rd12. Asterisks 
indicate significant differences between WT and rd12 from post-hoc analysis: *P 
< 0.05, **P < 0.01, ***P < 0.001. At 1 month n = 4, at 3 months n = 4 and at 8 
months n = 3 for both WT and rd12. 
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A rim of melanopsin previously reported at the retinal edge, with the strongest 
labelling in the nasal retina (Semo et al., 2014, Vugler et al., 2008b) was 
examined in the rd12 mouse. Images of melanopsin labelling in the SN and IN 
were analysed in both WT and rd12 (Figure 4.9). The density of melanopsin+-
cells was similar in the rd12 retina and WT, with similar cell numbers in SN and 
IN regions of both animal strains. Differences were seen in the melanopsin-
labelling in somas (melanopsin intensity) which is significantly reduced in rd12 
retinas (P = 0.0148, F (1, 20) = 7.113). Average pixel greylevel was 62.9 ± 4.9 in 
rd12 while WT greylevel was 87.7 ± 7.5. Similar to data reported in Figure 4.6, 
the melanopsin soma intensity in the IN region is greater than in the SN region 
(P = 0.0003, F (1, 20) = 18.89), seen in both WT and rd12 (P = 0.1, F (1, 20) = 
3).  
Dendritic coverage was significantly reduced in the rd12 at both the SN and IN 
marginal zone (Table 15Figure 4.9). There are different populations of weak and 
strong-expression of melanopsin in these dendrites, identified by the significance 
of the different thresholds. Post-hoc tests show a significant reduction in dendritic 
coverage in rd12 in both SN and IN at each threshold tested. No significant 
changes in melanopsin labelling at the CMZ were seen between 1 and 8 months 
in either WT or rd12. Melanopsin+-processes were seen projecting into the ciliary 
body in WT retinas (Figure 4.10), which have been previously reported (Semo et 
al., 2014). 
 
Table 15 Two-way ANOVA of melanopsin dendrites at rd12 retinal rim 
Two-way ANOVA SN IN 
Rd12 Vs WT P = 0.0014, F (1, 20) = 13.7 P < 0.0001, F (1, 20) = 25.7 
Threshold effect P < 0.0001, F (2, 40) = 309 P < 0.0001, F (2, 40) = 451 
Interaction P = 0.0104, F (2, 40) = 5.1 P = 0.2, F (2, 40) = 1.8 
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Figure 4.9 Analysis of melanopsin labelling at the retinal marginal zone. 
A rim of melanopsin is seen along the nasal retinal edge. The density of 
melanopsin+-cells along this rim is similar in rd12 (white, n = 11) and WT (black, 
n = 11) but the strength of melanopsin labelling is reduced in rd12 compared to 
WT and in the SN rim compared to the IN rim. Percentage area of dendritic 
coverage is also reduced in rd12 compared to WT. Representative images of 
melanopsin labelling in WT and rd12 at the SN and IN rim show this reduction in 
melanopsin labelling in the rd12 retina. The scale bar indicates 50 µm. 
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Figure 4.10 Melanopsin+-dendrite projecting into ciliary body. 
A melanopsin+-dendrite is seen projecting into the ciliary body (CB), indicated by 
the star, in an 8-month-old WT retina in the IN melanopsin rim. The scale bar 
represents 50 µm. 
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To investigate if the loss of melanopsin cells is a result of an overall decrease in 
the number of ganglion cells rather than ipRGCs specifically, retinas were 
labelled for Brn3a, which is expressed by the majority (~90%) of RGCs (Mead et 
al., 2014, Nadal-Nicolas et al., 2009) and only about 2% of ipRGCs in WT mouse 
retinas (Valiente-Soriano et al., 2014).  
No differences in the number of Brn3a+-cells nor in the strength of Brn3a labelling 
were detected between WT and rd12 (Figure 4.11).  Brn3a+-cells counts in rd12 
retinas were 2628 ± 132 cells per mm2, similar to 2707 ± 75.2, seen in WT (P = 
0.6, F (1, 20) = 0.3), suggesting that the reduction of melanopsin+-cells is not due 
to an overall reduction in the RGC population of rd12 mice. There are significant 
differences in the Brn3a+-cell populations in the different regions of the retina (P 
< 0.0001, F (3, 60) = 17.46). The ST region has fewer RGCs than other regions 
in both WT and rd12 (Figure 4.11) and similar results are seen in the literature 
(Valiente-Soriano et al., 2014). The average density of Brn3a+-cells in the ST 
region in WT is 2029.545 ± 251.5 per mm2 and 1622.156 ± 105.261 per mm2 in 
rd12, which is considerably less than the retinal average mentioned above. The 
regional differences in RGC populations is similar in both WT and rd12 (P = 0.6, 
F (3, 60) = 0.7). There was no significant loss of Brn3a+-cells over time (1 – 8 
months) in either WT or rd12 retinas. 
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Figure 4.11 RGC analysis in WT and rd12 retina. 
Representative images of Brn3a labelling are taken from 3-month WT and rd12 
retina. Scale bar indicates 100 µm. There are no significant differences between 
WT (black, n = 11) and rd12 (white, n = 11) in regional analysis of Brn3a+-cell 
density or labelling strength. Significant differences in Brn3a+-cell density are 
seen between regions of the retina, with less Brn3a+-cells in the ST region. There 
were no significant changes in RGC population between 1 (WT n = 4, rd12 n = 
4), 3 (WT n = 4, rd12 n = 4) and 8 (WT n = 3, rd12 n = 3) months. 
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 Discussion 
It has been shown by the action spectrum of melanopsin that it requires a vitamin 
A-based photopigment (Berson et al., 2002). While melanopsin uses 
chromophore for phototransduction, the source of this chromophore is only just 
beginning to be elucidated (Zhao et al., 2016). While the RPE is the classic site 
of 11-cis isomerisation, it is separated by several layers from the ipRGCs, on the 
inner retina. In this experiment, the effects of the rd12 mutation on melanopsin 
expression was examined. It was discovered that the density of melanopsin+-cells 
was significantly reduced in the rd12 retina and this density did not significantly 
change between 1 and 8 months. The density of RGCs was not reduced in the 
rd12 retina, thus, the reduction in melanopsin+-cells was not due to an overall 
loss of RGC but specific loss of ipRGCs. The loss of melanopsin+-cells was 
accompanied by a reduction of melanopsin in these cells, with melanopsin 
labelling intensity reduced by 30% in rd12 melanopsin+-somas. Melanopsin+-
dendrites were also significantly reduced in the rd12 retina. 
Interestingly, the number of melanopsin+-cells along the nasal CMZ were not 
reduced in the rd12 retina, while, melanopsin labelling intensity in melanopsin+-
somas was significantly reduced similarly to melanopsin+-somas in the central 
retina. Melanopsin+-dendrites were also reduced in rd12 CMZ. 
All these metrics were examined at 1, 3 and 8 months and no significant changes 
were see over this time period in WT or rd12. 
Melanopsin expression has been shown to be affected by other RPE mutations. 
The RCS dystrophic rat retina has a significant (>90%) reduction of melanopsin 
mRNA and protein levels (Sakamoto et al., 2004). The rat can still produce 
chromophore, raising the question if the effects on melanopsin expression are 
due to the loss of outer-retinal photoreceptor function. Contradicting this is the 
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ability for phototransduction in ipRGCs in new born mice, prior to rod and cone 
function which occurs after P10 (Hannibal and Fahrenkrug, 2004, Sekaran et al., 
2005). Also, the influence of the Mertk mutation on the visual cycle cannot be 
ruled out. Without phagocytosis of shed POS there is a lack of chromophore 
being recycled and shed POS in the debris zone may absorb any chromophore 
produced by the RPE. 
These results support those reported in the rpe65-/- mouse, showing a reduction 
in melanopsin and attenuated melanopsin functions (Doyle et al., 2006) and add 
to the growing body of evidence that the RPE visual cycle is important for 
melanopsin expression. It is known that the loss of the visual cycle reduces the 
sensitivity of the PLR more so than the loss of the outer-retinal photoreceptors 
(Tu et al., 2006), highlighting the importance of the visual cycle for melanopsin 
function. 
While the loss of the visual cycle in rd12 mice causes a significant reduction in 
melanopsin expression, it is not clear if this, like cone opsin, is directly due to loss 
of chromophore produced in the RPE. The melanopsin system is often not 
considered when assessing retinal degeneration, yet, it has the clear potential to 
provide additional readouts on RPE function. Thus, in the next experiment, the 
effect of the rd12 mutation on retinal function is examined, with recordings of both 
outer-retinal photoreceptor function and ipRGC function. 
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 Visual function in the rd12 mouse 
 Introduction 
Without RPE65, rhodopsin is undetectable by spectral absorbance in the rd12 
retina (Nusinowitz et al., 2006, Pang et al., 2005), despite this, there is still visual 
function. Rd12 mice respond to photopic ERG (Pang et al., 2005, Pang et al., 
2006) and despite the absence of detectable rhodopsin by spectral absorbance, 
it is thought that these photopic responses are rod driven, from studies in rpe65-
/- mice (Cachafeiro et al., 2010, Dai et al., 2015, Seeliger et al., 2001). The lack 
of chromophore in rd12 mice allows rods to function at brighter light intensities 
without bleaching. In this experiment, the residual visual function in rd12 mice 
driven by both outer-retinal photoreceptors and ipRGCs is recorded. 
 Methods 
ERG 
ERGs were recorded as described in paragraph 2.2.1 from 3-month WT (n = 14) 
and rd12 (n = 10). To investigate the rod response at high intensities some 
animals were also recorded from a high light intensity scotopic protocol with flash 
intensity from -4.5 to 3.5 lg cd.s/m2. To reach these light intensities a xenon light 
source was used, unfortunately, this xenon light required long periods of rest 
between uses and so only 2 WT (n = 4) and 1 rd12 (n = 2) mice were recorded 
using this protocol. After light adaption for 15 minutes, photopic responses were 
recorded in WT (n = 14) and rd12 (n = 10). 
 193 
 
Assessment of retinal function using light-driven Fos induction 
Fos is a transcription factor that is found in the cytosol in dark adapted DA-ACs. 
Upon exposure to bright light, Fos is localised to the nucleus in DA-ACs. The 
presence of nuclear Fos after light exposure can therefore be used as a method 
of determining inner retinal circuitry function. This method has been published 
previously (Cameron et al., 2009). In brief, mice were dark adapted overnight and 
then exposed to 190 uW/cm2 (~380 Lux) white light for 120 minutes and then 
euthanised and perfused for tissue collection as described in paragraph 2.3.1. 
Control animals remained in the dark and were euthanised and perfused in the 
dark. Retinas were isolated from the left eye of 3 WT and 3 rd12 and labelled for 
Fos and tyrosine hydroxylase (TH), as described in paragraph 2.3.3. TH, is used 
to identify DA-ACs and is the rate-limiting enzyme in catecholamine biosynthesis, 
which results in dopamine production and release. Anti-Fos was raised in rabbit 
and used at a dilution of 1:5000 (Cell Signal). Anti-TH was raised in sheep and 
diluted 1:5000 (Milipore). Secondary antibodies used were FITC-labelled anti-
rabbit and TRITC-labelled anti-sheep, both raised in donkey diluted 1:200 
(Jackson ImmunoResearch, West Grove, PA, USA).  Images from the different 
retinal quadrants in rd12 and WT were captured as described in paragraph 2.3.4 
and analysed by counting DA-ACs with and without nuclear Fos. A nuclear fos 
signal was considered as a positive result, whereas a cytoplasmic or absent Fos 
signal was considered as a negative result. Regional results were analysed in 
eyes which were exposed to light by two-way repeated measures ANOVA. Fos 
activation between WT and rd12, dark adapted and light exposed were analysed 
by averaging the regional data per animal and applying a two-way ANOVA. Both 
tests were followed by Holm-Sidak’s multiple comparisons tests. 
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BLA 
The presence of light aversion was tested at 1 month and 3 months as described 
in paragraph 2.2.2. Animals were either placed into an area which had the front 
half illuminated (light) or in an area that was completely in the dark (dark). 
Numbers of WT and rd12 assessed in the BLA arena are shown in Table 16. 
Table 16 Numbers of WT and rd12 assessed in BLA arena 
Numbers 1-month WT 1-month rd12 3-month WT 3-month rd12 
Light 5 9 16 11 
Dark 7 9 7 10 
PLR 
The PLR was recorded and analysed as described in paragraph 2.2.3. The light 
powers tested were 80 (WT n = 6, rd12 n = 6), 800 (WT n = 1, rd12 n = 8) and 
8000 (WT n = 1, rd12 n = 8) µW/cm2/s. 
iPLR 
The iPLR was recorded as described in paragraph 2.2.4. 3-month rd12 (n = 4) 
constriction was compared to WT (n = 10). Aged rd12 (n = 6) was compared to 
3-month rd12 the same way. 
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 Results 
ERG recordings from the rd12 retina 
At three months, the rd12 mouse has no evidence of a scotopic a-wave (Figure 
4.12.B). The scotopic b-wave is identifiable at 1 lg cd.s/m2, albeit reduced by 82% 
compared to WT (Figure 4.12.B). This difference between rd12 and WT scotopic 
b-wave amplitude is significant (Table 17). 
 
Table 17 Two-way ANOVA of scotopic b-wave amplitude in 3-month rd12 
Two-way ANOVA F (DFn, DFd) P value 
Rd12 F (1, 126) = 154.94 P < 0.0001 
Light intensity F (6, 126) = 113 P < 0.0001 
interaction F (6, 126) = 54.02 P < 0.0001 
Subjects (matching) F (21,126) = 4.749 P < 0.0001 
 
 
Figure 4.12 Scotopic ERG in 3-month-old WT and rd12 mice. 
At three months, the scotopic b-wave amplitude is severely diminished in the rd12 
mouse (blue, n=10), compared to WT (black, n = 14) (A). There is no evidence of 
an a-wave and only a very small b-wave can be seen at high intensities in some 
rd12 animals. Asterisks indicate significance: **** P<0.0001. Representative 
traces for 3-month WT and rd12 are displayed (B). Vertical scale indicates 200 
µV and horizontal scale indicates 200 ms. 
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Another scotopic protocol was also used to determine if the rd12 mouse could 
respond similarly to the WT with very high intensities up to 3.5 log cd/m2 under 
scotopic conditions. Unfortunately, due to the temperamental nature of the xenon 
bulb used in this protocol, it was not possible to run large numbers of animals 
with this protocol, thus these results are assessed from a small population of 
samples. This protocol revealed that even at high intensities there is still no 
evidence of an a-wave for any intensity in the rd12 mouse (Figure 4.13.B). At 0.5 
lg cd.s/m2 the WT rod a-wave saturates and the a-wave amplitude starts to 
reduce. Scotopic b-wave can be seen at high light intensities in the rd12, 
however, it does not increase with light intensity (Figure 4.13.A) and remains 
significantly smaller than WT (Table 18). WT b-wave amplitude starts to saturate 
at 2 lg cd.s/m2, and the b-wave amplitude starts to reduce and WT b-wave implicit 
time reduce steadily with increasing light intensity (Figure 4.13.B). This protocol 
shows that under scotopic conditions, even at very high intensities the rd12 
mouse cannot produce an a-wave and its b-wave is severely diminished. 
Table 18 Two-way ANOVA rd12 b-wave amplitude at high light intensities 
Two-way RM ANOVA F (DFn, DFd) P value 
Rd12 F (1, 64) = 1047 P < 0.0001 
Light Intensity F (16, 64) = 36.45 P < 0.0001 
Interaction F (16, 64) = 15.66 P < 0.0001 
Subjects (matching) F (4, 64) = 1.23 P = 0.3 
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Figure 4.13 Scotopic ERG at higher light 
intensities in WT and rd12 mouse. 
Using a scotopic protocol that reached high 
levels of intensity the rd12 (blue, n = 2) still 
have a significantly reduced b-wave which 
plateaus and does not grow with increased 
intensity (A). Asterisks indicate significance 
level from post-hoc tests: **P<0.01; **** 
P<0.0001. Representative traces at each light 
intensity are displayed (B). rd12 do not have an 
obvious a-wave. The vertical scale bar 
represents 500 µV and the horizontal scale bar 
represents 500 ms. 
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The photopic b-wave in the rd12 mouse is much more robust (Figure 4.14). 
Although, it is still significantly reduced compared to WT (Table 19). At 1.5 lg 
cd.s/m2 the rd12 amplitude is reduced by 45% (Figure 4.14). Both WT and rd12 
amplitude increases with light intensity (Table 19). Photopic b-wave implicit time 
is not significantly different between rd12 and WT (Figure 4.14). 
Table 19 Two-way ANOVA of rd12 photopic ERG at 3 months 
Two-way ANOVA Photopic B-wave Amplitude Photopic B-wave Implicit 
Time 
Rd12 F(1, 21) = 25.1, P < 0.0001 F(1, 21) = 1.8, P = 0.1976 
Light Intensity F(3, 63) = 67.9, P < 0.0001 F(3, 63) = 12.5, P < 0.0001 
Interaction F(3, 63) = 13.9, P < 0.0001 F(3, 63) = 0.9, P = 0.4605 
Subjects 
(matching) 
F(21, 63) = 2.8, P = 0.001 F(21, 63) = 1.9, P = 0.0303 
 
 
Figure 4.14 Photopic ERG in 3-month-old WT and rd12 mice. 
The photopic b-wave amplitude is significantly reduced in rd12 mice (blue, n = 
10) compared to WT (black, n = 14). Photopic latency is similar between rd12 and 
WT. Asterisks indicate significance levels from post-hoc test: * P<0.05; **** 
P<0.0001. Representative traces from 3-month-old WT and rd12 mice are 
displayed on the right. The vertical scale bar represents 100 µV and the horizontal 
scale bar represents 100 ms. 
Fos induction in DA-ACs of rd12 mice. 
The retinal dopamine system provides another useful measure of photoreceptor 
function (Nir et al., 2000), observed by the induction of Fos activation in DA-ACs. 
Fos is a transcription factor, which is found in the cytosol of DA-ACs in dark-
adapted retinas. After exposure to light, Fos is located in the nucleus. It is 
unknown if it is caused by translocation of Fos, de novo synthesis of Fos, or a 
combination of both. Following light exposure, rd12 and WT retina were stained 
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for Fos and TH (DA-AC marker) and sample images from each retinal quadrant 
were blinded and analysed. Fos activation is also found in the GCL, and can be 
found in the INL in TH negative cells, and so the TH labelling allows the isolation 
of DA-ACs in the analysis (Hanzlicek et al., 2004). WT mice had a significantly 
greater increase in nuclear fos in TH+-cells than rd12 mice (Table 20). While adult 
WT mice had a 31-fold increase in nuclear Fos following 2 hours of light exposure, 
3-month rd12 mice showed no significant increase in Fos activation (Figure 4.15). 
Dark-adapted WT had nuclear Fos in 3 ± 2.2 % of DA-ACs, which following light 
exposure increased to 95.5 ± 3.5 %.  Rd12 had 4.3 ± 2.5 % TH cells with nuclear 
Fos after dark adaptation which increases to 8.8 ± 4.5 % following light exposure. 
Two-way ANOVA analysis shows that light exposure has a significant effect on 
nuclear fos, but this effect is significantly different between WT and rd12 (Table 
20). Post-hoc analysis revealed significantly greater fos activation in WT exposed 
to light compared to WT kept in the dark (P < 0.0001) and, also compared to rd12 
exposed to light (P < 0.0001). Fos activation in the different retinal regions were 
analysed and showed no significant regional differences (Table 20). This was 
similar in both animal strains. Thus, DA-ACs are activated similarly among the 
different retinal regions in both WT and rd12 (Figure 4.15). Post-hoc tests showed 
that each region had significantly greater fos activation in WT compared to rd12. 
 
Table 20 Two-way ANOVA fos expression in rd12 
Two-way ANOVA F (DFn, DFd) P value 
WT Vs rd12 F (1, 8) = 166.9 P < 0.0001 
Light Exposure F (1, 8) = 214.8 P < 0.0001 
Light exposure*strain F (1, 8) = 176.8 P < 0.0001 
Retinal region F (3, 12) = 2 P = 0.2 
Retinal region*strain F (3, 12) = 3 P = 0.1 
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Figure 4.15 Fos activation in DA-ACs of WT and rd12 mice. 
FOS activation peaks ~2 h after light exposure. WT retinal images show fos 
labelling in nuclei of 95.5 ± 3.5 % TH-expressing DA-ACs. This is significantly 
greater than animals kept in the dark or rd12 exposed to light. No regional 
differences of fos activation were seen in WT or rd12. The scale bar represents 
50 µm. **** indicates a significance level of P < 0.0001. N = 3 for all group. 
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BLA response in rd12 mice 
WT mice have an aversion to light, and prefer to seek out an area of darkness 
when placed in an illuminated area (Figure 4.16). 1-month-old WT mice spend 
twice as much time in the dark back half of the arena when the front half is 
illuminated (light) than when the front half is also dark (P < 0.05). WT mice spent 
21 ± 2 % of their time in the back half when the front half of the arena is also dark. 
This is increased to 42 ± 9 % when the front half is illuminated. This is not 
significantly different in 1-month rd12 mice (P = 0.7, F (1, 26) = 0.2), which spend 
26 ± 3 % of their time in the back half when the whole arena is in darkness and 
34 ± 4 % when the front half is illuminated. Illumination of the front half of the 
arena has a significant effect on the amount of time spent in the dark back half 
(P = 0.0022, F (1, 26) = 11.53) and this effect is not significantly different between 
WT and rd12 (P = 0.2, F (1, 26) = 2).  
WT mice behave differently when in a completely dark arena compared to when 
the front half is illuminated (P = 0.0359, F (1, 74) =4.56526). When the arena is 
completely dark WT mice spend significantly less and less time in the back half 
(Table 21). They show a preference for the dark open front half and spend 
significantly increasing amounts of time there. This behaviour is likely driven by 
neophobia and a desire to return to their cage, thus returning to the side of the 
arena into which the mouse was initially placed (Semo et al., 2010). This effect 
of light on the BLA of WT mice is only seen when examined over the 30 minutes 
(Table 22). During the last 5 minutes WT mice spend 3 times as much time in the 
dark back half when the front half is illuminated (Figure 4.16). 
One-month rd12 do not adjust their preference for the front or back half of the 
arena over the 30 minutes (Table 21), and continually spend more time in the 
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back half of the arena over the 30 minutes, when the front half is illuminated (P= 
0.0111, F (1, 105) = 6.7). 
Table 21 Linear Regression of time 1-month rd12 spent in back half of BLA arena 
Linear Regression Slope r2 Is slope significantly non-zero? 
WT Dark -0.4 ± 0.2 0.1098 F (1, 40) = 4.9, P = 0.032 
WT Light 0.7 ± 0.5 0.05115 F (1, 34) = 1.8, P = 0.1847 
Rd12 Dark -0.02 ± 0.2 0.00009 F (1, 52) = 0.005, P = 0.9449 
Rd12 Light -0.4 ± 0.3 0.02881 F (1, 52) = 1.5, P = 0.2198 
Table 22 Two-way ANOVA effects of light and time on the BLA in 1 month rd12 
Two-way ANOVA WT Rd12 
Light F (1, 11) = 2.2, P = 0.1664 F (1, 16) = 3, P = 0.1028 
Time F (5, 55) = 1, P = 0.4286 F (5, 80) = 1.9, P = 0.107 
Light effect over time F (5, 55) = 3, P = 0.0169 F (5, 80) = 0.3, P = 0.8905 
Subjects (matching) F (11, 55) = 12.4, 
P < 0.0001 
F (16, 80) = 2.9, P = 0.0009 
 
 
Figure 4.16 BLA in WT and rd12 mice at 1 month. 
At 1 month, rd12 mice have some BLA. The total amount of time spent in the 
back half is not significantly different from WT, which spend significantly more 
time in the dark back half when the front half of the arena is illuminated compared 
to a completely dark arena. WT mice spend significantly less and less time in the 
dark back half when the front half is also dark (n = 7) compared to WT in an arena 
with the front half illuminated (n = 5). By the end of the 30 minutes the WT mice 
in an arena with the front half illuminated spend 3 times as much time in the dark 
back half compared to WT in a dark arena. The effect of light exposure on the 
BLA does not increase over time in 1-month rd12, but rd12 spend more time in 
the dark back half when the front half is illuminated (n = 9) compared to when the 
arena is fully dark (n = 9). Asterisk indicates a significance level of P < 0.05. 
 
At 3 months, the BLA is strengthened in the WT and lost in the rd12 mouse 
(Figure 4.17). There is a significant difference between WT and rd12 in the total 
amount of time spent in the back half (P = 0.0295, F (1, 31) = 5.2). Both WT and 
rd12 spend more time in the back half of the arena when the front half is 
illuminated (P = 0.0002, F (1, 31) = 17.9). Though, this effect of time is 
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significantly greater in WT than rd12 (P = 0.0053, F (1, 31) = 9). 3-month-old WT 
spend significantly more time in the back half when the front half is illuminated 
compared to WT placed in a dark arena (P < 0.001) and compared to rd12 placed 
in an arena with the front half illuminated (P < 0.01). WT mice will spend 26.3 ± 
3.5 % of their time in the back half when the whole arena is in darkness. This 
doubles to 54.7 ± 5.2 % when the front half is illuminated (Figure 4.17). 3- month 
rd12 spend 29.1 ± 2.8 % of their time in the back half when the whole arena is in 
darkness. This only increases to 33.9 ± 3.9 % when the front half is illuminated 
(Figure 4.17).  
3-month WT spend significantly decreasing amounts of time in the dark back half 
when the whole arena is in darkness (Table 23), similar to what was seen at 1-
month. This behaviour is significantly different to the behaviour of WT mice in an 
arena with the front half illuminated (P = 0.0379, F (1, 128) = 4.40231). At 3-
months, significant differences in the time spent in the back half are seen earlier 
than they were in 1-month WT mice. While at 1-month a significant difference 
between light and dark was seen only in the last 5 minutes with post-hoc tests, at 
3-months, significant differences are seen in the last 15 minutes (Figure 4.17). 
During the last 15 minutes, WT mice spend twice as much time in the back half 
than the front half when it is illuminated. 
By 3 months rd12 mice have greatly lost their BLA (Figure 4.17). There are no 
significant differences in how they behave over the 30 minutes (P = 0.8, F (1, 
122) = 0.05) and no preference for the back half under illumination or total 
darkness (P = 0.07, F (1, 123) = 3), calculated by linear regression. 3-month rd12 
do not increase or decrease the preference for the front half in darkness or 
illumination (Table 23). These results are reiterated by those found by two-way 
ANOVA (Table 24). 
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Table 23 Linear Regression of time 3-month rd12 spend in BLA arena back half 
Linear Regression Slope r2 Is slope significantly non-zero? 
WT Dark -0.4 ± 0.2 0.1 P = 0.0374, F (1, 40) = 4.6 
WT Light 0.5 ± 0.3 0.03 P = 0.0962, F (1, 88) = 2.8 
Rd12 Dark -0.1 ± 0.2 0.005 P = 0.578, F (1, 58) = 0.3 
Rd12 Light -0.05 ± 0.2 0.0006 P = 0.8409, F (1, 64) = 0.04 
 
Table 24 Two-way ANOVA of time and light influence on the BLA in 3-month rd12 
Two-way ANOVA WT Rd12 
Light P = 0.0036, F (1, 20) = 10.9 P = 0.34, F (1, 19) = 1 
Time P = 0.64, F (5, 100) = 0.7 P = 0.44, F (5, 95) = 1 
Light effect over time P = 0.098, F (5, 100) = 1.9 P = 0.997, F (5, 95) = 0.07 
Subjects (matching) P < 0.0001, F (20, 100) = 6 P < 0.0001, F (19, 95) = 6 
 
 
Figure 4.17 BLA in 3-month-old WT and rd12 mice. 
3-month WT mice spend twice as much time in the back-half when the front-half 
of the arena is illuminated (n = 16), compared to when the arena is in darkness 
(n = 7). No difference is seen for 3-month rd12 mice when the front half is lit 
(n=11) or in total darkness (n=10). The effect of arena illumination on percentage 
of time WT mice spend in the back-half increases with time. There are no 
significant changes in the amount of time rd12 spend in the back half over the 30 
minutes, regardless of illumination in the arena. Asterisks indicate significant level 
from post-hoc tests: *P < 0.5; **P < 0.01; ***P < 0.001. 
The PLR in rd12 mice 
Both RPE65 (Fu et al., 2005, Tu et al., 2006) and melanopsin (Hattar et al., 2003, 
Lucas et al., 2003, Lucas et al., 2001) have been reported to affect the PLR. The 
PLR is reduced in rd12 mice (Figure 4.18). Analysis at each irradiance level 
examined showed a reduced constriction in rd12 mice compared to WT and rd12. 
There is no significant difference between baseline pupil area of WT and rd12 (P 
= 0.18). Statistical analysis is restricted to 80 µW/cm2/s as WT are reduced to 
N=1 at higher irradiances. 
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At 80 µW/cm2/s there is a significant difference in the PLR between WT and rd12 
(Table 25). Time had a significant effect on the constriction and this was also 
significantly different between strains. At 80 µW/cm2/s, significant differences are 
seen between rd12 and WT from 1 s post-light onset until the end of the light 
stimulus. WT mice have a significant constriction (P < 0.0001), and this is 
significant at all time points during light stimulation. rd12 mice do not have a 
significant constriction to 80 µW/cm2/s (P = 0.08), and this is true at all time points 
during light stimulation. Peak constriction in WT reached 0.1 ± 0.008 normalized 
pupil area after light exposure, while rd12 maximum pupil constriction only 
reached 0.89 ± 0.04. 
At 800 µW/cm2/s, both WT (P < 0.0001) and rd12 (P < 0.0001) had a significant 
constriction, although, no particular timepoint is significant in the rd12 
constriction.  Peak constriction reached 0.8 ± 0.07 in rd12, and reached 0.057 in 
WT. At 8000 µW/cm2/s, both WT (P < 0.0001) and rd12 (P < 0.0001) had a 
significant constriction. The rd12 constriction is significant from 3s after light onset 
and significant for the remainder of the light stimulation. The rd12 constriction 
reached 0.34 ± 0.07 and WT reached 0.025. Analysis of peak constriction showed 
a significant different in peak constriction between WT and rd12 at 80 µW/cm2/s 
(P < 0.0001). 
 
Table 25 Two-way ANOVA PLR in rd12 
Two-way ANOVA WT Vs rd12 Time Interaction 
80 µW/cm2/s F (1, 416) = 196.1 F (51, 413) = 7.4 F (51, 413) = 8.2 
P < 0.0001 P < 0.0001 P < 0.0001 
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Figure 4.18 PLR in 3-month rd12 mice. 
No PLR is seen in 3-month-old rd12 mice at 80 µW/cm2/s (n = 6), while WT have 
a peak constriction of 0.1 ± 0.043 (n = 6). A small response is seen in rd12 at 800 
µW/cm2/s (n = 8) and a 50 % constriction is seen in rd12 at 8000 µW/cm2/s (n = 
8). At 800 and 8000 µW/cm2/s WT pupils are almost fully constricted, with peak 
constriction reaching 0.057 (n = 1) and 0.025 (n = 1), respectively. Black and 
white bars under constriction graphs indicate light stimulus off and light stimulus 
on, respectively. Asterisks indicate significance levels of post-hoc test: ***P < 
0.001; ****P < 0.0001. Video stills were taken before light stimulus and around 30 
s after light stimulus onset. Arrows highlight pupil diameter. 
The intrinsic Pupillary Light Reflex is deficient in rd12 mice 
While, the mechanism of the iPLR is not fully understood, constriction to light 
appears to involve both melanopsin signalling in the iris/ciliary body and ipRGCs 
in the retina (Semo et al., 2014, Vugler et al., 2015). In the rd12 mouse there is a 
very small constriction, only detectable when pupil area is measured (Figure 
4.19), and is significant (P < 0.001). Although, this constriction is not significant 
at any specific time point. WT mice also have a significant constriction (P < 
0.0001), which is significant from 2s after light onset and remained significantly 
constricted throughout the recording. WT mice have a constriction which starts to 
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dilate after the end of light stimulation, while rd12 do not re-dilate, although, their 
eyes are significantly less constricted. There is a significant difference between 
the iPLR of WT and rd12 (P < 0.0001, F (1, 712) = 807.5). Light had a significant 
effect on the constriction (P < 0.0001, F (50, 712) = 10.6). Though, WT and rd12 
reacted differently over time (P < 0.0001, F (50, 712) = 5.312). Post-hoc tests 
show a significant difference between WT and rd12 from 7s post light onset until 
the end of the recording. There is a significant difference in the maximum 
constriction (P < 0.001). WT mice have a constriction which reaches 0.43 ± 0.05 
and rd12 only reaches 0.81 ± 0.07. WT mice reach 90% constriction at 37.7 ± 6 
s, and rd12 mice reach 90% constriction at 81.3 ± 33.6 s. The rd12 mutation did 
not affect baseline pupil area (P = 0.4). 
Aged mice (12 months) were also assessed for the iPLR, as it has been shown 
that the iPLR can improve with age in retinal degenerate mice (Vugler et al., 
2015). Interestingly, the iPLR is significantly reduced in rd12 mice by 12 months 
(Figure 4.19), with maximum constriction only reaching 0.92 ± 0.04. The rd12 
mice do have a significant constriction (P = 0.0002) at 12 months, and similarly 
to the young rd12 this is not significant at any isolate time point. Some 12-month 
rd12 do not have a constriction. Comparing the iPLR at 3-months and 12-months, 
there is a significant difference (P < 0.0001, F (1, 408) = 78.46). Time is no-longer 
significant (P = 0.1, F (50, 408) = 1) and the interaction of these different ages 
over time is not significant (P = 0.9999, F (50, 408) = 0.4). No time points were 
significantly different between rd12 at 3 months and 12 months in post-hoc tests. 
Latency in the 12-month rd12 iPLR is 42 ± 22.2 s.  
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Figure 4.19 iPLR in rd12 mice. 
The top graph shows 3-month rd12 (blue, n = 4) pupil constriction compared to 
WT (black, n = 10) in the isolated eye. Rd12 mice have a small pupil constriction 
which is maintained, while WT reached 50% pupil constriction. Images are 
representative video stills from 3-month WT and rd12 before light stimulus and 
around 30s after light onset. Arrows highlight the pupil diameter. The bottom 
graph shows that the iPLR constriction is diminished in 12-month rd12 (n = 6). 
Bars under graphs indicate light stimulus off (black) and on (white). 
 Discussion 
Before attempting to treat with RPE cell transplantation, it is important to 
understand baseline retinal function in the rd12 mouse. While the previous 
experiment showed that rods are largely intact at 3 months, the scotopic ERG is 
significantly reduced. The scotopic ERG response appears only as a small b-
wave response at very high light intensities. There is no evidence of an a-wave 
response at any intensity. The photopic ERG is much more robust but still 
significantly reduced from that of WT. It has been reported that these amplitudes 
diminish with age (Pang et al., 2005, Pang et al., 2006). Usually, cones are 
responsible for the photopic response due to bleaching of rods, despite this, it is 
known that without RPE65, the photopic response is rod driven (Cachafeiro et 
al., 2010, Dai et al., 2015, Seeliger et al., 2001). Perhaps the lack of chromophore 
 209 
 
prevents rods from bleaching and thus allows rods to respond under bright light. 
It has also been reported that P18 rd12 mice have visually evoked potentials to 
low spatial and temporal frequencies but this response is lost at high spatial and 
temporal frequencies (Nusinowitz et al., 2006), suggesting rod and a lack of cone 
function at P18. Under scotopic conditions when high intensities are reached rd12 
mice still have a significantly reduced b-wave compared to WT mice even after 
saturation in WT b-wave. Under normal conditions the scotopic b-wave can reach 
much higher amplitudes than under photopic conditions, when cones are 
responsible for this response. What is interesting is that under the same flash 
intensities the scotopic response in the rd12 is higher than that of the photopic, 
which has an additional background light, thus there may be some bleaching in 
the rd12 rods or perhaps there is more chromophore available under scotopic 
conditions. The source of the chromophore is unknown; although, it has been 
shown that rods can use isorhodopsin, which contains 9-cis retinal as an 
alternative chromophore, in the absence of a functioning visual cycle. Although, 
the level of this is only detectable after a long period of dark-rearing (Fan et al., 
2003).Interestingly, these results are similar to those seen in the NaIO3-treated 
animals of the previous chapter, which also saw a reduced scotopic ERG with a 
robust photopic ERG. 
FOS activation in DA-ACs is seen after exposure to two hours of light in wild-type 
animals. However, in the rd12 mouse, even though there is still a small ERG 
response at three months, this is insufficient to drive FOS activation. Thus, it 
raises the question of how useful the remaining ERG response is to the rd12 
vision. Although DA-ACs and ipRGC dendrites have a close physical association 
(Vugler et al., 2007b) and there is evidence of melanopsin driving sustained 
depolarisation of DA-ACs (Zhang et al., 2012), the evidence that Fos activation 
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in DA-ACs can be melanopsin driven is unclear as it was shown that melanopsin 
was neither necessary nor sufficient to drive this photoresponse (Cameron et al., 
2009), and yet, after blocking ON-bipolar cells, Fos induction was still observed 
(Zhang et al., 2008). However, the loss of activation of DA-ACs may have an 
effect on melanopsin cells. As, under normal conditions, dopamine would 
modulate the sensitivity of ganglion cells in response to light (Jensen and Daw, 
1986), via increased dopamine release. 
The rd12 shows a behavioural light aversion at 1 month. BLA is driven by both 
outer-retinal photoreceptors and ipRGCs (Semo et al., 2010). However, at 3 
months this behavioural light aversion is lost in the rd12 mouse. There is an 
obvious preference for the front half, when the experiment is run with the arena 
in complete darkness. This may be due to neophobia and as the animal is placed 
in the open front half at the beginning on the experiment, it will return there looking 
for a route home.  
The PLR in 3-month rd12 is significantly reduced. A response is only seen at high 
light levels, where the WT have an almost total pupil constriction. It is known that 
rpe65-/- and lrat-/- mice have a less sensitive PLR than WT, but also have a less 
sensitive PLR than rdta or rd1 mice (Tu et al., 2006). The PLR in rd12 mice is 
more severely affected than that seen in NaIO3-treated mice. This lower baseline 
observed in rd12 mice is therefore potentially useful for assessing transplanted 
RPE cell function. 
There is evidence to suggest that the iPLR is melanopsin driven (Xue et al., 2011) 
and at three months rd12 mice only produce a small constriction, which is lost 
with age. This result does not necessarily mean that the melanopsin system is 
reliant on the chromophore produced in the RPE, as it has been shown in two 
papers that melanopsin function is significantly restored in mice with both outer-
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retinal photoreceptor and visual cycle loss compared to loss of visual cycle alone 
(Doyle et al., 2006, Tu et al., 2006). In rpe65-/- and lrat-/- mice ipRGC have 
electrophysiological responses to light at P8, an age that precedes the onset of 
outer-retinal photoreceptor function (Tu et al., 2006). Another theory could be that 
melanopsin function is lost as the photoreceptors start to compete for 
chromophore. 
In conclusion, at 3 months the rd12 mouse has a residual ERG response, 
however, this does not translate to DA-AC activation or BLA. The PLR is 
significantly less sensitive and the iPLR can only produce a small response. It is 
clear that outer-retinal photoreceptor function and ipRGC function are both 
significantly reduced in the rd12 mouse, but not absent and hopefully function 
can be restored by RPE cell transplantation. 
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 Can retinal function be rescued in the rd12 mouse? 
 Introduction 
In this chapter, the retinal function in the rd12 mouse is shown to be severely 
diminished, yet, retinal degeneration is slow and it is anticipated that the 
diminished rod and melanopsin function can be rescued. In this experiment, 
chromophore is administered in the form of 9-cis retinal, and outer-retinal 
photoreceptor function and ipRGC function are assessed by ERG and the iPLR, 
respectively. The iPLR is used to assess melanopsin function as it is solely driven 
by melanopsin (Semo et al., 2014, Xue et al., 2011).  
9-cis retinal has not been previously shown to rescue the rd12 phenotype, 
however, there is evidence showing phenotypic improvements in rpe65-/- mice. 
Oral delivery of 9-cis retinal has been shown to rescue ERG recordings, PLR and 
retinal histology in rpe65-/- mice (Maeda et al., 2009a, Van Hooser et al., 2000, 
Aleman et al., 2004). 9-cis retinal was able to fully restore ipRGC function in 
single cell recordings (Fu et al., 2005). It is also thought that isorhodopsin, which 
uses 9-cis retinal, rather than rhodopsin mediates the residual rod function in 
rpe65-/- mice (Fan et al., 2003). 
This is an important experiment to determine if functional recovery can be 
detected in rd12 mice treated with 9-cis retinal, prior to RPE cell transplantation. 
 Methods 
Preparation and administration of 9-cis retinal 
9-cis retinal was prepared and administered to rd12 mice as described in 
paragraph 2.4.2. 
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Scotopic ERG 
Following 9-cis retinal administration, 3-month animals were placed in the dark 
overnight and prepared for scotopic ERG as described in paragraph 2.2.1. Only 
the brightest scotopic intensity of 1 Lg cd.s/m2 was used. Responses from three 
repeats of this flash intensity were recorded with intervals of 60 seconds. 
Amplitudes, latency and implicit time were analysed by one-way ANOVA and 
Holm-Sidaks multiple comparisons tests. Both eyes were analysed. WT: n = 6; 
rd12 Saline: n = 6; rd12 9-cis retinal: n = 5. 
iPLR 
Following 9-cis retinal administration, animals were placed in the dark overnight. 
Animals were sacrificed and their eyes prepared and recorded as described in 
paragraph 2.2.4, using a white light at 8000 µW/cm2/s. Maximum constriction in 
WT (n = 10) and 3-month rd12 with either saline (n = 4) or 9-cis retinal (n = 6) 
were analysed by one-way ANOVA. Aged rd12 (12 months) maximum 
constriction with saline (n = 6) or 9-cis retinal (n = 6) treatment was compared to 
young rd12 by two-way ANOVA. 
Melanopsin Labelling and analysis 
16 hours after 9-cis retinal was administrated to 3-month rd12, animals were 
sacrificed and the tissue fixed by perfusion with 4% paraformaldehyde, as 
described in paragraph 2.3.1. Improvements in the rd12 iPLR with 9-cis retinal 
were seen 16 hours after administration of the chromophore. Thus, it was 
important to keep this incubation time constant for his experiment to determine if 
an increase in melanopsin was driving the improved iPLR. Retinas were removed 
and stained as described in paragraph 2.3.3. Retinas were labelled with primary 
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antibodies raised in rabbit against melanopsin (1:5000, UF006; Advanced 
Targeting Systems, San Diego, CA, USA) and secondary antibody used was 
raised in donkey against rabbit FITC-labelled (1:200, Jackson ImmunoResearch, 
West Grove, PA, USA). Confocal images were taken on Zeiss 700 of SN, ST, IN 
and IT regions of the retina and superior-nasal rim and inferior-nasal rim which 
covered 399.72 µm x 399.72 µm. Analysis of images is described in paragraph 
2.3.4. Thresholds used for dendrite analysis were 0.1, 0.05 and 0.02. There were 
6 saline-treated rd12 retinas and 7 9-cis retinal-treated retinas. Results were 
analysed using one-tailed Mann Whitney tests. 
 Results 
Rd12 Scotopic ERG responses with 9-cis retinal treatment 
9-cis retinal was administered as a replacement for 11-cis retinal, which due to 
the mutation in rpe65 is not produced in the rd12 mouse. 9-cis retinal significantly 
improved the scotopic ERG in rd12 mice (Figure 4.20.E). Although, comparing 
these improved ERG results to that of WT, this was not a full recovery.  
9-cis retinal significantly improved both the a-wave amplitude (P = 0.0411, t-test) 
= 30.45) and the b-wave amplitude (P = 0.026, t-test) of rd12 mice. This 
improvement in amplitude was seen with an increase in latency and implicit time, 
much greater than that of rd12 or WT mice (Figure 4.20.B and D).  
There are significant differences in the a-wave amplitudes of the WT, rd12 with 
saline and rd12 with 9-cis retinal (F (2, 14) = 30, P < 0.0001). The a-wave 
amplitude is reduced by 76% in rd12, reaching -39 ± 8 µV after exposure to 1 Lg 
cd.s/m2 (Figure 4.20.A), compared to WT amplitudes of -162 ± 10 µV. 9-cis-retinal 
significantly restored scotopic a-wave amplitude in the rd12 mouse to 49% that 
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of WT, reaching -80 ± 17 µV. Though, this was still significantly reduced 
compared to WT a-wave amplitude (P < 0.001). 
The a-wave latency of 9-cis retinal-treated rd12, 76 ± 17 ms, is 5 times longer 
than that of WT mice, 14 ± 2 ms. The a-wave latency of the saline-treated rd12 
mice was not recorded due to the difficulty detecting the a-wave (Figure 4.20.E). 
There are also significant differences between b-wave amplitudes (F (2, 14) = 32, 
P < 0.0001). B-wave amplitudes are reduced in 3-month rd12 mice (Figure 
4.20.C), with peak amplitude of 97 ± 25 µV which is 22% that of WT b-wave 
amplitudes of 431 ± 41 µV. 9-cis retinal, could provide partial recovery of the b-
wave to 195.5 ± 21.10 µV increasing the b-wave to 45% of WT, still significantly 
less than WT. 
Significant differences are also seen in the b-wave implicit time (P < 0.0001, F (2, 
14) = 90.49). The rd12 b-wave implicit time of 93 ± 3 ms was not significantly 
different from WT implicit time, 92 ± 9 ms (Figure 4.20.D). However, the b-wave 
implicit time of rd12 mice treated with 9-cis retinal increased to 221 ± 9 ms, which 
is significantly longer than both saline-treated animals and WT. 
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Figure 4.20 Scotopic ERG from rd12 mice treated with 9-cis retinal. 
9-cis retinal can significantly increase the a-wave by 108% (A) and the b-wave 
amplitude by 102% (C) in the 3-month rd12 mouse. Interestingly, the latency is 
increased. The a-wave latency of 9-cis retinal-treated rd12 is 5 times longer than 
that of WT (B) and the b-wave implicit time has increased by 138% in rd12 when 
treated with 9-cis retinal (D). Asterisks indicate significance level from post-hoc 
tests: *P< 0.05; ***P< 0.001; ****P< 0.0001. Both eyes were analysed; WT n = 6, 
rd12 saline n = 6 and rd12 9-cis retinal n = 5. E shows representative traces from 
a WT, rd12 with saline and rd12 with 9-cis retinal, respectively. Amplitude is 
indicated by the vertical scale bar, representing 200 µV and latency is indicated 
by the horizontal scale representing 200 mS. 
Improvements in the rd12 iPLR with 9-cis retinal 
The iPLR was examined as it is a means of isolating melanopsin function (Semo 
et al., 2014, Xue et al., 2011) and nothing is known about chromophore 
dependence in the iPLR. While 9-cis retinal only partially recovered the rd12 
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ERG, the synthetic chromophore produced an extra constricted iPLR (Figure 
4.21). Maximum constriction was significantly different among WT, rd12 saline 
and rd12 9-cis reitnal (P < 0.0001, F (2, 17) = 36.57). The rd12 mouse has a 
diminished iPLR with peak constriction of 0.81 ± 0.07 normalised pupil area, and 
the addition of 9-cis retinal not only increases the iPLR maximum constriction to 
0.08 ± 0.01 (P < 0.0001), but this even surpasses that of WT (P < 0.001), which 
have a peak constriction of 0.43 ± 0.05 (Figure 4.21.B). From 2s post-light-onset 
rd12 animals treated with 9-cis retinal had a significantly greater constriction than 
both rd12 treated with saline and WT mice, which remained significantly greater 
until the end of the recording. 
Latency was analysed by time to 90% peak constriction and was significant 
between groups (P = 0.0005). There was a significant difference between WT 
and rd12 9-cis retinal (P < 0.05), where 90% peak constriction is reached at 37.7 
± 6 s for WT and 9.7 ± 2.1 s for rd12 9-cis.  rd12 9-cis retinal also have a 
significantly faster constriction compared to rd12 saline (P < 0.001), which reach 
90% peak constriction at 81.3 ± 33.6. 
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Figure 4.21 iPLR in rd12 mice with 9-cis retinal. 
A shows a graph of the average constriction ± SEM normalised to baseline pupil 
area in isolated eyes of 3-month rd12 mice with saline (n = 4) or 9-cis-retinal (rd12 
+ 9-cis, n = 6) and WT (n = 10) to 8000 µW/cm2/s white light. B plots the maximum 
constriction. 9-cis retinal can not only restore the intrinsic pupil light reflex, it 
resulted in a constriction of 91%, which is beyond that of WT at 58% and rd12 
saline at 19%. Asterisks indicate significance level from post-hoc tests: ***P < 
0.001; ****P < 0.0001. Video stills underneath the graphs show a representative 
image of the iPLR in WT, rd12 treated with saline and rd12 treated with 9-cis 
retinal, prior to light exposure and after 30 seconds of light exposure. Arrows 
highlight pupil diameter. 
iPLR recovery in aged rd12 mice 
This significant increase in the iPLR in rd12 with 9-cis retinal was still seen in 12-
month old rd12 mice (Figure 4.22.A). There is a significant effect of 9-cis retinal 
on the iPLR in both 3-month and 12-month rd12 (Table 26). Maximum constriction 
(Figure 4.22.B) was significantly greater in animals treated with 9-cis retinal 
compared animals treated with saline (P < 0.0001, F (1, 18) = 428.2). Although, 
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younger animals had a greater constriction compared to the older rd12, whether 
treated with saline or 9-cis retinal (P = 0.0086, F (1, 18) = 8.697). 9-cis retinal 
increased the maximum constriction from 0.92 ± 0.04 to 0.19 ± 0.01 in 12-month 
rd12. 
9-cis retinal accelerates the constriction (P = 0.00186, F (1, 17) = 6.77). Latency 
to 90% maximum constriction is not affected by age (P = 0.5, F (1, 17) = 0.4). 9-
cis retinal has the same effect on both ages (P = 0.1, F (1, 17) = 3). 12-month 
saline-treated rd12 took 42 ± 22.2s to reach 90% maximum constriction and 12-
month rd12 mice treated with 9-cis retinal took 27.5 ± 2.8s. The effect of age is 
also seen when comparing the point at which the iPLR from animals treated with 
9-cis retinal become significantly more constricted than saline-treated animals. At 
3-months rd12 treated with 9-cis retinal have a significantly greater constriction 
from 2s post light onset. At 12-months, this is increased to 3s. 
12-month 9-cis retinal-treated rd12 continued their constriction following light off, 
while younger mice had greater pupil dilation when the light stimulation end. 
Thus, while younger mice had a constriction that surpassed the aged mice, after 
light stimulation, the constriction of the young mice became significantly less than 
that of aged mice, due to dilation. The constriction is of 3-month 9-cis retinal-
treated rd12 is significantly greater than 12-month 9-cis retinal-treated rd12 from 
2 s after light onset until 30 s, where the aged mice’s constriction starts to reach 
maximum. Then when light stimulation ends, the young 9-cis retinal-treated rd12 
have pupil dilation and from 55 s after the light stimulation ended until the end of 
the recording the constriction of aged aged rd12 becomes significantly greater 
than the young rd12. Age also had an effect on the baseline pupil area (P = 
0.0104, F (1, 18) = 8.171), significantly increasing the baseline pupil area. 9-cis 
retinal had no effect on the baseline pupil area (P = 0.4, F (1, 18) = 0.6). 9-cis 
 220 
 
retinal treated 12-month rd12 had a significantly larger baseline pupil area 
compared to 9-cis retinal-treated 3-month rd12 (P < 0.05). 
Table 26 Two-way ANOVA of effects of 9-cis retinal on the rd12 iPLR 
Two-way ANOVA 3 months 12 months 
9-cis retinal F (1, 408) = 156, P < 0.0001 F (1, 512) = 9036, P < 0.0001 
Time F (51, 408) = 86, P < 0.0001 F (51, 512) = 52, P < 0.0001 
Interaction F (51, 408) = 38, P < 0.0001 F (51, 512) = 43, P < 0.0001 
 
 
Figure 4.22 iPLR in aged rd12 with 9-cis retinal. 
12-month rd12 mice also produce a constriction which surpasses that of WT, 
when given 9-cis retinal, albeit less constricted than 3-month rd12 mice (A). Aged 
rd12 have a slower latency when treated with either saline (n = 6) or 9-cis retinal 
(n = 6) compared to 3-month rd12 saline (n = 4) and 9-cis retinal (n = 6). B shows 
the maximum constriction and asterisks indicate significance levels determined 
by post-hoc tests: ****P < 0.0001. 
Effects of 9-cis retinal on melanopsin expression 
This increase in iPLR by 9-cis retinal is not accompanied by an increase in 
melanopsin labelling in the rd12 retina, 16 hours after 9-cis retinal administration 
(Figure 4.23). Density of ipRGCs in saline-treated rd12 is 83.5 ± 6.07 cells per 
mm2 and 81.43 ± 5.2 in 9-cis retinal-treated rd12 (t-test, P = 0.5). Average 
greylevel per soma in saline-treated rd12 is 51.95 ± 4.5 and 60.33 ± 5.5 in rd12 
treated with 9-cis retinal (t-test, P = 0.2). Dendritic coverage is also similar in 
saline-treated and 9-cis retinal-treated rd12 covering 0.41 ± 0.04 % and 0.49 ± 
0.07 % of total area, respectively, when threshold at 0.1 (t-test, P = 0.3). Other 
thresholds of 0.05 (t-test, P = 0.2) and 0.02 (t-test, P = 0.2) also showed no 
significant differences between saline-treated and 9-cis retinal-treated rd12 (data 
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not shown). Regional analysis also showed no significant differences between 
saline-treated and 9-cis retinal-treated rd12 (data not shown). 
 
 
Figure 4.23 Melanopsin labelling in rd12 mice 16 hours following 9-cis retinal. 
A shows representative images from the different retinal quadrants from both 
saline-treated and 9-cis retinal-treated rd12 mice. There was no change in the 
number of melanopsin+-cells (B), nor melanopsin-labelling in somas (C). The 
dendritic coverage of melanopsin cells also remained unchanged. D is the graph 
of dendritic coverage at threshold 0.1, showing that the percentage area covered 
by rd12 with 9-cis retinal (grey, n = 7) was not significantly different from rd12 
with saline (white, n = 6). This graph is similar to that seen at other thresholds. 
 Discussion 
This experiment is important to determine if functional recovery is possible, prior 
to attempting retinal rescue with RPE cell transplantation. In this experiment rod 
function is investigated by scotopic ERG and ipRGC function is investigated by 
examining the iPLR. Cone function was not investigated by ERG because a finite 
amount of chromophore was administered, and this may be bleached in the light-
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adaption process, also, as these photoreceptors suffer the most degeneration in 
the rd12 mouse, they would likely be the most difficult to recover function. 
Replacing the chromophore significantly restored the amplitude of the scotopic 
a- and b-wave. This functional restoration was still significantly smaller than that 
seen in the WT retina, indicating retinal degeneration in the 3-month rd12 retina. 
However, this increase in amplitude comes at a cost of increased latency and 
implicit time. This could indicate problems with remaining photoreceptor function 
and synaptic connections in the retina. These ERG results are similar to those 
seen in NaIO3-treated mice which received 9-cis retinal; there is an increase in 
amplitude but also an increase in latency and implicit time. While 9-cis retinal has 
been used to improve the ERG of many animal with visual cycle defects, none 
have reported on changes to the latency (Gao et al., 2012, Maeda et al., 2006, 
Maeda et al., 2009b, Parker and Crouch, 2010, Parker et al., 2009, Tang et al., 
2010). 
While 9-cis retinal only partially recovered the rd12 ERG, the synthetic 
chromophore produced a super constricted iPLR. Normal rd12 mice have a 
significantly diminished iPLR, while, 9-cis retinal drives this constriction to 
surpass that of WT. This is unexpected as the melanopsin expression is very low 
in the retina and the response from the rods in the scotopic ERG was not as 
strong as WT. This suggests that the iPLR function is only diminished due to the 
lack of chromophore and an increase in chromophore results in an increased 
constriction. Along with significantly increased constriction, rd12 treated with 9-
cis retinal had a significantly shorter latency of constriction compared to WT. At 
12 months, this striking increase in the iPLR is still seen. Age increased the 
latency in rd12 treated with 9-cis retinal. Age also sustained pupil constriction 
following light-off in rd12 treated with 9-cis retinal. This effect of age was not 
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reported in WT or rd mice (Vugler et al., 2015). This loss of re-dilation in aged 
rd12 may be a loss of cholinergic transmission as the constriction pattern 
resembles that of WT treated with atropine (Vugler et al., 2015). 
This super iPLR is surprising given the significant reduction in melanopsin 
labelling and loss of melanopsin+-cells seen in experiment 4.3. One possible 
theory was that melanopsin, being similar to a rhabdomeric opsin, may need 
chromophore to fold properly (Ozaki et al., 1993). This hypothesis was tested by 
replacing the chromophore with 9-cis retinal supplementation. Results showed 
that 9-cis retinal had no effect on melanopsin expression levels nor on the density 
of melanopsin+-cells. While this expression was examined only 16 hours after 9-
cis retinal administration, this is the same time between 9-cis retinal 
administration and the increased iPLR is recorded. 
Other uses of 9-cis retinal in the literature show that 9-cis retinal is able to improve 
both rod and cone function in rpe65-/- mice. Cone function and opsin levels were 
increased in rpe65-/- mice following 9-cis retinal administration (Tang et al., 2010, 
Znoiko et al., 2005). Currently, 9-cis retinyl acetate is being trialled for treatment 
of patients with mutation in rpe65 or lrat (Koenekoop et al., 2014, Scholl et al., 
2015). 
This is an important experiment to determine if retinal functional in rd12 mice can 
be improved with 9-cis retinal treatment, prior to RPE cell transplantation. From 
this experiment, it is determined that while the rd12 mouse has severely 
diminished retinal function, it is possible to recover a significant level of retinal 
function by providing chromophore. In the next experiment, the possibility of 
achieving functional recovery by RPE cell transplantation is examined. 
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 Can RPE transplantation improve rd12 retinal function? 
 Introduction 
Very few studies have been reported using the rd12 mouse as a cell therapy 
recipient. ESC-derived neuroprogenitors were injected into the vitreous and 
appeared to integrate into the neural retina (Chaudhry et al., 2009).  
Li et al injected 1,000 iPSC-RPE cells into 2-day old albino rd12 mice and saw 
pigmented RPE cells at 5 months. They also injected 1,000 iPSC-RPE cells into 
P2 rd12 crossed with Prkdcscid/Prkdcscid mice for a double homozygous 
SCID/rpe65 mutation. While increased b-wave amplitude was seen, the a-wave 
was still absent (Li et al., 2012b). 
Despite the small number of studies using the rd12 mouse as cell therapy 
recipient, previous experiments in this chapter have shown that the rd12 has a 
slow retinal degeneration and retinal function is severely reduced, both of which 
are ideal factors for studying the effects of RPE cell transplantation. In this 
experiment, hESC-derived RPE cells were transplanted subretinally into rd12 
mice to determine the utility of this model for studying RPE cell transplantation. 
This is determined by the ability of RPE cell transplantation to improve retinal 
function and the survival of the graft in the subretinal space in the rd12 mouse. 
 Methods 
hESC-RPE cell preparation and injection 
Cells were prepared and injected subretinally into both eyes as described in 
paragraph 2.4.3. 8 rd12 animals received 75,000 hESC-derived RPE cells in 1.5 
µL DRS suspension and 5 rd12 mice received 1.5 µL DRS only. A range of ages 
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were treated from 1.5 months – 11 months balanced by age and sex between 
groups. 
ERG 
Scotopic and photopic ERG recordings were carried out on both eyes as 
previously described in paragraph 2.2.1. 
PLR 
PLR was recorded in left eyes as described in paragraph 2.2.3. The light powers 
examined were 80, 800 and 8000 µW/cm2/s. The number of animals tested at 
each light power is displayed in Table 27. 
Table 27 Number of rd12 which received hESC-RPE assessed by PLR 
Light Power 8000 µW/cm2/s 800 µW/cm2/s 80 µW/cm2/s 
hESC-RPE 6 6 8 
Control 4 3 3 
Immunohistochemistry 
Animals were perfused with 4% PFA as described in paragraph 2.3.1 and 
immunohistochemically stained as described in paragraph 2.3.2. Eyes were 
labelled with anti-human mitochondria (1:500, MAB1273, Millipore) and 
secondary anti-mouse raised in donkey tagged with FITC (1:200, Jackson 
ImmunoResearch, West Grove, PA, USA). 
 Results 
Changes in the scotopic and photopic ERG in eyes with hESC-RPE cell grafts. 
Differences in the scotopic and photopic ERG are seen between eyes which 
received cells and eyes which received the vehicle only (Figure 4.24). There are 
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small increases in the scotopic a-wave and b-wave amplitude and a significant 
decrease in the photopic b-wave amplitude in eyes which received the cell graft. 
Scotopic a-wave analysis does not show a significant difference between animals 
which received cells and animals which received vehicle (Table 28), albeit at -2 
Lg cd.s/m2, where post-hoc tests show that animals which received cells have a 
significantly greater a-wave compared to vehicle (P < 0.01) (Figure 4.24.A). 
Traces, at -2 Lg cd.s/m2, have a distinguishable a-wave in eyes which received 
hESC-RPE cells (Figure 4.24.E), which is lost at higher light intensities. 
Analysis of the scotopic b-wave amplitude reveals that there is not a significant 
difference between eyes which received hESC-RPE cells and those which 
received vehicle (Table 28), although, post-hoc tests show a significant difference 
between these eyes at Lg 0 cd.s/m2 (P < 0.01) (Figure 4.24.B). 
The Photopic b-wave amplitude is significantly higher in vehicle-treated eyes 
compared to eyes which received hESC-RPE (Table 28). Post-hoc tests revel 
that amplitude at the highest light intensity is significantly greater in eyes treated 
with vehicle (P < 0.001), reaching 75 ± 8 µV, compared to eyes treated with 
hESC-RPE cells which reached 37 ± 8 µV (Figure 4.24.C). 
Table 28 Two-way ANOVA of ERG in rd12 following hESC-RPE graft 
Two-way ANOVA Scotopic A-wave Scotopic B-wave Photopic B-wave 
hESC-RPE F (1, 144) = 3.84, 
P = 0.0617 
F (1, 144) = 1.35, 
P = 0.2563 
F (1, 95) = 10.66, 
P = 0.0015 
Light Intensity F (6, 144) = 8.08, 
P < 0.001 
F (6, 144) = 14.2, 
P < 0.0001 
F (3, 95) = 18.79, 
P < 0.0001 
Interaction F (6, 144) = 1.71, 
P = 0.1221 
F (6, 144) = 2.15, 
P = 0.0516 
F (3, 95) = 5.04, 
P = 0.0028 
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Figure 4.24 Scotopic and photopic ERG recordings following hESC-RPE cell 
grafting into rd12 mice. 
Eyes which received hESC-RPE cell grafts have a scotopic wave that changes 
with inceasing light intensities. Eyes which received hESC-RPE cell grafts had a 
significantly greater a-wave amplitude at -2 Lg cd.s/m2 only (A). Scotopic b-wave 
amplitude is significantly greater in eyes which received hESC-RPE cells at 0 Lg 
cd.s/m2 only (B). Photopic b-wave amplitude is reduced in hESC-RPE-treated 
eyes (C). Asterisks indicate post-hoc significant differences between hESC-RPE- 
treated eyes (n = 16) and vehicle treated eyes (n = 10): **P < 0.01, ***P < 0.001. 
Traces show the average scotopic (D) and photopic (E) trace ± SEM of eyes 
treated with hESC-RPE cells (black) and vehicle (blue). The vertical scale bar in 
D and E represent 50 µm and the horizontal scale bars indicate 50 ms.  
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PLR recordings in rd12 mice following hESC-RPE cell grafting 
The PLR has significantly greater constriction in eyes treated with hESC-RPE 
cells at 80 µW/s/cm2 (Figure 4.25.A), but not at the higher light intensities (Table 
29). The presence of a significant constriction is determined by the average 
normalised pupil area during light stimulation (0-60s), being significantly lower 
than 1 (baseline area). At 80 µW/s/cm2 eyes treated with vehicle do not have a 
significant constriction (P = 0.6). The maximum constriction reached was 0.92 ± 
0.05. The Average pupil area is significantly less than 1 in eyes treated with 
hESC-RPE at 80 µW/s/cm2 (P = 0.0071). These pupils reached a peak 
constriction of 0.81 ± 0.04. This is greater than untreated rd12, which had a peak 
constriction of 0.89 ± 0.04. The normalised pupil area between 0-60s in 
significantly lower than 1 in both animals treated with hESC-RPE cells and vehicle 
at both 800 and 8000 µW/s/cm2 (Figure 4.25.B and C). Peak constrictions 
reached 0.66 ± 0.14 in eyes that received vehicle at 800 µW/s/cm2 and 0.24 ± 
0.03 at 8000 µW/s/cm2. Eyes that received hESC-RPE had a peak constriction 
of 0.67 ± 0.1 at 800 µW/s/cm2 and 0.22 ± 0.04 at 8000 µW/s/cm2. Untreated rd12 
had a peak constriction of 0.34 ± 0.07 at 800 µW/s/cm2, which is greater than 
both treatment groups. This is possibly due to the average age increase of around 
1.5 months of these rd12 and the untreated rd12 assessed in 4.4.3. No significant 
differences were found between hESC-RPE- and vehicle-treated eyes at these 
light powers. Maximum pupil constriction within the first 30s after light onset was 
not significantly different between animals treated with hESC-RPE cells and 
animals treated with vehicle (P = 0.5, F (1, 24) = 0.4) (Figure 4.25.D). 
Constrictions became greater with increased light power (P < 0.001, F (2, 24) = 
40.4). This increased constriction with increased light power was not different 
between eyes treated with hESC-RPE and vehicle (P = 0.7, F (2, 24) = 0.3). 
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Table 29 Statistics from PLR of rd12 treated with hESC-RPE 
Two-way 
ANOVA 
8000 µW/s/cm2 800 µW/s/cm2 80 µW/s/cm2 
Interaction P = 0.9993 
F (12, 92) = 0.17 
P = 0.9758 
F (13, 76) = 0.37 
P = 0.0506 
F (13, 109) = 1.81 
Time P < 0.0001 
F (12, 92) = 30.24 
P = 0.0746 
F (13, 76) = 1.99 
P = 0.0085 
F (13, 109) = 2.34 
Group P = 0.7671 
F (1, 92) = 0.09 
P = 0.0746 
F (1, 76) = 3.27 
P = 0.0015 
F (1, 109) = 10.59 
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Figure 4.25 PLR in rd12 treated with hESC-RPE cells. 
At 80 µW/s/cm2 (A), hESC-RPE-treated eyes (n = 8) have a significantly greater 
constriction than vehicle-treated eyes (n = 3), which did not have a significant 
constriction. At 800 µW/s/cm2 (B), there is no significant different between hESC-
RPE- (n = 6) and vehicle-treated (n = 3) animals. At 8000 µW/s/cm2 (C), there is 
no significant difference between hESC-RPE- (n = 6) and vehicle-treated (n = 4) 
animals. Representative images before (dark) and around 30s after (light) light 
onset are seen to the right of each graph of corresponding light powers. 
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Cell transplant histology 
No viable hESC-RPE cells were found in the subretinal space of transplanted 
eyes. Eyes were labelled for anti-human mitochondria, which was raised in 
mouse and thus, created a large background stain with the anti-mouse secondary 
antibody, as can be seen in Figure 4.26.C. While using an antibody raised in 
mouse to stain mouse tissue is not ideal, this anti-body was helpful in screening 
for cells. hESC-RPE cells were also labelled as a positive control. The site of 
injection was located by a mass of pigmented cells in the subretinal space. 
However, these cells did not show stain positive for human mitochondria (Figure 
4.26) 
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Figure 4.26 Absence of labelling of human mitochondria in injection site in rd12 
mice. 
The image A shows nuclei staining (blue), human mitochondria (green) and 
transmitted light in hESC-RPE cells. The image B shows a cluster of cells in the 
subretinal space with pigmented cells and nuclei. C shows the same image with 
transmitted light and human mitochondria labelled. D show the image with nuclei 
staining and human mitochondria. The cells do not label positive for human 
mitochondria as the green fluorescence is seen outside the cell bodies. Scale 
bars indicates 50 µm. 
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 Discussion 
This was an important experiment to determine if the rd12 is a useful model for 
studying RPE transplantation, i.e. can retinal function be rescued with hESC-RPE 
cells and can hESC-RPE cells survive in the rd12 retina? In this experiment, it 
was found that eyes which received hESC-RPE cells had some improvements 
on the scotopic a- and b-wave amplitude but reductions in the photopic b-wave 
amplitude. While under normal conditions a reduction in photopic b-wave 
amplitude would be an obvious loss of function, in the rd12 mouse it is known 
that this photopic ERG response is rod driven (Dai et al., 2015), thus, a loss of 
photopic function could mean a loss of rods or could indicate an increase in 
chromophore preventing rods from functioning under photopic conditions. When 
also considering the scotopic amplitudes in the hESC-RPE-treated eyes, the 
former theory is less likely. 
The PLR had a small improvement at 80 µW/s/cm2, but not at higher irradiances. 
It is unknown if this improvement is from outer-retinal photoreceptors or ipRGCs 
or both. Unfortunately, the iPLR which can isolate melanopsin function was not 
examined as animals were perfused to preserve retinal histology. 
While the site of injection was hound in rd12 eyes, cells did not stain positive for 
human mitochondria, suggesting that the cells were no-longer viable. Studies 
reporting similar results have previously been reported in eyes where no viable 
cell grafts were found. Improvements in head tracking and fos activation, along 
with preservation of photoreceptors, were recorded in RCS rats 13 weeks after 
receiving iPS-RPE cells, while no viable cell grafts were found (Carr et al., 2009). 
These animals received oral cyclosporin immunosuppressant, although, 
xenografts can be compromised even after triple immunosuppression (Del Priore 
et al., 2003). It is possible that macrophage/microglia infiltration and activation 
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play a role in the improvement of retinal histology and function. Improvements 
have been reported where grafted cells are no longer viable but many large 
pigmented cells positive for macrophage markers are found near the graft site 
(Carr et al., 2009, Del Priore et al., 2003). 
 General Conclusions 
The mutation in rpe65 in the rd12 mouse results in the absence of RPE65 protein 
formation, which was validated here by immunohistochemistry. RPE65 is 
necessary for the recycling of chromophore. This loss of chromophore leads to 
retinal degeneration. At 3 months, no M/L-opsin was detected and S-opsin is 
mislocated to PIS, ONL and IPL. This mislocation of cone opsin and cone loss 
may be due to the requirement of chromophore for correct opsin folding and 
trafficking (Bandyopadhyay et al., 2013) and timeline of cone loss observed in the 
literature  (Li et al., 2011, Pang et al., 2010) coincides with WT development of 
peak expression of RPE65 (Bowes et al., 1988, Manes et al., 1998, Hamel et al., 
1993). Rods have a slower rate of degeneration, and rhodopsin is found located 
in the POS in rd12 at 3 months. It has been published that rhodopsin spectral 
absorbance is not detected in the rd12 mouse (Pang et al., 2005), however, 
rhodopsin protein presence and location have not been previously reported in 
rd12 by immunohistochemistry. ERG recordings under scotopic conditions have 
a small b-wave response only at high light intensities in 3-month rd12. There is a 
more robust photopic b-wave, however, it is known that this is rod driven (Dai et 
al., 2015). Thus, rods in the rd12 mouse can function albeit at much lower 
sensitivity. Patients with mutations in rpe65 have similar ERG patterns (Lorenz et 
al., 2000). This rod response is insufficient to activate Fos in DA-ACs. 
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IpRGCs make up a third type of photoreceptor. Often these photoreceptors are 
overlooked because they do not play a strong role in image forming vision. It is 
unknown to what extent these cells require the RPE for normal function, however, 
it is clear in the rd12 mouse that the mutation in rpe65 has resulted in loss of 
these cells and reduction in melanopsin from 1 month. This loss of melanopsin 
and loss of ipRGC did not significantly reduce further up to 8 months. This 
reduction may be developmental. This loss of ipRGCs is also specific to this 
subtype of RGC as no significant reduction is seen in the RGC population in rd12 
mice. Melanopsin expression has been shown to be affected by other RPE 
mutations, such as mutation in mertk (Li et al., 2012a, Sakamoto et al., 2004, 
Vugler et al., 2007b, Vugler et al., 2008b). 
The deficit in melanopsin function is evident in the rd12 mouse. The BLA which 
is driven by both outer-retinal photoreceptors and ipRGCs is present at 1 month, 
but is lost by 3 months. This behaviour is seen in mice without rods or cones and 
so melanopsin alone can drive the response (Semo et al., 2010), despite this, 
melanopsin is not able to drive this behaviour in 3-month rd12 mice. The PLR is 
also driven by outer-retinal photoreceptors and melanopsin (Lucas et al., 2003) 
and is significantly reduced in the rd12 mouse. A response is only seen at high 
light levels, where the WT have an almost total pupil constriction. Comparing 
these results to those published by Lucas et al, it suggests that both outer-retinal 
photoreceptors and ipRGC have reduced function in the rd12. The iPLR is a 
functional readout selective for melanopsin function (Semo et al., 2014, Xue et 
al., 2011). At three months rd12 mice only produce a small constriction, which is 
lost with age. 
The rd12 mouse was chosen to be studied because it appears to be an ideal 
model for investigating RPE therapies. Cone, rod and ipRGC function is 
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significantly reduced in the rd12 mouse, even though, the retinal degeneration is 
slow for rods and ipRGCs. Functional recovery was tested, prior to RPE cell 
transplantation, by providing chromophore in the form of 9-cis retinal, to 
determine if the remaining photoreceptors were functional. Rod function was 
examined by scotopic ERG and ipRGC function was assessed by analysing the 
iPLR, this allowed separation from cone function, which is likely to be the most 
difficult function to restore, as they undergo a faster degeneration. 9-cis retinal 
provided a significant increase in both scotopic a- and b-wave amplitudes, 
although this was at the cost of longer latency and implicit time. The amplitudes 
were significantly lower than WT. The loss of a-wave amplitude signifies the level 
of rod degeneration at 3 months in the rd12 retina. The longer latencies could 
indicate problems with remaining photoreceptor function and synaptic 
connections in the retina. 
While 9-cis retinal only partially recovered the rd12 scotopic ERG, the synthetic 
chromophore produced a super constricted iPLR. Normal rd12 mice have a 
significantly diminished iPLR, still, 9-cis retinal drives this constriction to surpass 
that of WT and at a significantly faster latency. This is unexpected as the 
melanopsin expression is significantly lower in the rd12 retina and the response 
from the rods in the scotopic ERG was not as strong as WT. This suggests that 
the iPLR function is only diminished due to the lack of chromophore and an 
increase in chromophore results in an increased constriction. This ability of 9-cis 
retinal to recover the iPLR was still seen at 12 months, suggesting a strong 
preservation of this functional pathway. Latency is lost in the rd12 mouse with 
age and pupil re-dilation was lost in aged mice, as the mechanism of the iPLR is 
largely unknown. It is difficult to speculate why this effect of age is seen, 
especially when this was not reported in aged WT or rd mice (Vugler et al., 2015). 
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Though, these mice were only 9-months and this may account for a difference, 
when comparing them to mice used in this study, which were 12 months. 
The super iPLR, created by 9-cis retinal is surprising given the significant 
reduction in melanopsin labelling and loss of melanopsin+-cells in the rd12 
mouse. One possible theory was that melanopsin, may require chromophore to 
fold properly, similar to cone photoreceptors. Contrasting this, no significant 
changes to melanopsin expression levels nor on the density of melanopsin+-cells 
were seen in rd12 mice treated with 9-cis retinal. This demonstrates that the 
enhanced iPLR seen in rd12 mice treated with 9-cis retinal was achieved with 
significantly lower melanopsin expression and melanopsin+-cell density. 
The rd12 mouse was chosen to be studied because it appears to be an ideal 
model for investigating RPE therapies. Cone, rod and ipRGC function is 
significantly reduced, even though, the retinal degeneration is slow. It is also 
shown that retinal function can be significantly improved by supplementing 
chromophore. It was then determined if hESC-RPE cell grafting could improve 
retinal function and following the grafting of hESC-RPE cells into the subretinal 
space some functional improvements were seen in the scotopic ERG and the 
PLR. It is difficult to determine if the PLR improvements seen were from outer-
retinal photoreceptors or ipRGCs. Unfortunately, no viable hESC-RPE cells were 
found in the rd12 retina. Cells were discovered at the site of injection and did not 
integrate into the rd12 retina. It is difficult to attribute the visual function 
improvements to the hESC-RPE cells grafted, perhaps they released trophic 
factors, or if the improvements should be attributed to an increased immune 
response, which has been reported in many studies (Lawrence et al., 2000, Carr 
et al., 2009, Del Priore, 2005). 
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Chapter 5 Investigating if the RPE supplies 
chromophore for ipRGC function and the iPLR. 
 Introduction 
It is not known if ipRGCs require the RPE for chromophore production. Rods and 
cones have many physical connections with the RPE aiding chromophore 
transportation, however, ipRGCs are situated in the inner retina and separated 
from the RPE by many layers of cells. While melanopsin has been reported to 
work as a bi-stable pigment (Melyan et al., 2005, Fu et al., 2005), my experiment 
in chapter 4 suggest that this bistability is insufficient to drive a normal iPLR in 
the rd12 mouse. However, it was shown in experiment 4.5 that supplementing 
the rd12 mouse with systemically administered 9-cis retinal not only restores the 
iPLR but actually causes a super iPLR constriction which significantly exceeds 
that seen in the WT mice. This phenomenon occurred without an increase in 
melanopsin+-cells or an increase in melanopsin expression, a finding which 
raises the question of whether this supplementary chromophore was acting on 
ipRGCs in the retina or was it driving the function of an opsin in the iris/ciliary 
body? 
As such, leading on from these interesting observations in this last experimental 
chapter, the important question of whether the RPE supplies chromophore for 
ipRGCs and if these retinal cells drive the iPLR is addressed. 
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 Is the iPLR driven by chromophore acting in the retina? 
 Introduction 
The super iPLR, created by 9-cis retinal in rd12 mice, seen in experiment 4.5 is 
surprising given the significant reduction in melanopsin labelling and loss of 
melanopsin+-cells in the rd12 mouse, which was not enhanced by 9-cis retinal. 
One possible explanation is that the supplemental chromophore was acting 
directly on the iris/ciliary body. It is unknown if the iPLR is initiated in the retina or 
is solely a result of light acting directly on the iris (Semo et al., 2014, Wang et al., 
2017, Xue et al., 2011). As such, in this experiment, it is determined if the 9-cis 
retinal driving the iPLR in rd12 mice is acting on the retina or on the iris/ciliary 
body directly. This is done using intrinsic pupillometry on isolated anterior 
chambers together with immunohistochemical staining for RPE65, to confirm the 
presence or absence of this key enzyme in WT mouse iris. 
 Methods 
Histology 
To determine where RPE65 is expressed in the iris, WT (n = 1) retina and iris 
was labelled for RPE65. The animal was perfused as described in paragraph 
2.3.1. The eyes were fixed overnight in 4% PFA, embedded, sectioned and 
stained as described in paragraph 2.3.2. The antibodies used were: anti-RPE65 
raised in rabbit (1:500, ab173596; Abcam) with the secondary antibody raised in 
donkey against rabbit tagged with FITC (1:200, Jackson ImmunoResearch, West 
Grove, PA, USA). Images were taken on a Zeiss 700 microscope. 
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9-cis retinal preparation and administration 
9-cis retinal was prepared and administered to 16 rd12 mice as described in 
paragraph 2.4.2, with 6 additional rd12 mice receiving a control injection. Animals 
were kept in darkness overnight 16 – 18 hours prior to recording iPLR function. 
iPLR 
Following 9-cis retinal administration and dark-adaptation, animals were culled 
by cervical dislocation under dim red light. Each animal had one eye cut along 
the CMZ to remove the retina (- retina) and isolate the anterior chamber and 
ciliary body. The other eye was cut 1mm below the CMZ in order to retain a ring 
of retina attached to the anterior chamber (+ retina). This technique was 
previously published and described by this lab (Semo et al., 2014). Anterior 
chambers +/- retinas were then examined for an iPLR using methods described 
in paragraph 2.2.4. Animals treated with 9-cis retinal and animals treated with 
saline were alternated for iPLR recordings. The first and second eye were also 
counterbalanced between receiving a + or – retina cut. 
 Results 
RPE65 labelling in the WT retina 
RPE65 labelling is only seen in the RPE of the WT mouse (Figure 5.1). No RPE65 
labelling was seen in the iris of this animal. 
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Figure 5.1 RPE65 labelling in WT retina and iris. 
RPE65 (green) is seen in the RPE in the wild-type retina (A and C), however, 
there is no evidence of RPE65 in the iris (B and D). Images B and D display 
pigmented iris and clear cornea. Images A and B were taken with transmitted 
light to identify the pigmented tissue in the RPE and iris. Scale bar represents 50 
µm. 
Chromophore acting in the retina drives the iPLR 
To determine if 9-cis retinal is acting on the retina or ciliary body/iris to produce 
the iPLR in rd12 mice, the iPLR was examined in rd12 treated with 9-cis retinal 
when the retina was removed. To do this, eyes were prepared by either cutting 
along the CMZ to remove retina but keep the ciliary body intact (- retina) or eyes 
were cut ~1 mm below the CMZ to include a rim of retina (+ retina). When testing 
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the iPLR animals were alternated between saline-treated and 9-cis retinal-
treated. One eye was prepared + retina and the other prepared - retina. This was 
also alternated to remove a bias of testing one eye first. Neither retinal attachment 
(P = 0.3) nor order of examination had an effect on the baseline pupil area (P = 
0.2).  
All groups have an average pupil area, during light stimulation (0-60s), that is 
significantly smaller than baseline pupil area: saline + retina (P = 0.0004), saline 
– retina (P = 0.0287), 9-cis retinal + retina (P < 0.0001) and 9-cis retinal – retina 
(P < 0.0001). Rd12 mice treated with 9-cis retinal that have a rim of retina 
attached to the anterior chamber have a significantly constricted pupil from 2s 
after light onset onwards. While rd12 mice treated with 9-cis retinal without retina 
have a significant constriction at 20s and 60s only.  Rd12 mice treated with saline 
with retina attached to the anterior chamber only show a significantly reduced 
pupil area at 60s post-light onset. Rd12 mice treated with saline without retina 
attached to the anterior chamber do not have a significantly smaller pupil area at 
any specific time point during light stimulation. So, while saline-treated rd12 pupil 
- retina have a pupil area during light stimulation that is significantly less than 1, 
this is not apparent at any specific time point. 
It has already been shown that 9-cis retinal increases the constriction rd12 whole 
eye preparations (Figure 4.21). This is shown to be the case when only a 1 mm 
rim of retina is attached to the anterior chamber (Figure 5.2.A). Rd12 mice with a 
rim of retina attached to the anterior chamber have a significantly greater iPLR 
when treated with 9-cis retinal, compared to rd12 mice treated with saline. A 
significant difference is seen from 7s to 117s after light onset. 
Comparing this to isolated anterior chambers (-retina), there is no longer an 
obvious constriction (Figure 5.2.B). Without retina attached there is no longer an 
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effect of 9-cis retinal (P = 0.6, F (1, 949) = 0.3). Interestingly, no significant 
changes in pupil area were detected throughout the recording (P = 0.9997, F (51, 
949) = 0.5), reiterating the loss of an obvious constriction. Even though, isolated 
anterior chambers from both saline-treated and 9-cis retinal-treated rd12 mice 
have an average pupil area that is significantly less than baseline during light 
stimulation. 
Retinal attachment significantly increases the effect of 9-cis retinal on the iPLR. 
Rd12 mice treated with 9-cis retinal that have a rim of retina attached to the 
anterior chamber have a significantly greater iPLR than rd12 mice treated with 9-
cis retinal without retina (P < 0.001, F (1, 1512) = 842). A significant difference 
between pupil area is seen from 7s after light onset until the end of the recording 
(Figure 5.2.C).  
Comparing these results to those obtained from whole eye preparations, there is 
no significant difference at any time point between saline-treated rd12 whole eye 
pupil area and that of 9-cis retinal-treated rd12 without retina, saline-treated rd12 
without retina or saline-treated with retina. 
Calculating the maximum constriction showed that treatment with 9-cis retinal 
provided a greater constriction (P = 0.0016, F (1, 39) = 11.53) (Figure 5.2.D). 
Retinal attachment also improved the constriction (P = 0.001, F (1, 39) = 12.73) 
and the greatest constriction was seen in pupils with retina attached from mice 
treated with 9-cis retinal-treatment (P = 0.026, F (1, 39) = 5.354). Maximum 
constriction in rd12 treated with 9-cis retinal and retina attached is 0.35 ± 0.05. 
Without retina attached, constriction is reduced to 0.76 ± 0.05 (Figure 5.2.D). 
Maximum constriction in rd12 pupils with retina attached from animals treated 
with saline only reached 0.75 ± 0.05. Without retinal attachment maximum 
constriction reached 0.84 ± 0.09, from saline-treated animals. 
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Neither retina attached to the anterior chamber (P = 0.9, F (1, 38) = 0.4) nor 9-
cis retinal supplementation (P = 0.07, F (1, 38) = 3) had a significant effect on the 
latency. 
 
Figure 5.2 iPLR in isolated anterior chambers of rd12 mice with 9-cis retinal. 
Pupil constriction of anterior chambers with a rim of retina attached (+ retina) is 
greater when the animal was treated with 9-cis retinal (n = 16), compared to 
saline-treated animals (n = 6) (A). No difference is seen in the iPLR between 
animals treated with 9-cis retinal (n = 16) or saline (n = 5) when the retina is 
removed from the anterior chamber (- retina) (B). The constriction in rd12 mice 
treated with 9-cis retinal is significantly greater + retina compared – retina (C). 
Black (lights off) and white (lights on) bars below graphs indicate light stimulation. 
D plots peak pupil constrictions. Asterisks indicate post-hoc test significance: ***P 
< 0.001; ****P < 0.0001. E shows representative images of the pupil area at 
baseline (dark) and at 30s post-light onset (light-on). Arrows highlight pupil area. 
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 Discussion 
This experiment examined the question of whether the iPLR was driven by 
chromophore working in the retina. What is evident from the iPLR data presented 
here, is that 9-cis retinal is acting in the retina. In Figure 4.21, treatment with 9-
cis retinal produced an iPLR in rd12 mice, which surpassed that of WT. It was 
unknown if this chromophore was acting directly on the iris/ciliary body. In 
contrast to this, 9-cis retinal does not improve the iPLR when the iris/ciliary body 
is isolated from the retina. This functional data is consistent with RPE65 labelling 
in WT eye, which shows RPE65 expression restricted to the RPE and being 
absent from the iris. 
When the current results are compared to those in Figure 4.21, no difference is 
apparent at any time point when comparing saline-treated rd12 intact eye with 
saline-treated rd12 with only a 1mm rim of retina, saline-treated rd12 with no 
retina or 9-cis retinal-treated rd12 with no retina. Interestingly, when 9-cis retinal-
treated rd12 have only 1 mm retina the constriction is significantly less than that 
of 9-cis retinal-treated rd12 with an intact eye. 
It has previously been shown that melanopsin and an intact CMZ are necessary 
for a complete iPLR response (Semo et al., 2014, Xue et al., 2011). In this 
experiment, functional evidence that chromophore may be acting in the retina to 
drive the iPLR is provided. It has also been shown that melanopsin can work as 
a bistable pigment (Fu et al., 2005), still, it is clear that this capability is insufficient 
in the rd12 mouse to drive normal melanopsin function and, that 9-cis retinal can 
improve melanopsin function significantly, suggests that ipRGCs require another 
source of chromophore. 
While this experiment provides compelling evidence that chromophore may act 
on the retina to produce the iPLR, it is unknown if RPE65 in the RPE would 
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normally supply chromophore to drive any retinal component of the iPLR. In the 
next experiment, addressing this question is attempted using a more targeted 
approach. 
 Is the iPLR driven by chromophore from the RPE? 
 Introduction 
Previous work has shown the presence of RPE65 in human M/L-cones (Tang et 
al., 2011), which has so far not been detected in mice. While it was shown in the 
previous experiment of this chapter, that RPE65 labelling appeared restricted to 
the RPE, the possibility cannot be excluded that this is not the only location of 
RPE65 expression in the mouse retina. In this experiment rpe65 expression will 
be restored in the rd12 mouse by gene therapy. The gene will be delivered in a 
viral vector placed into the subretinal space in one eye and into the vitreous of 
the other eye. The aim here is to see if RPE65 is expressed in cells of the inner 
retina using the intravitreal delivery route and if so, to determine how RPE65 
expressed at this location influences, the iPLR relative to the predominantly RPE 
based expression of RPE65 expected by the subretinal delivery route. 
 Methods 
Delivery of virus 
3-month rd12 mice received pAAV5-CAG-RPE65-Venus subretinally into the left 
eye (RPE65 SBR) and intravitreally in the right eye (RPE65 IVT) (n = 11) as 
described in paragraph 2.4.4. A separate group of 3-month old rd12 mice 
received a control virus (n = 9), which did not contain the rpe65 gene (pAAV5-
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CAG-Venus). This was also placed subretinally into the left eye (Control SBR) 
and intravitreally into the right eye (Control IVT) of each mouse. The viral 
construct included Venus, a fluorescent reporter protein, to aid visualisation of 
transfected retinal cell types. The virus was constructed by our collaborator Dr 
Eriko Sugano, University of Iwate, Japan. Visual function (ERG, BLA and PLR) 
was used to assess the success of this gene therapy approach 7 – 8 weeks after 
viral administration, prior to examination of the iPLR. 
Scotopic and Photopic ERG 
7 weeks after virus administration, scotopic and photopic ERGs were recorded 
from all animals, as described in paragraph 2.2.1. 
BLA 
7 weeks after virus administration BLA was assessed as described in paragraph 
2.2.2. 5 rpe65 and 5 control animals were placed in an arena with the front half 
illuminated. 2 rpe65 and 4 control animals were placed in a dark arena. 
PLR 
8 weeks after virus administration PLR was recorded from left and right eyes of 
animals as described in paragraph 2.2.3. The number of animals assessed are 
presented in  
Table 30. 
 
Table 30 Number of rd12 treated with virus assessed by PLR 
µW/cm2/s 800 80 8  0.8  0.08  
Control SBR 5 5 8 0 0 
Control IVT 5 4 0 0 0 
Rpe65 SBR 9 5 4 4 9 
Rpe65 IVT 11 4 11 3 0 
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iPLR 
8 weeks after the delivery of the virus, animals were culled and the iPLR was 
recorded from all eyes as described in paragraph 2.2.4. Following iPLR 
recordings, the cornea was pierced and the eye placed in 4% PFA overnight. 
RPE65 labelling 
In order to keep the iris intact, eyes did not have their lens removed prior to 
embedding. Whole eyes were embedded, sectioned and labelled for RPE65 
using immunohistochemistry as described in paragraph 2.3.2. The antibodies 
used were anti-RPE65 raised in rabbit (1:500, ab173596; Abcam) with the 
secondary antibody raised in donkey against rabbit tagged with Alexa Fluor 568 
(1:2000, ab10042; Abcam). Images were captured on a Zeiss 700 microscope. 
Venus (green) was also imaged to show the extent of viral expression within the 
retina. 
 Results 
Scotopic ERG following virus administration 
A trend of increased scotopic a- and b-wave amplitude was seen in eyes which 
received a virus encoding rpe65 subretinally (Figure 5.3). There was no 
significant effect on the scotopic a-wave of having rpe65 encoded in the virus or 
where the virus was inserted (Table 31). There was a greater effect on the 
scotopic b-wave amplitude. While the encoding of rpe65 on its own was not 
significant (Table 31), it had a significant effect over the different light intensities 
(F (6, 60) = 2.887, P = 0.0154) and post-hoc tests shows significant differences 
between eyes receiving a subretinal injection of a virus encoding rpe65 and the 
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control virus at -1 (P < 0.05) and 0 Lg cd.s/m2 (P < 0.01). Also, where the virus 
encoding rpe65 was placed had a significant effect on the scotopic b-wave. 
Table 31 Two-way ANOVA of virus and site of injection on scotopic ERG in rd12 
Two-way ANOVA Scotopic A-wave Scotopic B-wave 
RPE65 Vs Control F (1, 10) = 1.2, P = 0.2998 F (1, 10) = 3.05, P = 0.1111 
SBR Vs IVT F (1, 18) = 2.55, P = 0.1274 F (1, 18) = 4.91, P = 0.0398 
 
 
Figure 5.3 Scotopic ERG results in rd12 mice which received gene therapy. 
Graphs plot scotopic a-wave amplitude (A) and b-wave amplitude (B) for eyes 
which received virus encoding rpe65 subretinally (RPE65 SBR, n = 11), virus 
encoding rpe65 intravitreally (RPE65 IVT, n = 11), control virus subretinally (n = 
9) and contrl virus intravitreally (n = 9). C displays the average trace ± SEM for 
each group at each light intensity. Vertical scale represents 50 µV and the 
horizontal scale indicates 200 ms. 
Photopic ERG in rd12 mice which received virus treatment 
There is a trend of increased b-wave amplitude in eyes which received virus 
encoding rpe65, but this is not a significant effect (Figure 5.4). There was not a 
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significant effect of the virus encoding rpe65 or the site of injection on the photopic 
b-wave amplitude (Table 32). 
Table 32 Two-way ANOVA of effects of virus encoding rpe65 on Photopic ERG 
Two-way ANOVA F (DFn, DFd) P value 
Rpe65 Vs Control F (1, 18) = 1.766 P = 0.2005 
SBR Vs IVT F (1, 20) = 2.136 P = 0.1594 
 
 
Figure 5.4 Photopic ERG in rd12 mice treated with virus. 
A displays the photopic b-wave amplitude which increases with increased light 
intensity in eyes which received rpe65 gene subretinally (RPE65 SBR, n = 11), 
rpe65 gene intravitreally (RPE65 IVT, n = 11) and eyes which received a control 
virus subretinally (Control SBR, n = 9) or intravitreally (Control IVT, n = 9). B 
shows average traces ± SEM at the different light intensities. The vertical scale 
indicates 20 µV and the horizontal scale represents 50 ms. 
BLA in rd12 mice treated with virus 
Both control-treated mice and mice receiving the rpe65 gene spent more time in 
the back half when the front half was illuminated compared to when the whole 
arena was in darkness (P = 0.0136, F (1, 12) = 8.354). This indicates the 
presence of BLA. Rd12 which received the virus with rpe65 spent 11.3 ± 9.4 % 
of their total time in the back half when the arena was in darkness, this was 
increased to 39.6 ± 8.1 % when the front half was illuminated (Figure 5.5.A). 
Control mice spent 19.7 ± 1.9 % of total time in the back half when the arena was 
in darkness and this increased to 31.5 ± 4.9 % when the front half is illuminated.  
The virus encoding rpe65 did not increase BLA. There was no significant 
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difference between animals receiving the virus which contained rpe65 and the 
control virus (P = 0.98, F (1, 12) = 0.0008). Comparing this to untreated rd12, 
which spent 34 ± 4 % of their time in the back half when the front half was 
illuminated, rd12 receiving virus encoding rpe65 spend more time avoiding the 
light. 
Rd12 receiving the control virus spend significantly more time in the back half off 
the arena when the front half is illuminated compared to when the front half is 
dark (P = 0.0061, F (1, 51) = 8). The preference for the back half, of mice placed 
in an illuminated or dark arena, does not significantly change over the 30 minutes 
(P = 0.3, F (1, 50) = 0.9). Although, preferences diverge enough that, in the last 
5 minutes, rd12 receiving the control virus spent 3 times more time in the back 
half of the arena when the front is illuminated, than when the front half is also 
dark (Figure 5.5.B).  
The behavior of rd12 receiving virus encoding rpe65 have significantly different 
behavior when placed in the arena under an illuminated front half compared to 
being placed in a dark arena (P = 0.0355, F (1, 8) = 6). Rd12 receiving virus 
encoding rpe65 have a growing preference for the back half when placed in an 
arena with the front half illuminated, while if they are placed in a dark arena, they 
have a growing preference for the front half (Table 33). This is likely driven by the 
desire to return home. Rd12 receiving virus encoding rpe65 spend significantly 
more time in the back half when the front half is illuminated (Table 34). This was 
not seen in untreated 3-month rd12 (Figure 4.17). 
Table 33 Linear regression of BLA in rd12 receiving virus encoding rpe65 
Linear 
Regression 
Slope r2 Is the slope significantly non-
zero? 
Equation 
Control Dark -0.3 ± 0.3 0.03 P = 0.422, F (1, 22) = 0.6696 Y = -0.3x + 25 
Control Light 0.2 ± 0.3 0.01 P = 0.5823, F (1, 28) = 0.31 Y = 0.2x + 28 
Rpe65 Dark -0.5 ± 0.4 0.1 P = 0.2557, F (1, 10) = 1.454 Y = -0.5x + 19 
Rpe65 Light 0.2 ± 0.4 0.01 P = 0.6068, F (1, 27) = 0.271 Y = 0.2x + 35 
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Table 34 Two-way ANOVA of effects of virus on BLA over 30 minutes 
Two-way ANOVA Control Virus Virus encoding rpe65 
Light P = 0.826, F (1, 7) = 4.099 P = 0.0004, F (1, 29) = 15.92 
Time P = 0.9092, F (5, 35) = 0.30 P = 0.9919, F (5, 29) = 0.097 
Light over time P = 0.3952, F (5, 35) = 1.07 P = 0.9345, F (5, 29) = 0.254 
 
 
Figure 5.5 BLA in rd12 mice treated with virus. 
A shows the total time spent in the dark back half of the arena when the front half 
was illuminated (light) or in darkness (dark). Both rd12 which received virus with 
rpe65 (red) and rd12 mice receiving control virus (blue) spent more time in the 
back half when the front half was illuminated. B illustrates the amount of time 
spent in the back half by rd12 mice receiving control virus over the 30 minutes. 
During the last time bin of 25 – 30 minutes, control mice spent significantly more 
time in the back half when placed in an illuminated arena (n = 5) compared to a 
dark arena (n = 4) (P < 0.05). C illustrates the amount of time rd12 mice receiving 
the rpe65 gene spent in the back when the front half was illuminated (n = 5) and 
when the arena was in darkness (n = 2). 
PLR of rd12 mice treated with virus 
Improvements are seen in the PLR in eyes that received virus encoding rpe65 
subretinally. At 800 µW/s/cm2, all treatment groups had a significant constriction 
(Figure 5.6.E). During light stimulation (0 – 60s) the average pupil area was 
significantly different to 1, the normalised baseline (P < 0.0001 for each treatment 
group). Analysis of each time point showed that eyes which received rpe65 
subretinally were significantly constricted throughout the light stimulation (0-60s), 
with a peak constriction of 0.21 ± 0.06. Eyes receiving rpe65 intravitreally were 
significant from 2 – 60s and had a peak constriction of 0.41 ± 0.05. Eyes that 
received the control virus subretinally had significant constriction from 4 – 60s 
and a peak constriction of 0.42 ± 0.07. Eyes that received the control virus 
intravitreally were significantly constricted from 3 – 60s and had a peak 
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constriction of 0.4 ± 0.04. Comparing these results to untreated rd12, which had 
a peak constriction of 0.34 ± 0.07 at this light power, only eyes which received 
virus encoding rpe65 subretinally appear to have an improved constriction. 
Untreated rd12 also did not have a significant constriction at this light power. Their 
maximum constriction reached 0.89 ± 0.04. At 800 µW/s/cm2, there was a 
significant difference between virus treatment groups and how they constricted 
to light stimulation (Table 35). Eyes receiving rpe65 subretinally had a better 
constriction than other virus treatments (Figure 5.6.E). They were significantly 
more constricted than eyes receiving the control virus subretinally and eyes 
receiving rpe65 intravitreally from 2 – 69s. There were no significantly different 
time points between rd12 which received the control virus subretinally and those 
that received it intravitreally, and no significant difference between animals that 
received intravitreal injections of control virus or the virus encoding rpe65. These 
improvements to the constriction do not have a significant effect on the latency to 
90% maximum constriction. 
At the lower irradiances of 80 µW/s/cm2 (Figure 5.6.D), the average pupil area is 
significantly less than 1 during light on for eyes receiving the rpe65 virus 
subretinally (P < 0.0001) or intravitreally (P < 0.0001). Eyes receiving the control 
virus either subretinally or intravitreally did not have an average pupil area 
significantly less than 1. Analysis of each time point showed that eyes receiving 
rpe65 subretinally were significantly constricted from 1 – 60s and had a peak 
constriction of 0.26 ± 0.06. Eyes that received rpe65 intravitreally, although, they 
had an average pupil area significantly less than 1 during lights on, were only 
significantly less than 1 at 20s, and other time points were not individually 
significant. Their peak constriction reached 0.83 ± 0.03. Eyes which received the 
control virus subretinally had a peak constriction of 0.99 ± 0.04, also not 
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significantly less than 1 (P = 0.8). Eyes treated with control virus intravitreally had 
a peak constriction of 0.86 ± 0.05, also not significantly different from 1 (P = 0.06). 
Thus, it is clear that eyes which received the control virus did not have a 
constriction at this light power. At 80 µW/s/cm2, there was a significant difference 
between virus treatment groups and how they constricted to light stimulation 
(Table 35). Eyes receiving rpe65 subretinally had a better constriction than other 
virus treatments (Figure 5.6.D). They were significantly more constricted than 
eyes receiving the control virus subretinally and eyes receiving rpe65 
intravitreally from 2 – 69s. There were no significantly different time points 
between rd12 which received the control virus subretinally and those that 
received it intravitreally, and no significant difference between animals that 
received intravitreal injections of control virus or the virus encoding rpe65. 
At 8 µW/s/cm2, the average normalised pupil area was significantly less than 1 
during lights on in eyes receiving rpe65 subretinally (P < 0.0001) and intravitreally 
(P = 0.0031). Eyes receiving the control virus subretinally did not have an average 
pupil size significantly less than 1. Eyes receiving the rpe65 virus subretinally had 
a significantly constricted pupil during light stimulation, 1 – 60s (Figure 5.6.C). 
Their peak constriction was 0.51 ± 0.06. Eyes receiving the rpe65 virus 
intravitreally had significant pupil constriction from 3 – 20s and a peak constriction 
of 0.74 ± 0.05. Eyes receiving the control virus subretinally did not have a 
significant constriction at any time point and their maximum constriction reached 
0.93 ± 0.02. At 8 µW/s/cm2, there was a significant difference between virus 
treatment groups and how they constricted to light stimulation (Table 35). Eyes 
receiving rpe65 subretinally had a better constriction than other virus treatments 
(Figure 5.6.C). They were significantly more constricted than eyes receiving the 
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control virus subretinally from 1 – 69s and significantly greater than eyes 
receiving rpe65 intravitreally from 7 – 77s. 
At 0.8 µW/s/cm2, only eyes which received the virus encoding rpe65 were 
examined (Figure 5.6.B). Both subretinally and intravitreally injected eyes had an 
average normalised pupil area that was significantly less than 1 during lights on 
(SBR: P < 0.0001, IVT: P = 0.0104). Subretinally injected eyes had significant 
constriction at 1 - 4s, 7 – 11s and at 40s, though, 5s, 15-30s and 50 -60s were 
not significant (Figure 5.6.B). Their peak constriction reached 0.51 ± 0.11. There 
were no timepoints in eyes treated with an intravitreal injection that were 
significantly less than 1. Their peak constriction reached 0.86 ± 0.08, but was not 
significantly less than 1 (P = 0.2). At 0.8 µW/s/cm2, there was a significant effect 
of the site of injection and the constricted to light stimulation ( 
Table 35). Eyes receiving rpe65 subretinally had a better constriction than eyes 
receiving rpe65 intravitreally (Figure 5.6.B). They were significantly more 
constricted than eyes receiving rpe65 intravitreally at 3s and 11-15s (P < 0.05). 
Eyes receiving rpe65 subretinally were also examined at 0.08 µW/s/cm2. Average 
normalised pupil area was significantly less than 1 from 0-60s (Figure 5.6.A). 
Analysis of individual time points only showed a significant constriction at 4s post 
light onset (P = 0.0043). Their peak constriction reached 0.76 ± 0.06. 
 
Table 35 Two-way ANOVA of PLR in rd12 receiving virus encoding rpe65 
Two-way 
ANOVA 
Virus treatment Light Interaction 
800 µW/s/cm2 P < 0.0001, 
F (3, 1063) = 89.8 
P < 0.0001, 
F (51, 1063) = 33 
P < 0.0001, 
F (153, 1063) = 2 
80 µW/s/cm2 P < 0.0001, 
F (3, 460) = 195.7 
P < 0.0001, 
F (46, 460) = 4.75 
P < 0.0001, 
F (138, 460) = 2.63 
8 µW/s/cm2 P < 0.0001, 
F (2, 580) = 234.6 
P < 0.0001, 
F (30, 580) = 5.73 
P < 0.0001, 
F (60, 580) = 5.42 
0.8 µW/s/cm2 P = 0.0063, 
F (1, 112) = 25.76 
P = 0.0388, 
F (32, 112) = 1.6 
P = 0.0063, 
F (32, 112) = 1.931 
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Figure 5.6 PLR in 
 rd12 mice 
treated with 
virus. 
A-E display 
graphs of the 
pupil area 
normalised to 
baseline at time 
0. Video stills 
show 
representative 
images of pupil 
area before 
(dark) and ~30s 
after (light) light-
onset. Arrows 
highlight the 
pupil diameter. 
Eyes treated with 
virus containing 
rpe65 
subretinally 
(RPE65 SBR) 
had a PLR at 
0.08 µW/s/cm2 
(A, n = 9). At 0.8 
µW/s/cm2 (B), 
both RPE65 SBR 
(n = 4) and eyes 
which received 
the rpe65 virus 
intravitreally 
(RPE65 IVT, n = 
3) had significant 
constrictions 
during lights on, 
with RPE65 SBR 
PLR significantly 
greater. At 8 
µW/s/cm2 (C), RPE65 SBR (n = 11) had significant pupil constrictions and RPE65 
IVT (n = 4) less restricted and no response in eyes receiving the control virus 
subretinally (Control SBR n = 8). At 80 µW/s/cm2 (D), RPE65 SBR (n = 5), RPE65 
IVT (n = 4) and Control SBR (n = 4) had significant pupil constrictions. At 800 
µW/s/cm2 (E), RPE65 SBR (n = 9), RPE65 IVT (n = 11) and Control SBR (n = 5) 
and Control IVT (n = 5) all had significant pupil constrictions, with the strongest 
response in the RPE65 SBR group for both D and E. There was no difference 
between Control IVT and Control SBR, or Control IVT and RPE65 IVT in E. F 
displays a graph of peak pupil constrictions Asterisks indicate significance levels 
between RPE65 SBR and RPE65 IVT (orange asterisks) or Control SBR (blue 
asterisks): ****P < 0.0001, *P < 0.05. G displays the same peak constrictions as 
F but also has WT and rd12 untreated results included for comparison. 
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iPLR of rd12 mice treated with virus 
Finally, mice were culled and the iPLR was recorded from isolated eyes (Figure 
5.7). The virus treatment received had a significant effect on the constriction (P = 
0.0248, F (3, 1762) = 3.13). All treatment groups have a significant constriction 
(P< 0.0001, for all groups), but the greatest constriction was seen in eyes which 
received virus encoding rpe65 subretinally. 
Assessing the effects of rpe65 the site of injection on the maximum constriction, 
neither the encoding of rpe65 (P = 0.8, F (1, 34) = 0.09) in the virus (P = 0.8, F 
(1, 34) = 0.09) nor the site of injections alone significantly increased the 
constriction. A combination of rpe65 encoded in the virus and subretinal 
administration produced a significantly greater constriction (P = 0.021, F (1, 34) 
= 5.311). Peak constriction reached 0.55 ± 0.05 in eyes treated with virus 
encoding rpe65 subretinally and 0.71 ± 0.04 in eyes receiving rpe65 virus 
intravitreally. Eyes that received the control virus subretinally had a peak 
constriction of 0.68 ± 0.05 and eyes receiving the control virus intravitreally had 
a peak constriction of 0.6 ± 0.06. Thus, while eyes which received the virus 
encoding rpe65 subretinally had the greatest constriction, this was not 
considerably greater than the other treatment groups. There were no significant 
changes in the latency of the constriction between treatment groups (Figure 
5.7.E).  
What becomes apparent when the results are compared to untreated rd12 
(Figure 5.7.C) is that all treatment groups have a greater constriction than 
untreated rd12, which has a maximum constriction of 0.81 ± 0.07. This may be 
an effect of the surgery, as it has been shown previously that improvements in 
visual function are seen which are unspecific to the treatment (see sections 3.7.3 
& 4.6.3). Although, a key factor for regard in this experiment is that the virus 
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produced the expression of venus, which emits a green wavelength, capable of 
activating melanopsin. This is an important consideration as such a confounding 
factor could also dilute the effect of re-introducing rpe65. 
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Figure 5.7 iPLR in rd12 mice treated with virus. 
A displays a graph of the iPLR constriction of rd12 treated with virus. Eyes 
received the rpe65 virus subretinally (RPE65 SBR, N = 9), rpe65 virus 
intravitreally (RPE65 IVT, n = 11), control virus subretinally (Control SBR n = 9) 
or Control virus intravitreally (Control IVT n = 9). The black and white bars below 
the graph represent lights off (black) and lights on (white). B displays 
representative video stills from before (Dark) and 30s after (Light) light onset. C 
shows data from A with WT and untreated rd12 data for comparison. E displays 
the peak constriction. E displays the time taken to reach 90% peak constriction. 
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RPE65 labelling with venus 
RPE65 was identified by both immunohistochemical staining for RPE65 and 
venus reporter fluorescence. Immunostaining for RPE65 was restricted to the 
RPE of eyes which received virus encoding the rpe65 gene delivered subretinally 
(Figure 5.8). However, eyes which received the virus encoding the rpe65 gene 
delivered intravitreally did not label for RPE65 by immunohistochemistry. RPE65 
was not detected by immunohistochemistry outside of the RPE in any eye 
examined. While the venus reporter (green) was seen in all cells expressing the 
virus in various retinal layers, including, the RPE of eyes receiving virus 
subretinally. However, eyes that received virus intravitreally had venus 
expression throughout the retina, with the exception of the RPE. Venus 
expression was also found in the iris and the endothelial layer of the cornea, in 
eyes which received virus subretinally and intravitreally but RPE65 expression 
was absent from these structures by immunostaining. 
One noticeable trend observed was that the eyes which received the control virus 
had greater expression of venus compared to eyes which received the virus 
which also encoded rpe65. This difference was not quantified. It is unknown why 
this is the case, but this may be brought about by the size of the genetic material 
in the vector. AAV vectors are limited to carrying ~4.5 Kb of exogenous genetic 
materal. This is much more limited compared to retroviruses, adenoviruses or 
herpes simplex viruses. The viral vector encoding rpe65 is 1.6 Kb larger than the 
control virus. This is a considerable amount and may affect the infection and 
expression of the viral vector. 
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Figure 5.8 RPE65 labelling and venus expression in rd12 eyes treated with virus. 
RPE65 labelling (red) is only found in the RPE of eyes receiving virus encoding 
rpe65, delivered subretinally. Venus (green) shows where the virus is expressed. 
It is found in all eyes. Eyes receiving the virus subretinally show venus expression 
in the RPE as well as other retinal layers. Eyes receiving the virus intravitreally 
express venus in many retinal layers but not the RPE. Scale bar indicates 50 um. 
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 Discussion 
This experiment was carried out to determine if rpe65 could be expressed outside 
the RPE and drive the iPLR. In the last experiment, it was seen that in WT retina 
RPE65 labelling was only detected in the RPE, however, this did not necessarily 
mean that it was not expressed in low levels elsewhere. By placing the rpe65 
gene intravitreally and comparing the results to placing the gene subretinally it 
was hoped that the origin of chromophore required for the iPLR could be 
determined. RPE65 was only seen in eyes which received the virus containing 
rpe65 subretinally and its expression was restricted to the RPE.  
ERGs were recorded to determine if the gene therapy improved outer-retinal 
photoreceptor function. While positive trends were seen, the rpe65 virus was not 
able to significantly improve the scotopic a-wave amplitude, however, at 0 Lg 
cd.s/m2 eyes treated with rpe65 subretinally had a significantly greater b-wave 
amplitude than eyes which received the control virus subretinally. The photopic 
ERG also showed a positive trend of improved b-wave amplitude in eyes treated 
with rpe65, however, this was not significant. 
BLA is a functional read out of both outer retinal photoreceptor function and 
melanopsin function. While animals that received the virus showed a BLA 
response, there was no significant difference between animals which received 
the virus encoding rpe65 and animals that received the control virus. Although, 
there is a trend of increase light aversion in animals which received rpe65. This 
may become statistically significant with a greater n-number as there is large 
deviation from the mean with this test. There is also a lack of literature using this 
test for investigating restoration of visual function. Thus, there could be many 
factors unknown about restoring this behavioural function including restoration of 
vision in only one eye. 
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The PLR can also be used as a functional readout of both outer-retinal 
photoreceptors and ipRGCs. However, this readout showed a greater difference 
between eyes treated with the control virus and eyes treated with rpe65. All 
treatment groups had a significant constriction only at 800 µW/s/cm2. At 80 
µW/s/cm2, only eyes treated with rpe65 had a significant constriction. Eyes 
receiving the control virus did not have a significant constriction. At 8 and 0.8 
µW/s/cm2 both eyes with rpe65 subretinally and intravitreally had significant pupil 
constrictions. Only eyes which received rpe65 subretinally were examined at 0.08 
µW/s/cm2, and they had a significant pupil constriction to this irradiance. Eyes 
receiving rpe65 subretinally had a significantly greater constriction than eyes 
receiving the control virus subretinally or eyes which received rpe65 intravitreally 
at every irradiance examined. No significant differences were seen between eyes 
receiving the control virus intravitreally and eyes receiving the rpe65 virus 
intravitreally and any irradiance, nor were there any significant differences seen 
between control eyes receiving the virus subretinally and control eyes which 
received the virus intravitreally at any irradiance. 
Subretinal placement of rpe65 significantly improved the constriction and also the 
sensitivity of the PLR. Placement of rpe65 intravitreally had a significant effect on 
the sensitivity of the PLR, as there was a significant constriction at 0.8 µW/s/cm2, 
however the constriction was not significantly greater than eyes which received 
the control virus intravitreally at either 800 or 80 µW/s/cm2. Comparing these 
results to untreated rd12 mice, the sensitivity was increased in all treated eyes 
as rd12 peak constriction only reached 0.82 ± 0.07, at 800 µW/s/cm2, but was not 
significantly less than 1. While the effects of sham injections on retinal 
preservation and improved function is well known (Woch et al., 2001, Keegan et 
al., 2003, Del Priore, 2005), there is a concern that this improved PLR could be 
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due to the presence of venus, which emits green light, and is possibly able to 
stimulate melanopsin in ipRGCs. 
The iPLR has the greatest constriction in eyes receiving the rpe65 virus 
subretinally and the effect of treatment was significant. However, there were no 
significant differences in post-hoc tests. Given the widespread expression of 
venus it is difficult to separate any sham effect from the possible effect of venus 
on the iPLR. Venus is a very useful tool for evaluating viral delivery and 
expression, however, the presence of this flurorescent protein may well influence 
functional assessments. As such, this experiment is replicated without venus. 
 Re-assessing the question “Is the iPLR driven by chromophore 
from the RPE?” using a virus without venus. 
 Introduction 
Given the improved PLR and iPLR of the control groups in the last experiment it 
was decided that the experiment needed to be repeated without venus encoded 
in the virus. 
 Methods 
Delivery of virus 
12, 2-month old rd12 received pAAV5-CAG-RPE65 subretinally into the left eye 
and intravitreally into the right eye as described in paragraph 2.4.4. 10 2-month 
old rd12 mice received a control virus, which did not contain the rpe65 gene, 
pAAV5-CAG. Visual function was analysed 7 – 8 weeks after viral administration. 
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BLA 
6 weeks after virus administration BLA was assessed as described in paragraph 
2.2.2. 4 rpe65 and 5 control animals were placed in an arena with the front half 
illuminated. 3 rpe65 and 5 control animals were placed in a dark arena. 
PLR 
7 weeks after virus administration PLR was recorded from left and right eyes of 
animals as described in paragraph 2.2.3. The number of animals assessed are 
shown in Table 36. 
Table 36 Numbers rd12 treated with virus without venus assessed by PLR 
µW/s/cm2 Control SBR Control IVT Rpe65 SBR Rpe65 IVT 
800 10 7 12 11 
80 4 7 12 11 
0.08 4 0 11 0 
iPLR 
7 weeks after the delivery of the virus, iPLR was recorded from all eyes as 
described in paragraph 2.2.4. Following iPLR recordings, the cornea was pierced 
and the eye placed in 4% PFA overnight to fix prior to immunohistochemically 
labelling retinas. 
RPE65 and melanopsin labelling 
Eyes did not have their lens removed prior to embedding, to keep the iris intact. 
Whole eyes were embedded, sectioned and labelled for RPE65 and some 
sections were then also labelled for melanopsin using immunohistochemistry as 
described in paragraph 2.3.2. The antibodies used were anti-RPE65 raised in 
rabbit (1:500, ab173596; Abcam) with the secondary antibody raised in donkey 
against rabbit tagged with Alexa Fluor 568 (1:2000, ab10042; Abcam). Then anti-
 266 
 
melanopsin (1:5000, UF006; Advanced Targeting Systems, San Diego, CA, 
USA) was used with the secondary antibody used was raised in donkey against 
rabbit FITC-labelled (1:200, Jackson ImmunoResearch, West Grove, PA, USA). 
Because both anti-RPE65 and anti-melanopsin are raised in rabbit, this FITC 
labelled secondary will adhere to both primary antibodies. This will create a yellow 
label for RPE65 (green and red) and a green label for melanopsin. Images were 
captured on a Zeiss 700 confocal microscope. Analysis of melanopsin in the On 
and Off sublamina of the IPL was conducted in imageJ by thresholding above a 
greylevel of 20. Images were cropped to 67.4 µm x 404.4 µm and pixel intensity 
was measured on remaining pixels. N-numbers: (AAV5 RPE65 SR, n = 9, AAV5 
RPE65 IVT, n = 6, AAV5 Control SR, n =6, AAV5 Control IVT, n =6). 
 Results 
BLA in rd12 mice with virus lacking venus 
Both control-treated mice and mice which received the rpe65 gene spent more 
time in the back half when the front half was illuminated compared to when the 
whole arena was in darkness (P = 0.011, F (1, 13) = 8.77). This indicates the 
presence of BLA. Rd12 which received the virus with rpe65 spent 28.9 ± 3.7 % 
of their total time in the back half when the arena was in darkness, this was 
increased to 37 ± 4.8 % when the front half was illuminated (Figure 5.9.A). Control 
mice spent 22.7 ± 3.2 % of total time in the back half when the arena was in 
darkness and this increased to 37.9 ± 3.5 % when the front half is illuminated.  
There was no significant difference in the total time spent in the front half between 
animals which received the virus encoding rpe65 and the control virus (P = 0.5, 
F (1, 13) = 0.5). The effect of light was not significantly different between rpe65 
and control animals (P = 0.4, F (1, 13) = 0.8), and, these results are not 
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substantially greater than untreated rd12 with spend 34 ± 4 % of their time in the 
back half when the front half is illuminated. 
Rd12 which received the control virus exhibit BLA (Figure 5.9.B). When placed in 
an arena with the front half illuminated spend more time in the back half than then 
placed in a dark arena (P<0.0001, F (1, 57) = 30.5). Although, with time, control 
animals placed in an arena with the front half illuminated, spend less time in the 
dark back half (Table 37). 
Unfortunately, Rd12 which received virus encoding rpe65 do not exhibit a BLA 
(Figure 5.9.C). While, overall, these mice spend more time in the back half when 
the front half is illuminated, this is not significant (Table 38). The preference for 
the back half does not change over the 30 minutes (Table 37).  
Table 37 Linear Regression of BLA over time in rd12 with virus without venus 
Linear 
Regression 
Slope r2 Is the slope 
significantly non-zero? 
Equation 
Control Dark -0.3 ± 
0.2 
0.07 P = 0.1475 
F (1, 28) = 2.2 
Y = -0.3x + 28 
Control Light -0.6 ± 
0.3 
0.16 P = 0.0277 
F (1, 28) = 5.4 
Y = -0.6x + 48 
Rpe65 Dark -0.005 
± 0.3 
0.00001 P = 0.9885 
F (1, 16) = 0.0002 
Y = -0.005x + 29 
Rpe65 Light -0.3 ± 
0.3 
0.05 P = 0.2267 
F (1, 28) = 1.5 
Y = -0.3x + 41 
 
Table 38 Two-way ANOVA of BLA of rd12 with virus encoding rpe65 
Two-way ANOVA Control virus Virus encoding rpe65 
Light P < 0.0001, F (1, 48) = 28 P = 0.4348, F (1, 36) = 2.09 
Time P = 0.2432, F (5, 48) = 1.4 P = 0.4348, F (5, 36) = 1 
Change in BLA 
over time 
P = 0.5865, F (5, 48) = 0.8 P = 0.8765, F (5, 36) = 0.35 
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Figure 5.9 BLA in rd12 mice with virus lacking the venus reporter. 
A shows the percentage of total time spent in the back half by animals treated 
with virus containing rpe65 (red) or control virus (blue) placed in an arena that is 
in darkness (dark) or an arena which has the front half was illuminated (light). B 
plots the percentage of time control animals spent in the back half when the front 
half of the arena was illuminated (Control Light, n = 5) and when the whole arena 
was in darkness (Control Dark, n = 5). The asterisk indicates a significance 
between Control light and control dark (P < 0.05). C plots the percentage of time 
animals treated with virus containing rpe65 spent in the back half when the front 
half of the arena was illuminated (RPE65 Light, n = 4) and when the whole arena 
was in darkness (RPE65 Dark, n = 3). 
PLR of rd12 treated with virus lacking venus. 
Again, the results show that rpe65 gene replacement improves the PLR in rd12 
mice when delivered subretinally (Figure 5.10). At 800 µW/s/cm2, all treatment 
groups did have a significant constriction (Figure 5.10.C); during lights on (0 – 
60s) the average pupil size was significantly different to 1, the normalised 
baseline (P < 0.0001 for each treatment group). Analysis of each time point 
showed that eyes receiving rpe65 subretinally were significant during light 
stimulation 1 – 60s, with a peak constriction of 0.18 ± 0.04. Eyes receiving rpe65 
intravitreally were significantly constricted from 2 – 60s and had a peak 
constriction of 0.58 ± 0.05. Eyes receiving the control virus subretinally had 
significant constriction from 2 – 60s and a peak constriction of 0.58 ± 0.05. Eyes 
which received the control virus intravitreally were significant from 5 – 30 s and 
at 60 s, but not from 40 – 50 s, and had a peak constriction of 0.67 ± 0.02. Only 
eyes which received virus encoding rpe65 subretinally had a greater constriction 
than untreated rd12, which had a maximum constriction of 0.34 ± 0.7 at this light 
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power. Eyes receiving rpe65 subretinally had a better constriction than other virus 
treatments (Figure 5.10.C). Eyes which received a subretinal injection of virus 
encoding rpe65 had a significantly greater constriction than eyes which received 
a subretinal injection of the control virus from 1 – 101s post light-onset. 
Constriction in eyes receiving rpe65 subretinally was also significantly greater 
than eyes receiving rpe65 intravitreally from 2 – 77s post light-onset. Eyes that 
received the virus encoding rpe65 intravitreally had a significantly greater 
constriction than eyes that received the control virus intravitreally at 30s (P < 
0.05). There were no significantly different time points between rd12 which 
received the control virus subretinally and intravitreally. There was no significant 
effect of the virus treatment on the latency. 
At 80 µW/s/cm2 (Figure 5.10.B), the average pupil area is significantly less than 
1 during light on for eyes receiving rpe65 subretinally (P < 0.0001) and eyes 
receiving the control virus subretinally (P < 0.001) or intravitreally (P < 0.0001). 
Eyes which received the rpe65 virus intravitreally did not have an average pupil 
area significantly less than 1 (P = 0.2). Analysis of each time point showed that 
eyes receiving rpe65 subretinally were significantly constricted during light 
stimulation 1 – 60s and had a peak constriction of 0.47 ± 0.07. Eyes which 
received virus encoding rpe65 intravitreally did not have a pupil area significantly 
less than 1 at any individual time point. Their peak constriction reached 0.89 ± 
0.04. Eyes which received the control virus subretinally were also not significantly 
less than 1 at any individual time point, although their average pupil area was 
significantly less than 1. Their peak constriction was 0.83 ± 0.1. Eyes treated with 
control virus intravitreally were significantly less than 1 at 5s, 15 - 20s and 40 – 
50s. At 7 – 11s and 30s the pupil constriction was not significantly less than 1. 
 270 
 
Their peak constriction was 0.87 ± 0.07. Untreated rd12 did not have a significant 
constriction at this light power. Their maximum constriction reached 0.89 ± 0.04. 
There was a significant difference in the constriction at this light power between 
the treatment groups (Table 39). Eyes receiving rpe65 subretinally were 
significantly more constricted than eyes receiving the control virus subretinally 
from 2 – 61s. Eyes receiving rpe65 subretinally were also significantly more 
constricted than eyes receiving the rpe65 intravitreally from 2 – 69s. There were 
no significantly different time points between rd12 which received the control virus 
subretinally and intravitreally, and no significant difference between animals 
receiving the intravitreal injections of the control virus or the virus with rpe65. 
At 0.08 µW/s/cm2 (Figure 5.10.A), only eyes that received subretinal injections of 
either rpe65 or control virus were examined. At this irradiance, eyes receiving 
rpe65 (P < 0.0001) and eyes injected with control virus (P = 0.0386) had an 
average pupil area that was significantly less than 1. Analysis of individual time 
points showed a significant constriction at 7s and 20 – 30s in eyes which received 
rpe65 subretinally. At 11-15s the constriction was not significant. These eyes had 
a peak constriction of 0.79 ± 0.05. Eyes which received the control virus 
subretinally only had a significant constriction at 1s. Their peak constriction 
reached 0.91 ± 0.003. There was a significant difference between these two 
groups (Table 39). 
Table 39 Two-way ANOVA of rd12 PLR with virus encoding rpe65 without venus 
Two-way ANOVA Virus treatment Light Interaction 
800 µW/s/cm2 P < 0.0001, 
F (3, 1269) = 177 
P < 0.0001, 
F (50, 1269) = 28 
P < 0.0001, 
F (150, 1269) = 3 
80 µW/s/cm2 P < 0.0001, 
F (3, 638) = 98.93 
P < 0.0001, 
F (23, 638) = 3.79 
P < 0.0001, 
F (69, 638) = 3.67 
0.08 µW/s/cm2 P < 0.0299, 
F (1, 297) = 4.762 
P = 0.3, 
F (30, 297) = 1 
P = 0.98, 
F (30, 297) = 0.5 
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Figure 5.10 PLR in rd12 mice treated with virus lacking the venus reporter. 
A displays the PLR at 0.08 µW/s/cm2 of eyes which received control virus 
subretinally (Control SBR, n = 4) and eyes which received virus encoding rpe65 
subretinally (RPE65 SBR, n = 11). Note the small RPE65 SBR response. Bars 
beneath the graph indicate lights off (black) and lights on (white). video stills are 
representative of animals before (dark) and ~30s after (light) lights on. B displays 
the PLR at 80 µW/s/cm2, where there is a robust constriction in RPE65 SBR (n = 
12), and is not apparent in Control SBR (n = 4) or Control IVT (n = 7). Eyes 
receiving the rpe65 virus intravitreally (RPE65 IVT, n = 11) did not have 
constriction. At 800 µW/s/cm2, all treatment groups had a significant constriction 
(C). RPE65 SBR (n = 12) had a significantly greater constriction than Control 
SBR (n = 10) and REP65 IVT (n = 11). RPE65 IVT had a significantly greater 
constriction than Control IVT (n = 7). There was no significant difference between 
Control SBR and Control IVT. D displays the peak constriction within the first 30s 
after lights on. Orange asterisk above the graph represents a significant 
difference between RPE65 IVT and control IVT (P < 0.05). The other orange 
asterisks indicate significance levels between RPE65 SBR and RPE65 IVT (P < 
0.0001) and the blue asterisks represent a significance between RPE65 SBR and 
Control SBR (*P < 0.05, ****P < 0.0001). E shows data from D, plus untreated 
rd12 (green) and WT (black) data for comparison. 
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iPLR of rd12 mice with virus treatment lacking venus. 
Replacement of rpe65 in rd12 mice increases the iPLR, with all treatment groups 
showing significant constrictions and the largest constriction found when virus 
encoding rpe65 is delivered subretinally (Figure 5.11.A). Eyes which received the 
virus with rpe65 subretinally had a significant constriction from 3s until the end of 
the recording. Eyes which received the virus encoding rpe65 intravitreally had a 
significant constriction from 5s until 40s after light-onset. Eyes receiving the 
control virus subretinally had a significant constriction at 5s, 20s, 40s and 69s – 
150s. Eyes that received the control virus intravitreally had a significant 
constriction from 3 – 30s and from 50s – 150s. There was a significant effect of 
different virus treatments on the iPLR (Table 40). 
Eyes which received virus encoding rpe65 subretinally had a significantly greater 
constriction compared to eyes which received the control virus subretinally from 
7 – 30s and eyes which received the rpe65 virus intravitreally from 7s until the 
end of the recording (Figure 5.11.A). There was no significant difference between 
eyes which received the control virus subretinally and intravitreally. Also, there 
was no significant difference between eyes which received intravitreal injections 
of control virus and virus encoding rpe65 (Figure 5.11.A and B). 
Rpe65 encoded in the virus did not have a significant effect on the maximum 
constriction on its own (Table 41). When this virus is administered subretinally 
this has a significant effect on the iPLR maximum constriction. The subretinal 
injection by itself saw an improvement on the iPLR maximum constriction. This 
site of injection may allow greater number of macrophage to infiltrate the retina, 
which can improve visual function. Despite this, eyes that received the virus 
containing rpe65 subretinally had the greatest constriction, that reached a peak 
constriction of 0.7 ± 0.04 (Figure 5.11.C). Eyes that received the control virus 
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subretinally peaked at 0.83 ± 0.04. Placement of the virus encoding rpe65 into 
the vitreous had a peak constriction of 0.93 ± 0.008 and this was significantly less 
than eyes which received virus encoding rpe65 subretinally. Eyes which received 
the control virus intravitreally had a peak constriction of 0.87 ± 0.02 which is not 
significantly different from eyes which received the control virus subretinally. 
There were no significant changes to the latency of the iPLR response. Eyes 
which received virus encoding rpe65 are the only group which had an iPLR that 
was greater than those recoded in untreated rd12, which had a maximum 
constriction of 0.81 ± 0.07. 
When comparing these results to those received with a virus that also encoded 
venus, it is clear to see the effects of the venus on the iPLR (Figure 5.7). Venus 
allowed the pupil to constrict around 15% more, and the greatest effects were 
seen in eyes which received the virus encoding venus intravitreally, positioning 
the venus in the inner retina, close to the ipRGCs. 
 
Table 40 Two-way ANOVA of rd12 iPLR with virus encoding rpe65 without venus 
Two-way ANOVA P-value F (DFn, DFd) 
Virus treatment P = 0.0006 F (3, 38) = 7.148 
Light P < 0.0001 F (51, 1938) = 19.05 
Interaction P < 0.0001 F (153, 1938) = 2.747 
 
Table 41 Two-way ANOVA of maximum iPLR constriction in rd12 with virus 
encoding rpe65 without venus 
Two-way ANOVA P-value F (DFn, DFd) 
Site of Injection P < 0.0001 F (1, 38) = 19.15 
Rpe65 P = 0.2 F (1, 38) = 2 
Interaction P = 0.0039 F (1, 38) = 9.425 
 
 274 
 
 
Figure 5.11 iPLR rd12 mice with rpe65 gene therapy lacking venus reporter. 
A displays the iPLR of rd12 mice treated subretinally with virus encoding rpe65 
(RPE65 SBR, N = 12), virus encoding rpe65 intravitreally (RPE65 IVT, N = 10). 
Control virus delivered subretinally (Control SBR, N = 10) or control virus 
delivered intravitreally (Control IVT, N = 10). The bars beneath indicate lights off 
(Black) and lights on (white). B displays video stills from T = 0 (dark) and T = 30 
(light). Arrows highlight pupil diameter. C plots peak constriction. Asterisks 
indicate significance level from post-hoc tests: *P < 0.05, ****P < 0.0001. 
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RPE65 labelling in rd12 mice treated with virus lacking venus. 
RPE65-labelling is only found in the RPE of eyes that received virus containing 
the rpe65 gene subretinally (Figure 5.12 and Figure 5.13). In these eyes RPE65 
labelling can be seen to extend to the retinal rim, but it was not found in the ciliary 
body/iris. Eyes that received the virus containing rpe65 injected into the vitreous 
did not label positively for RPE65 in any location. 
Autofluorescent cells are seen on the apical side of RPE cells in eyes receiving 
subretinal injections of both rpe65 (Figure 5.14) or the control virus (Figure 5.15). 
These cells are most likely macrophage. Interestingly, these macrophage-like 
cells were not found in eyes receiving intravitreal injections. It is possible that 
these played a role in improving the peak constriction in the iPLR, as it was found 
that eyes which received a subretinal injection had a greater maximum 
constriction. 
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Figure 5.12 RPE65 labelling in rd12 mice treated with virus lacking venus. 
Representative images of RPE65 labelling (red) are displayed. RPE65 labelling 
is found only in the RPE of eyes that received virus encoding rpe65 subretinally. 
Retina and ciliary body images are taken at the same magnification and the scale 
bar represents 50 µm. The iris is imaged at a higher magnification and the scale 
bar indicates 20 µm. 
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Figure 5.13 RPE65 labelling with transmitted light in rd12 mice treated with virus 
lacking venus. 
This figure displays the same images from Figure 5.12, with the transmitted light 
channel included. This helps identify the pigmented RPE, ciliary body and iris. 
Images of the retina and ciliary body are taken at the same magnification and the 
scale bar represents 50 µm. The iris is imaged at a higher magnification and the 
scale bar indicates 20 µm. 
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Figure 5.14 Macrophage in rd12 mice treated with virus encoding rpe65 without 
venus. 
This figure displays the same retinal image of RPE65 SBR as above in Figure 
5.12 and Figure 5.13, with the green channel turned on, which reveals auto-
fluorescent macrophage that appear in both the red and green channel. They sit 
on top of the RPE. The scale bar indicates 50 µm. 
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Figure 5.15 Macrophage in rd12 mice treated with control virus subretinally. 
This figure displays images from eyes that received a subretinal injection of 
control virus. Red cells appear in the subretinal space (A); however, the 
transmitted light helps to show that these cells lie on top of the RPE and do not 
co-localise to the RPE layer (C). The cells also appear under the green channel 
(B and D), suggesting that it is autofluorescence, rather than specific antibody 
binding. The scale bar indicates 50 µm. 
Melanopsin labelling in rd12 mice treated with virus lacking venus. 
Melanopsin labelling was examined in retinal section. No significant differences 
were found in either the density of melanopsin+-cells or the intensity of 
melanopsin labelling in the cell somas. Examining melanopsin expression in 
retinal sections provided a different perspective on the relationship between 
RPE65 and melanopsin staining. This sectional view revealed a significant 
increase in the melanopsin labelling of the off sublamina in eyes that received 
subretinal injections of the virus encoding rpe65. 
Both the on and off sublamina of IPL were analysed for dendritic coverage and 
the average melanopsin labelling intensity (Table 42). The on sublamina did not 
show a significant effect of virus treatment on the area of melanopsin+-dendritic 
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coverage (Figure 5.16.A) nor the intensity of melanopsin labelling (Figure 5.16.B). 
The off sublamina also did not show a significant effect of the virus or site of 
injection on the area of melanopsin+-dendritic coverage (Figure 5.16.C). The virus 
treatment did significant effect the intensity of melanopsin labelling in the off 
sublamina (Table 42).  Melanopsin expressed in the off sublamina of eyes which 
received virus encoding rpe65 subretinally was stronger than eyes which 
received virus encoding rpe65 intravitreally (P < 0.05) and eyes which received 
the control virus subretinally (P < 0.05) (Figure 5.16.D). 
This effect is seen in eyes that received the rpe65 virus subretinally, where rpe65 
expression was only partially restored in the RPE. In areas of the retina where 
RPE65 labelling is seen in the RPE, melanopsin-labelling in the off sublamina 
directly above this RPE has increased melanopsin labelling intensity (Figure 
5.16.E), whereas, areas of the same retinal section which do not show RPE65 
labelling, do not show a corresponding increase in melanopsin staining intensity, 
in the overlying off sublamina. 
 
Table 42 Two-way ANOVA of effects of rpe65 on melanopsin in IPL 
Two-way ANOVA Rep65 Site of injection Interaction 
On % area P = 0.4, 
F (1, 21) = 0.8 
P = 0.2 
F (1, 21) = 2 
P = 0.8 
F (1, 21) = 0.05 
intensity P = 0.7 
F (1, 21) = 0.3 
P = 0.6 
F (1, 21) = 3 
P = 0.4 
F (1, 21) = 0.7 
Off % area P = 0.1, 
F (1, 23) = 3 
P = 0.8, 
F (1, 23) = 0.05 
P = 0.5, 
F (1, 23) = 0.5 
intensity P = 0.08, 
F (1, 23) = 3 
P = 0.0178, 
F (1, 23) = 6.51 
P = 0.054, 
F (1, 23) = 4 
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Figure 5.16 Melanopsin labelling in the on and off sublamina of iPL in rd12 mice 
treated with virus lacking venus. 
A shows the percentage area covered by melanopsin+-dendrites in the on 
sublamina in eyes receiving control virus (black) subretinally (SBR, n = 7) or 
intravitreally (IVT, n = 6) and eyes receiving virus encoding rpe65 (white) SBR (n 
= 8) or IVT (n = 4). B shows the average pixel intensity (above a pixel threshold 
of 20) in the on-sublamina. C shows the percentage area covered by 
melanopsin+-dendrites in the off sublamina in eyes which received control virus 
SBR (n = 6) or IVT (n = 6) and eyes which received virus encoding rpe65 SBR (n 
= 6) or IVT (n = 6). D shows the average pixel intensity greater than 20 in the off 
sublamina. Asterisks indicate a significance level of P < 0.05, determined by post-
hoc tests. E displays a sagittal section of the retina labelled for RPE65 (yellow) 
and melanopsin (green). Enlarged Images show an area of the retina with RPE65 
labelling in the RPE and increased melanopsin labelling in the off sublamina 
(above) and an area where RPE labelling is absent, and reduced melanopsin 
labelling in the off sublamina (below). These higher magnification images are 
shown with nuclear marker, DAPI (blue, left, to illustrate retinal layers and without 
DAPI (right) to highlight melanopsin labelling. The scale bar indicates 50 µm. 
 282 
 
 Discussion 
This experiment was a repeat of the last experiment without the venus gene. 
Venus is a fluorescent protein that emits green light at 530 nm (Nagai et al., 
2002), which is within the spectral sensitivity of melanopsin (Berson et al., 2002). 
Thus, it was decided that the experiment should be repeated without the 
influencing factor of venus. 
The BLA results were similar to those from the experiment 5.3. Both control-
treated mice and mice which received the rpe65 gene spent more time in the 
back half when the front half was illuminated compared to when the whole arena 
was in darkness, indicating the presence of BLA. However, there was no effect 
of the virus, as there was no significant difference between animals which 
received the virus encoding rpe65 and the control virus. The BLA response 
provides a functional readout of both outer-retinal photoreceptors and ipRGCs, 
however, no improvements from receiving rpe65 were detected with this method. 
There is also a lack of literature using this test for investigating restoration of 
visual function. Thus, there could be many factors unknown about restoring this 
behavioural function including restoration of vision in only one eye, or whether 
this behaviour can be restored, as it is confounded by many other factors such 
as anxiety and learned behaviour.  
The PLR is another functional readout of outer-retinal photoreceptors and 
ipRGCs. A significant PLR in all treatment groups was seen at 800 µW/s/cm2. At 
80 µW/s/cm2, eyes receiving the rpe65 virus intravitreally no longer had a 
significant constriction, while other treatment groups did. Eyes receiving virus with 
rpe65 subretinally had a significantly greater constriction than eyes which 
received virus with rpe65 intravitreally and eyes receiving the control virus 
subretinally at both 80 and 800 µW/s/cm2. There was no significant difference 
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between eyes receiving the control virus subretinally and those receiving the 
control virus intravitreally at either 80 or 800 µW/s/cm2. At 800 µW/s/cm2, eyes 
which received the virus with rpe65 intravitreally had a significantly greater 
constriction than eyes receiving the control virus intravitreally at 30s post light 
onset, however, at 80 µW/s/cm2, eyes which received the virus with rpe65 
intravitreally no longer had a significant constriction, while eyes which received 
the control virus intravitreally did. However, at this irradiance there was no 
significant difference between eyes receiving intravitreal injection of the control 
virus and those receiving the virus with rpe65. At 0.08 µW/s/cm2, only eyes 
receiving subretinal injections of control virus or virus containing rpe65 were 
examined. At this light power, both treatments had a significant constriction. Two-
way ANOVA showed a significant difference between treatments, however, there 
was no significant difference in post-hoc tests. These results show a definite 
increase in the PLR in eyes which received rpe65 subretinally. They had a 
significantly greater constriction at each light power examined. 
The iPLR is a readout of melanopsin function and showed that while all treatment 
groups had a significant constriction, only eyes which received rpe65 subretinally 
had a constant constriction that was maintained. They also had a significantly 
greater constriction compared to eyes receiving the control virus subretinally and 
eyes that received the virus with rpe65 intravitreally. There was no significant 
difference between eyes which received the control virus subretinally and eyes 
which received the control virus intravitreally and no significant difference 
between eyes which received intravitreal injections of control virus and virus 
containing rpe65. These results are the same for the peak constriction. These 
results are more definitive than those from experiment 5.3, highlighting the effect 
of venus on melanopsin function and the importance of repeating this experiment.  
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Histology confirmed that RPE65-labelling is only found in the RPE of eyes which 
received virus containing the rpe65 gene subretinally. In these eyes RPE65 
labelling was seen to extend to the retinal rim, but was not found in the ciliary 
body/iris. In contrast, eyes which received the virus containing rpe65 in the 
vitreous did not label positively for RPE65. These results along with the functional 
data show that RPE65 is only found in the RPE and that placing virus containing 
rpe65 into the vitreous cavity cannot restore ipRGC function. Thus, the iPLR must 
require chromophore from the RPE. 
Autofluorescent cells were found in the subretinal space on the apical side of RPE 
in eyes that received subretinal injections of rpe65 or control virus. These cells 
are most likely macrophage but were not found in eyes which received intravitreal 
injections. The potential functional effects of these autofluorescent cells was 
examined by comparing eyes receiving the control virus subretinally to eyes 
receiving the control virus intravitreally. There was a trend towards greater 
constrictions in eyes which received the subretinal injection of control virus in both 
the PLR and the iPLR. 
An interesting observation found in the melanopsin expression pattern was an 
increase in the intensity of melanopsin in the off sublamina of eyes that received 
rpe65 subretinally. Topographically, within retinal sections, it was clear this 
increase in the melanopsin labelling intensity occurred potentially in areas where 
the RPE labelled positively for RPE65. There was no effect on the dendrites in 
the on sublamina of IPL and no significant differences were found in either the 
density of melanopsin+-cells or in the intensity of melanopsin labelling in the cell 
somas. 
M1 ipRGCs are the only sub-type of ipRGC to stratify exclusively in the off 
sublamina. While M3 ipRGCs can also stratify in the off sublamina, they are rare 
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and do not label strongly for melanopsin (Schmidt and Kofuji, 2011). M1 ipRGCs 
rely on intrinsic responses more than extrinsic (Schmidt and Kofuji, 2010), 
suggesting that they rely more heavily on chromophore than other subtypes and 
this perhaps is why the increase in chromophore in rd12 eyes receiving subretinal 
rpe65 gene therapy had a selective improvement on the dendrites of M1 ipRGCs. 
Brn3b-negative M1 ipRGCs have functions in the entrainment of the circadian 
clock (Berson et al., 2002, Provencio et al., 2000, Lucas et al., 2003, Lupi et al., 
1999), and project into the suprachiasmatic nucleus of the hypothalamus, the 
primary pacemaker in mammals (Baver et al., 2008, Chen et al., 2011). Brn3b-
negative ipRGCs also have projections from the retina into the ciliary body in mice 
(Semo et al., 2014), which may mediate the iPLR.  
Thus, it can be concluded from this experiment that the iPLR is driven by 
chromophore from the RPE and that M1 ipRGCs may mediate this response, as 
they appear to respond to RPE-driven chromophore with enhanced melanopsin 
expression. 
 General Conclusions 
This chapter was constructed to determine if ipRGCs require chromophore from 
the RPE to initiate the iPLR. Rods and cones have many physical connections 
with the RPE aiding chromophore transportation, however, ipRGCs are situated 
in the inner retina and separated from the RPE by many layers of cells. While 
melanopsin has been reported to work as a bi-stable pigment (Melyan et al., 
2005, Fu et al., 2005), this is insufficient to drive a normal iPLR in the rd12 mouse, 
as reported in chapter 4. In experiment 4.5, it was shown that by supplementing 
the rd12 mouse with 9-cis retinal the iPLR can not only be fully restored but the 
pupil constricts significantly more than that of the WT. This raised the question of 
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whether this supplementary chromophore was acting on ipRGCs in the retina or 
more directly on an opsin in the iris/ciliary body. This question was addressed in 
the first experiment of this chapter. Supplementary chromophore was only able 
to improve the iPLR when retina was attached to the anterior chamber and was 
unable to drive the iPLR in an isolated anterior chamber. Interestingly, the iPLR 
with anterior chamber with 1mm retina was much smaller than whole eye 
preparations from rd12 treated with 9-cis retinal, this may suggest that the iPLR 
is driven by the whole retina and not just the melanopsin rim, however this would 
have to be investigated further. While this experiment strongly suggests that 
chromophore acts on the retina to produce the iPLR, it did not prove that the RPE 
is the source of this chromophore. However, there was no evidence of RPE65 
labelling in the iris in WT retina, an observation that strongly implicated the RPE 
as being the site of chromophore production under normal circumstances.  
In chapter 4 it was shown that chromophore supplementation significantly 
improved the iPLR in rd12 mice, which suggested that melanopsin requires a 
source of chromophore to drive the iPLR and that the bi-stable property of 
melanopsin (Melyan et al., 2005, Fu et al., 2005) is insufficient to drive a normal 
iPLR. The source of this chromophore was investigated in this chapter. As 
ipRGCs lie on the vitreous side of the retina, and the RPE is located in the outer 
retina, by placing a virus encoding the rpe65 gene in the vitreous in rd12 mice 
and comparing melanopsin function with rd12 mice receiving the rpe65 gene 
subretinally (beside the RPE), it was determined that rpe65 in the RPE caused a 
significant improvement in melanopsin function. This was not the case when 
rpe65 was delivered in the vitreous, closer to ipRGCs, with no difference in 
melanopsin function compared to that seen following injection of a control virus. 
Anatomically, this was explained by the fact that labelling for RPE65 was only 
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seen in eyes receiving a subretinal injection of virus encoding rpe65 with 
expression of this protein restricted to the RPE layer. 
The expression of venus revealed the extent of retinal cells infected by the virus. 
This illustrated that intravitreal injections, while able to infect the neural retina, did 
not infect the RPE. Also, while many cell types expressed the venus reporter, 
only the RPE labelled for RPE65. Both venus and rpe65 used the same 
constitutive CAG promoter, with the rpe65 gene coming before the venus gene. 
As such, in eyes receiving the virus containing rpe65, wherever venus is 
expressed, rpe65 would have been expected to be transcribed in the same cells. 
However, RPE65 labelling was not detected in all cells expressing venus 
suggesting that not all cells can produce RPE65 from the mRNA.  
ERGs provide a functional readout of outer-retinal photoreceptors. While positive 
trends were seen in both scotopic and photopic ERGs, this was not-significant, 
except at 0 Lg cd.s/m2, where, the scotopic b-wave amplitude was significantly 
greater in eyes treated with rpe65 subretinally. This is possibly due to the age 
that the rd12 mice were treated, as it has been reported that the earlier the 
treatment, the greater the ERG rescue and that gene therapy at 3 months was 
not able to rescue the ERG (Pang et al., 2010, Li et al., 2011, Nusinowitz et al., 
2006). At 3 months, it was shown in chapter 4 that there are still many rod 
photoreceptors present and while rescue of scotopic ERG was not significant 
using gene therapy, it was significantly improved with supplemented 
chromophore. 
BLA provides a functional read out of outer retinal photoreceptor function and 
melanopsin function. While animals that received the virus exhibited a BLA 
response, there was no significant difference found between animals receiving 
the virus containing rpe65 and animals receiving the control virus. These results 
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were similar whether the virus contained venus or not. As each animal received 
an injection of virus subretinally into the left eye and an intravitreal injection into 
the right eye, this readout could not determine an effect of the site of injection. 
The PLR provides another functional readout of outer-retinal photoreceptors and 
ipRGCs, however, this readout did allow for comparisons between intravitreal and 
subretinal injections. The results of experiment 5.3 (with venus) and 5.4 (without 
venus) both showed that eyes which received rpe65 delivered subretinally had a 
significantly greater constriction compared to eyes which received the control 
virus and eyes which received virus with rpe65 delivered intravitreally at each 
irradiance. However, there was also a strong effect of the venus reporter, which 
is seen at 800 µW/s/cm2, the brightest light power examined. At 800 µW/s/cm2, 
eyes receiving the control virus subretinally or intravitreally and eyes which 
received virus with rpe65 intravitreally had an average peak constriction of 0.4 – 
0.42 with venus, this was reduced to 0.58 – 0.67 without venus. 
The iPLR is a readout of melanopsin function (Xue et al., 2011, Semo et al., 
2014). While both experiments 5.3 (with venus) and 5.4 (without venus) show 
that eyes receiving rpe65 subretinally had the greatest constriction, this failed to 
reach statistical significance in experiment 5.3 where venus is expressed. The 
effect of venus on the iPLR is strong; treatment groups had a 13 – 23% greater 
constriction when the virus contained venus. Experiment 5.4, which used virus 
without venus showed that while all treatment groups had a significant 
constriction, only eyes which received rpe65 subretinally had a robust constriction 
that was maintained. They also had a significantly greater constriction compared 
to eyes which received the control virus subretinally and eyes which received the 
virus with rpe65 intravitreally. There was no significant difference between eyes 
receiving the control virus subretinally and eyes receiving the control virus 
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intravitreally and no significant difference between eyes receiving intravitreal 
injections of control virus and virus containing rpe65. These results were the 
same for the peak constriction and collectively were much more definitive than 
experiment 5.3, highlighting the effect of venus on melanopsin function and the 
importance of repeating this experiment. It is clear from experiment 5.4 that the 
iPLR is driven by chromophore from the RPE. 
The expression of rpe65 in host RPE cells increased the melanopsin labelling 
intensity in M1 ipRGCs. M1 ipRGCs contain the most melanopsin under normal 
conditions and are thought to rely on their intrinsic responses more than extrinsic 
inputs from rods and cones (Schmidt and Kofuji, 2010). This suggests that M1 
ipRGCs rely more heavily on chromophore than other subtypes of ipRGC and 
perhaps this is why the increase in chromophore in rd12 mice receiving rpe65 
gene therapy subretinally had particular effect on M1 ipRGCs. 
Thus, it can be concluded from this experiment that the iPLR is driven by 
chromophore from the RPE and that M1 ipRGCs also receive chromophore from 
the RPE. 
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Chapter 6 Discussion 
 The importance of the RPE 
The RPE lies in the outer-retina adjacent to POS and acts as a support cell for 
outer-retinal photoreceptors. The RPE separates the retina from the blood supply 
(Tornquist et al., 1990). The RPE cells have tight junctions on their lateral side, 
making diffusion between cells difficult. This acts as part of the BRB preventing 
blood leaking and the infiltration of immune cells, selectively supplying rods and 
cones with oxygen, glucose, ions, metabolites and vitamin A from the blood. 
RPE cells have an apical and basal polarisation. The basal membrane is a 
component of Bruch’s membrane and interacts with the choroid. The apical 
membrane has large microvilli, which extend to surround the POS. This is 
important to facilitate close communication between RPE and photoreceptors to 
optimise RPE functions that enhance photoreceptor performance, including the 
secretion of pigment endothelium-derived factor (PEDF), which inhibits the 
growth of blood vessels and prevents apoptosis (Cayouette et al., 1999). 
Photoreceptors have a very high metabolic rate and accumulate toxic photo-
oxidative compounds due to the high light exposure, so they shed the tips of the 
POS every day and constantly renew the POS to maintain photoreceptor health. 
The long RPE apical processes phagocytose the shed POS and recycle useful 
components such as 11-cis-retinal, while, waste is excreted to the choroid. 
The RPE also absorbs toxins to prevent neurotoxicity of photoreceptors. Upon 
activation by light, extracellular glutamate is taken up by the RPE to prevent non-
specific stimulation during the light phase. Excess light is absorbed by the RPE 
for visual clarity by preventing light from reflecting into the retina. The RPE 
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contains a pigment called melanin, which absorbs the excess light and gives the 
RPE a dark colour. Water is pumped out of the retina by the RPE to maintain the 
retina in a proper state of hydration for visual clarity. These supporting roles of 
the RPE help to keep a healthy environment for photoreceptor survival. 
The RPE also plays a crucial role in vision by recycling vitamin A (all-trans-retinol) 
into 11-cis retinal, which forms the visual pigment with the opsin in 
photoreceptors, allowing for the detection of light. All-trans-retinol is sourced from 
the diet transported to the RPE via the choroid. It is esterfied by LRAT to all-trans-
retinyl ester and then hydrolysed and isomerised by RPE65 to form 11-cis-retinol 
(Redmond et al., 1998). This is oxidised by 11-cis-retinal dehydrogenase to form 
11-cis-retinal and subsequently transported to photoreceptors. In the 
photoreceptor 11-cis-retinal sits in the opsin to form the visual pigment. Upon 
illumination, 11-cis-retinal changes to all-trans-retinal and is then reduced by 
RDH to form all-trans-retinol, at which point it is transported back to the RPE for 
recycling. Mutations in lrat or rpe65 can result in many retinal degenerative 
diseases, such as retinitis pigmentosa and Leber’s congenital amaurosis 
(Morimura et al., 1998, Marlhens et al., 1997, Sweeney et al., 2007, Fan et al., 
2008, Senechal et al., 2006). 
With such a strong dependence on the RPE for photoreceptor function it is 
unsurprising that many diseases resulting in photoreceptor degeneration are 
primarily diseases of the RPE and many genes involved in the visual cycle can 
result in blindness. AMD is the leading cause of blindness in the developed world 
and is recognised as a disease of the RPE. The exact pathology and causes of 
AMD are not fully understood. There are many genes associated with the disease 
but no single gene accounts for all cases of the disease. There are also many 
environmental factors, such as smoking, diet and age, which contribute to the risk 
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and severity of the disease. This makes treating the source of the disease difficult. 
Replacement of RPE cells using stem cells is currently being validated as a 
suitable treatment for AMD (Schwartz et al., 2012, Carr et al., 2013, Nommiste et 
al., 2017, Kamao et al., 2014, Reardon and Cyranoski, 2014, da Cruz et al., 
2018). Stem cells provide a means of regenerative medicine by replacing 
damaged or lost tissue. Human embryonic stem cells (hESC) are stem cells 
derived from the inner cell mass of a blastocyst, an early-stage embryo (5 days 
post fertilisation). These cells are pluripotent and as such, can develop into any 
cell type in the body (Thomson et al., 1998) baring gametes. They are also 
renewable, such that stem cells derived from one blastocyst can produce cells to 
treat many patients. HESC-RPE cell shape, organisation and phenotype are 
almost identical to that of human macular RPE cells, which makes these cells 
prime candidates for cell therapy in AMD (Vugler et al., 2008a). 
To date, the majority of RPE cell transplant studies have been carried out on the 
RCS rat, a model of retinal dystrophy with progressive and early photoreceptor 
loss (Dowling and Sidman, 1962). The RCS rat has a mutation in mertk, a gene 
responsible for the phagocytosis of POS. This results in accumulation of shed 
POS, creating a debris zone and consequent separation of photoreceptors and 
RPE, resulting in fast photoreceptor degeneration (D'Cruz et al., 2000). This 
model of retinal degeneration was discovered almost 80 years ago, and it is a 
well-studied model. However, the RCS rat is a less than ideal model for studying 
the effects of RPE cell transplantation due to the early onset and fast rod and 
cone degeneration, making full visual restoration difficult. The death of RGCs in 
the RCS rat is also quite extensive and to date transplantation has failed to 
prevent RGC pathology (Klassen et al., 2001). Photoreceptor preservation and 
improved visual function in RCS rats has been improved by cell transplantation. 
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However, improvements can be achieved by an array of cells, including hESC-
RPE cells (Idelson et al., 2009, Zhu et al., 2013), iPS-RPE cells (Carr et al., 2009, 
Krohne et al., 2012), human RPE cells (Little et al., 1996), rat RPE cells (Jiang 
and Hamasaki, 1994), ARPE-19 cells (Coffey et al., 2002), but also, neural 
progenitors (Wang et al., 2008) and Schwann cells (Lawrence et al., 2000). Thus, 
identifying RPE-specific therapeutic effects is complicated as many studies show 
that photoreceptor survival is most likely due to trophic effects. This is supported 
by areas of photoreceptor rescue larger than the graft of human RPE cells and 
Schwann cells (Wang et al., 2005), suggesting the diffusion of trophic factors is 
responsible for cell survival. In this thesis two mouse models, NaIO3 and rd12 are 
examined as alternative models for studying RPE cell transplantation. 
 Is sodium iodate a suitable model for studying RPE cell 
transplantation? 
A major issue with RPE cell transplantation is achieving cell integration. Many 
animal models do not mirror the RPE cell loss seen in dry AMD, in which 
photoreceptors die subsequent to RPE cell death. In many studies involving sub-
retinal transplantation into rodent models where host RPE cells remain, the 
grafted RPE cells clump together to form a bolus of cells and do not sit down in 
a monolayer (Carido et al., 2014, Li and Turner, 1991, Seaton and Turner, 1992, 
Sheedlo et al., 1991, Carr et al., 2009). Studies have shown that RPE cells 
undergo apoptosis in the absence of a suitable substrate to attach to (Tezel and 
Del Priore, 1997, Tezel et al., 2004). This is known as anoikis. In human, it is 
possible to surgically remove RPE and this occurs with AMD progression in the 
form of geographic atrophy. However, due to the small size of a rodent eye, 
physical removal of the host RPE prior to grafting is unfeasible, but chemical 
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removal of the RPE is feasible. However, the loss of RPE cells prior to 
transplantation will damage the BRB (Wenkel and Streilein, 1998) which can 
complicate donor cell survival.  
Sodium iodate (NaIO3) is a drug, which is selectively toxic to the RPE and causes 
RPE cell necrosis. Benefits of using NaIO3 to create a model of retinal 
degeneration include it’s selective effects on the RPE after a single administration 
and the rapid onset of RPE cell death, with oedema observed 1 hour after 
administration via the tail vein (Hariri et al., 2013). This selective death of the RPE 
is followed by photoreceptor cell apoptosis. 
It was determined in this thesis that the route of administration of NaIO3 had a 
large effect on the efficacy of NaIO3. Administering NaIO3 IP created varied 
results. Animals that received the same dose of NaIO3 could have either flatline 
ERG recordings or an ERG that fell within normal parameters. Thus, this route of 
administration was deemed unsuitable for this study. Administering NaIO3 retro-
orbitally to the right eye, gave a consistent result of a significantly diminished 
scotopic and photopic ERG. While NaIO3 was only administered to the right eye, 
no statistical difference in ERG recordings was seen between right and left eyes. 
At 1 month after NaIO3 administration no RPE65 labelling was identified and S-
opsin was strikingly reduced and mislocated to the PIS and ONL. However, 
rhodopsin labelling was still present in the POS at 1 month and ~ 7 layers of cells 
in the ONL remained. These results may be attributed, at least in part, to the loss 
of chromophore, as rods are present but their function is almost completely lost. 
It has been seen in rpe65-/-  mice that cones are lost first and their opsin 
mislocates because cone opsin requires chromophore for correct folding and 
trafficking (Rohrer et al., 2005).  
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The ability to restore retinal function in NaIO3-treated mice was tested by scotopic 
ERG recordings following chromophore supplementation. This will only bypass 
one function of the RPE, however, if improvements were seen then 
photoreceptors and retinal circuitry are still functional and restoration may be 
possible. At 3 days following NaIO3 treatment an improvement in the scotopic 
ERG was only seen in half of the animals by chromophore supplementation and 
by 7 days 9-cis retinal treatment failed to show any improvements in the scotopic 
ERG. Interestingly, by 30 days after NaIO3 administration, when the ERG has 
almost flatlined, 9-cis retinal was able to rescue a lot of retinal function and 
significantly increased the a- and b-wave amplitude. It is unknown why 
chromophore did not improve the ERG at earlier time points. Although, 
improvements to the RPE and retinal function have been reported 1-3 months 
following NaIO3 administration (Franco et al., 2009, Kiuchi et al., 2002, 
Machalinska et al., 2013, Redfern et al., 2011). 
Given these results, it was decided to transplant RPE cells at 3 weeks following 
NaIO3-treatment, in the hope that a delay in treatment, may be a favourable 
environment for retinal recovery. Carido and colleagues transplanted hESC-RPE 
cells 7 days after NaIO3 treatment and saw RPE cell integration, but no functional 
recovery by ERG (Carido et al., 2014), which also guided the decision to 
transplant at a later timepoint. Unfortunately, eyes receiving hESC-RPE cells 
showed no improvements in ERG recordings 3 weeks after the transplant and no 
hESC-RPE cells were found to survive in the retina, although, it was shown that 
functional rescue was possible by chromophore supplementation. 
Thus, as of yet, NaIO3 has not proven to be a suitable model for studying 
functional benefits of RPE cell transplantation. However, an important factor to 
consider is the loss of choroid following RPE damage seen in AMD (McLeod et 
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al., 2009, McLeod et al., 2002). Without a healthy blood supply, it may be very 
difficult to recover retinal function, although, this is a factor seen in AMD and 
therefore an important factor to consider when treating AMD patients with RPE 
cell transplantation. 
Interestingly, the melanopsin function does not appear to be as affected as the 
function of outer-retinal photoreceptors. The PLR in NaIO3-treated animals is still 
quite robust at 1 month, although the constriction is reduced compared to WT. 
The greatest deficit in the PLR is seen at low light powers and the maximum 
constriction graph resembles that seen in rd/rd cl mice (Lucas et al., 2003), where 
melanopsin drives the PLR at high irradiances and cannot drive a constriction at 
lower irradiances of 11 log photons/cm2/s, comparable to the 0.8 µW/cm2/s used 
in this study. However, while the PLR at high light powers is still quite robust, the 
constriction does fall short of that seen in WT, suggesting that there may be a 
small loss to melanopsin function. Interestingly, ipRGCs that innervate the OPN 
core are Brn3b-positive and stratify in the on sublamina of IPL (Hattar et al., 2002, 
Morin et al., 2003, Hattar et al., 2003, Lucas et al., 2003, Chen et al., 2011, Baver 
et al., 2008, Guler et al., 2008), which corresponds to the loss of melanopsin 
expression seen in the on sublamina of IPL following ,NaIO3 administration in 
chapter 3. 
While the study of NaIO3, may or may not prove to be useful for studying RPE 
cell transplantation, it could be a potentially important source of information for 
studying the effects of RPE cell loss, seen in AMD, particularly with reference to 
the melanopsin system. 
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 Rd12: A model of LCA2 
The second model studied in this thesis is the rd12 mouse. This is a naturally 
occurring mouse model of LCA2 (Pang et al., 2005), which has a mutation in the 
gene for RPE65, also seen in LCA2 patients (refSNP cluster report: 
rs368088025), making it a clinically relevant model. LCA2 is characterised by 
early onset of central vision loss, sensory nystagmus, amaurotic pupils and 
absent signals on electroretinography (ERG). It is one of the earliest and severe 
forms of inherited retinal dystrophies. The rd12 mice were repeatedly 
backcrossed to a WT, C57BL/6J, to make a congenic inbred strain and C57BL/6J 
are accepted as a WT control when assessing rd12 mice (Pang et al., 2005). The 
rd12 mouse has a very similar phenotype to the previously described rpe65-/-, 
except that the rd12 develops distinctive white dots throughout the retina that 
become apparent at around 5 months of age, similar to those seem in LCA2 
patients (Pang et al., 2005). This characteristic of the rd12 mouse makes it a 
better model for human LCA2, as they are more likely to simulate the actual 
disease mechanism.  
While the rd12 mouse has significant loss of retinal function from an early age, it 
also exhibits a slow retinal degeneration, which are ideal features for attempting 
to recover retinal function. The first sign of the rd12 morphology has been 
reported at 3 weeks when lipid-like droplets are found in the RPE. At 6 weeks, 
occasional voids start to appear in the POS and by 3 months these voids become 
obvious, and much larger lipid-like droplets appear (Pang et al., 2005). In this 
thesis rhodopsin was found located in the POS in rd12 at 3 months. It has been 
published that rhodopsin spectral absorbance is not detected in the rd12 mouse 
(Pang et al., 2005), however, rhodopsin protein presence and location have not 
been previously reported in rd12 mice by immunohistochemistry. 
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While rods have a slow degeneration, cones are reported to be lost early in the 
rd12 mouse; by P21, the PNA-lectin positive cone count was reportedly reduced 
to 55% of that seen in WT, however, cones lose opsin before cone death (Li et 
al., 2011), so the surviving cones may no longer be functional. By P90 PNA-
positive cone counts were reportedly reduced to 16% that of WT, and only 15% 
of these express M/L-opsin, while no S-opsin was seen (Li et al., 2011). However, 
in this thesis, no M/L cones opsin was seen at 3 months and S-opsin was 
detected although it was mislocalised to the PIS and ONL. These discrepancies 
may be due to different techniques used (flatmount and retinal section) and/or 
different antibodies used.  
This mislocation of cone opsin and cone loss may be due to the requirement of 
chromophore for correct opsin folding and trafficking (Bandyopadhyay et al., 
2013). And, the timeline of cone loss observed in the literature (Li et al., 2011, 
Pang et al., 2010) coincides with WT development of peak expression of RPE65 
(Bowes et al., 1988, Manes et al., 1998, Hamel et al., 1993) and the development 
of the ERG (Bakall et al., 2003). It has been reported that the scotopic ERG starts 
to diminish as early as 3 weeks in the rd12 mouse with both scotopic and photopic 
ERGs decreasing with age (Pang et al., 2005, Pang et al., 2006). In this thesis, 
only a small scotopic b-wave was recorded at high light intensities in the 3-month 
old rd12. A more robust photopic ERG was recorded, although, it is known that 
this is rod driven (Seeliger et al., 2001, Cachafeiro et al., 2010, Dai et al., 2015). 
The lack of RPE65 in rd12 mice allows rods to function at brighter light intensities 
without bleaching. Interestingly, patients with mutations in rpe65 have similar 
ERG patterns (Lorenz et al., 2000). 
The rd12 mutation also influences the melanopsin system. This was first indicated 
by the absence of a negative masking effect in rd12 mice (Thompson et al., 
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2008). It has also been shown that rpe65-/- mice have a shifted circadian 
behaviour, which was corrected when exposed to increased illumination (Doyle 
et al., 2006). In this thesis, a loss of melanopsin+-cells and a loss in melanopsin 
expression was recorded in 1-month old rd12 mice. Also, melanopsin function is 
significantly reduced. The BLA response which is driven by both outer-retinal 
photoreceptors and ipRGCs is present at 1 month, but is lost by 3 months. The 
PLR, which is also driven by outer-retinal photoreceptors and melanopsin (Lucas 
et al., 2003), was shown to be significantly reduced in the 3-month old rd12 
mouse. A response is only seen at high light levels, where the WT has an almost 
total pupil constriction. Comparing these results to those published by Lucas et 
al, it suggests that both outer-retinal photoreceptors and ipRGC have reduced 
function in the rd12 (Lucas et al., 2003). The iPLR is a functional readout selective 
for melanopsin function (Semo et al., 2014, Xue et al., 2011) and was also 
significantly reduced in the 3-month rd12 mouse, where it only produces a small 
constriction. 
The effects of the rd12 mutation and NaIO3 are similar when studying outer-retinal 
photoreceptors; cones are lost early, their opsin becomes mislocated to PIs and 
ONL, rods survive longer but their function is severely reduced. Scotopic ERGs 
are severely diminished but photopic ERGs are more robust, thus, a lot of this 
can be attributed to the loss of chromophore. However, the severe loss of 
melanopsin function in the rd12 mouse is in contrast to results seen in the NaIO3 
model, while some loss to melanopsin function was seen, the PLR results 
suggested that the melanopsin function remains quite robust 1 month after 
NaIO3-treatment. One possible explanation is that NaIO3 has its strongest effect 
at the posterior pole and it is possible that melanopsin at the retinal rim is less 
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affected and driving the PLR, while the ERG is a whole field recording of the 
outer-retinal photoreceptors. 
The rd12 mouse has been used as a model for retinal rescue in many studies, 
however, most of these are by gene therapy (Nusinowitz et al., 2006, Li et al., 
2011, Pang et al., 2010). While testing gene therapy was not the objective of this 
thesis, these positive results by other groups reassure that retinal rescue is 
achievable in this model. Pang et al initiated gene therapy at P14 with a rAAV5-
CBA-hRPE65 vector, which resulted in RPE65 expression over large areas of the 
RPE, rhodopsin levels (measured by spectral absorbance) restored to 70% of 
WT levels and ERG signals restored to approximately 66% that of normal values 
when assayed at 7-months of age (Pang et al., 2006). Early treatment with gene 
therapy has been shown to keep remaining cones alive and to rescue opsin 
expression in these cones (Li et al., 2011). In animal models of RPE65 deficiency, 
rods undergo a slow progressive degeneration, and restoration of rod vision 
appears to be possible over a broad range of ages. 
In contrast to the widespread usage of this model in gene therapy studies, the 
rd12 mouse is an under-utilised animal for cellular therapies. Even though rd12 
is a model of LCA, stem cell work on this model can be translated to many other 
forms of retinopathy, such as testing RPE cell transplantation for application in 
age-related macular degeneration. Li and colleagues injected iPSC-derived RPE 
cells subretinally into 2-day old albino rd12 mice and showed the presence of 
pigment in the RPE at 5 months, unfortunately, this does not confirm integration 
as host RPE cells could phagocytose melanin from dead iPSC-RPE cells and 
these pigmented RPE cells were not labelled for any human markers. iPSC-RPE 
cells were also injected into rd12 mice crossed with Prkdcscid/Prkdcscid mice for a 
double homozygous with both SCID and rpe65 mutation. While increased b-wave 
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amplitude was seen, the a-wave was still absent and the presence of grafted RPE 
was not shown in these animals (Li et al., 2012b).  
In this thesis, functional recovery was tested, prior to RPE cell transplantation, by 
providing chromophore in the form of 9-cis retinal, to determine if the remaining 
photoreceptors were functional. Rod function was examined by scotopic ERG 
and ipRGC function was assessed by analysing the iPLR, this allowed separation 
from cone function, which is likely to be the most difficult function to restore (as 
they undergo a faster degeneration). Supplementation with 9-cis retinal provided 
a significant increase in both scotopic a- and b-wave amplitudes, although this 
was at the cost of longer latency and implicit time. The amplitudes were 
significantly lower than WT. The loss of amplitude signifies the level of rod 
degeneration at 3 months in the rd12 retina. The longer latencies could indicate 
problems with remaining photoreceptor function and synaptic connections in the 
retina. Interestingly, these longer latencies were also seen in the NaIO3 model, 
which also has a primary pathology in the RPE. 
Interestingly, while 9-cis retinal only partially recovered the rd12 scotopic ERG, 
the synthetic chromophore produced a super constricted iPLR. Normal rd12 mice 
have a significantly diminished iPLR, however, 9-cis retinal drives this constriction 
to surpass that of WT and with at a significantly shorter latency. This suggests 
that the pathway of the iPLR is fully developed and intact in rd12 mice. This was 
unexpected as the melanopsin expression is significantly lower in the rd12 retina 
and the response from the rods in the scotopic ERG in rd12 with 9-cis retinal was 
not as strong as untreated WT. This suggests that the iPLR function is only 
diminished due to the lack of chromophore and an increase in chromophore 
results in an increased constriction. This ability of 9-cis retinal to recover the iPLR 
was still seen at 12 months, suggesting a strong preservation of this functional 
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pathway. Interestingly, latency is increased in the rd12 iPLR with age and pupil 
re-dilation after lights-off was lost in aged mice. However, as the mechanism of 
the iPLR is largely unknown, it is difficult to speculate why this effect of age is 
seen, especially when this was not reported in aged WT or rd mice (Vugler et al., 
2015). However, these mice were only 9-months old and this may count for a 
difference, when comparing them to mice used in this study, which were 12 
months old. 
Given the improvements seen in the scotopic ERG following injection of 9-cis 
retinal, hESC-RPE cells were transplanted into the subretinal space and some 
improvements were seen in the scotopic ERG and the PLR. It is difficult to 
determine if the PLR improvements seen were from outer-retinal photoreceptors 
or ipRGCs. While the iPLR distinguishes these two, it was not recorded on these 
animals as it was decided that fixation of tissue by perfusion is ideal for 
preservation of grafted cells. Unfortunately, no hESC-RPE cells were found in the 
subretinal space of eyes which received the graft. A pigmented mass was found 
in many transplanted eyes; however, this did not stain positive for human 
mitochondria. The rd12 mouse is an interesting alternative to the RCS rat as a 
model for studying RPE cell transplantation. Due to the severely reduced retinal 
function, chromophore-mediated improvements can be detected. However, more 
research needs to be carried out to improve RPE cell graft integration and survival 
in this model. The possibility of combining the rd12 and the NaIO3 models was 
not explored in this thesis, due to limitations on time and the number of animals, 
although, smaller doses of NaIO3 would need to be explored and it is still unclear 
if normal retinal function can be restored following NaIO3 insult. 
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 Does the RPE supply chromophore for ipRGCs 
The reliance of outer-retinal photoreceptors on the RPE and the visual cycle is 
very clear. Without the visual cycle outer-retinal photoreceptors have severely 
reduced function and start to degenerate. This relationship is less clear with 
ipRGCs. In the rd12 mouse, melanopsin function is significantly reduced, 
however, removal of the RPE with NaIO3, reveals a much more robust 
melanopsin driven PLR. A key difference in these two models may lie in the 
development of the melanopsin system. The PLR becomes fully developed 
around P10 (McNeill et al., 2011), which is when RPE65 expression becomes 
stable in mice (Bowes et al., 1988). The reduction of melanopsin+-cells and 
melanopsin labelling in rd12 mice did not significantly change from 1 to 8 months, 
thus this reduction appears most likely to occur during development.  
Mice without a functioning visual cycle have a PLR less sensitive than that of rdta 
or rd1 mice (Tu et al., 2006), this shows that melanopsin function is reduced by 
the loss of chromophore and not just the loss of outer-retinal photoreceptors. In 
fact, the loss of outer-retinal photoreceptors can improve melanopsin function. 
Rdta mice, with selective deletion of rods exhibited an increased magnitude of 
circadian phase shift compared to WT controls and displayed tonic activation of 
RGCs (Lupi et al., 1999). Furthermore, selectively knocking out rods along with 
visual cycle (rpe65-/-:rdta or lrat-/-: rd/rd) improves circadian photosensitivity 
(Doyle et al., 2006) and knocking out rods and rpe65 or lrat improves the PLR 
compared to rpe65-/- or lrat-/- alone (Tu et al., 2006). Perhaps these effects are 
seen following an increase in chromophore, which otherwise would be taken up 
by rods. Evidence of competition for chromophore is also seen in R91W knock-
in mice, which can only produce small amounts of 11-cis retinal, with selective 
ablation of rhodopsin resulting in the correction of cone opsin localisation 
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(Samardzija et al., 2009). Rods are more numerous and contain more opsin, thus, 
they compete favourably for chromophore. 
It is not clear how ipRGCs get 11-cis retinal, as they are located in the inner retina 
and are separated by several layers of cells from the RPE in the outer retina, the 
classic site of 11-cis retinal isomerisation. Perhaps, 11-cis retinal diffuses through 
the retina. Another possible theory is that Müller cells, which have been 
recognised to play a role in opsin cycling for cones (Wang and Kefalov, 2011), 
regenerate chromophore and/or transport chromophore to the inner retina. There 
is evidence to support the ability of 11-cis retinal production in Müller cells (Das 
et al., 1992, Fleisch and Neuhauss, 2010). Müller cells span the thickness of the 
retina and have been reported to be closely associated with ipRGCs but not non-
melanopsin ganglion cells (Viney et al., 2007). It has also been shown that 
photoresponses from ipRGCs in isolated retina are less sustained when Müller 
glia are poisoned with a specific gliotoxin (Zhao et al., 2016). 
Melanopsin has also been reported to work as a bi-stable pigment, with 
photoisomerase capacity generating 11-cis retinaldehyde from all-trans 
retinaldehyde upon exposure to long wavelength light (Melyan et al., 2005, Fu et 
al., 2005). However, this would appear insufficient for driving normal melanopsin 
function in rd12 mice, albeit that these mice have significantly reduced levels of 
melanopsin protein (assessed by immunostaining). 
Different ipRGC subclasses also have a different reliance on chromophore 
directly, as some ipRGCs rely more on extrinsic responses and input from the 
outer-retinal photoreceptors (Zhao et al., 2014, Dacey et al., 2005, Schmidt et al., 
2008, Weng et al., 2013, Zhang et al., 2008). These extrinsic inputs allow ipRGCs 
to activate the correct brain regions even in the absence of melanopsin, where 
ipRGCs lose their intrinsic photosensitivity (Lucas et al., 2003, Wong et al., 2007). 
 305 
 
IpRGCs can be subdivided into five subtypes, M1, M2, M3, M4 and M5. M1 
ipRGCs, express the highest level of melanopsin and rely on intrinsic responses 
more than extrinsic (Schmidt and Kofuji, 2010). They are the only sub-type to 
stratify exclusively in the off sublamina of the IPL (Zhang et al., 2012, Zhang et 
al., 2008). M1 ipRGCs also have projections from the retina into the ciliary body 
in mice, which, may mediate the iPLR (Semo et al., 2014). M2-M5 express lower 
levels of melanopsin and  rely on extrinsic synaptic responses more than intrinsic 
(Schmidt and Kofuji, 2010), sending axons to the OPN, which control the PLR 
(Chen et al., 2011, Hattar et al., 2002, Morin et al., 2003, Hattar et al., 2003, 
Lucas et al., 2003, Baver et al., 2008, Guler et al., 2008). Cones bleach and 
compensate for high levels of light, this means that they do not communicate 
irradiance levels. Melanopsin can communicate high irradiance levels much more 
accurately and is necessary for a complete PLR (Lucas et al., 2003).  
An intrinsic pathway also controls the PLR in rodents, bypassing the OPN. 
Melanopsin and an intact CMZ are necessary for a complete iPLR response 
(Semo et al., 2014, Xue et al., 2011). The iPLR cannot be generated by cones 
and is unaffected by cone loss, however rod function and pigmentation appear to 
be essential for normal iPLR development in mice (Vugler et al., 2015). The iPLR 
develops progressively from P21-49 in mice (Vugler et al., 2015), much later than 
the PLR (McNeill et al., 2011). This may be due to late maturation of Brn3b-
negative M1 ipRGCs, which innervate the ciliary body, as it is known that these 
Brn3b-negative M1 ipRGCs mature their projections into the SCN around P21 
(McNeill et al., 2011).  
The effect of chromophore supplementation on ipRGC function has been shown 
in single cell recordings (Fu et al., 2005) and also in this thesis by the super 
constriction recorded in chromophore-supplemented isolated rd12 eyes. It is 
 306 
 
known that the iPLR requires melanopsin to function (Semo et al., 2014, Xue et 
al., 2011) and therefore the supplemented chromophore, which created a super 
constriction in the rd12 mouse, most likely acted on melanopsin directly. 
Importantly, supplementary chromophore was only able to improve the iPLR 
when retina remained attached to the anterior chamber, being unable to drive the 
iPLR in an isolated anterior chamber. Thus, it was shown that the chromophore 
was most likely acting on ipRGCs in the retina. 
As the importance of chromophore for ipRGC function and the iPLR was 
established, the source of that chromophore was then investigated. As it is known 
that RPE65 is required for chromophore production in normal mice, the location 
of RPE65 was examined and there was no evidence of RPE65 labelling outside 
the RPE in WT retina. As ipRGCs lie on the vitreous side of the retina, and the 
RPE is located in the outer retina, by placing the rpe65 gene into the vitreous of 
rd12 mice and comparing melanopsin function with that from rd12 receiving the 
rpe65 gene subretinally (adjacent to the RPE), it was determined that rpe65 in 
the RPE drove melanopsin function and the iPLR. Rpe65 placed into the vitreous, 
closer to ipRGCs, did not have a significant improvement on melanopsin function 
compared to a control virus. These results are further supported by recent in vitro 
studies showing that ipRGCs need the RPE visual cycle for prolonged light 
exposure and firing, with the removal of the RPE reducing the length of time that 
the response can be sustained (Zhao et al., 2016). The improvements in ipRGC 
function seen here in rd12 mice treated with the rpe65 gene delivered subretinally 
were not accompanied by significant increases in outer-retinal photoreceptor 
function as recorded by ERG. Labelling of RPE65 was only seen in eyes that 
received a subretinal injection of virus encoding rpe65 and its expression was 
restricted to the RPE. Delivery of the virus intravitreally was unsuccessful in 
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transfecting the RPE, a result in agreement with findings from the study by Li and 
colleagues (Li et al., 2009). 
Interestingly, an increase in melanopsin expression was seen in the off sublamina 
in areas of the retina that had RPE65 expression in the RPE. These dendrites 
are from M1 ipRGCs, which are likely to drive the retinal input of the iPLR (Semo 
et al., 2014) and are less reliant on outer-retinal photoreceptor input (Schmidt and 
Kofuji, 2010). 
The melanopsin system is often not considered when assessing visual function 
in retinal degeneration. However, it has been shown in this thesis that the 
melanopsin system relies on chromophore from the RPE and melanopsin 
function could therefore provide additional readouts of RPE-driven retinal 
function. These results also have important implications for diseases of the RPE 
such as AMD (Maynard et al., 2017) and LCA (Charng et al., 2017), where 
melanopsin function is also disrupted and it is important to consider this when 
developing potential therapies.  
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